Antibody-multi-drug conjugate precursors and synthetic intermediates thereof

Abstract

Provided is a conjugate precursor for obtaining a more useful anti-tumor drug by further improving a conventional antibody-drug conjugate. The antibody-multi-drug conjugate precursor is represented by general formula (I) [in the formula, the symbols have the meanings described in the description], or a salt of the antibody-multi-drug conjugate precursor, and a synthetic intermediate of the antibody-multi-drug conjugate precursor or a salt of the synthetic intermediate. # imgabs0 #

Description

[Technical field]

[0001] The present invention relates to an antibody-multi-drug conjugate (AMDC) precursor (hereinafter also referred to as a conjugate precursor) and a synthetic intermediate thereof (hereinafter also referred to as a conjugate precursor synthetic intermediate) for synthesizing AMDC used as an anti-tumor drug. [Background Technology]

[0002] Antibody Drug Conjugate (ADC), in which a cytotoxic drug (load) is conjugated to an antibody, which binds to an antigen expressed on the surface of tumor cells and can be internalized in the cells, can be expected to "selectively deliver the drug to cancer cells, release and accumulate the drug in cancer cells, and thus kill cancer cells" (NPL 1 to 3). As an example of ADC, Adcetril, in which monomethyl auristatin E is conjugated to an anti-CD30 antibody, s )(brentuximab ve doti n ) (PTL 1) is approved as a treatment for Hodgkin lymphoma and anaplastic large cell lymphoma, Kadcyla (trastuzumab emtansine), which is emtansine conjugated to an anti-HER2 antibody, is approved as a treatment for HER2-positive metastatic breast cancer, Enhertu (trastuzumab deruxtecan), which is deruxtecan conjugated to an anti-HER2 antibody, is approved as a treatment for HER2-positive metastatic breast cancer (PTL 2), Trodelvy (sacituzumab sacituzumab), which is SN-38 conjugated to an anti-TROP-2 antibody, is approved as a treatment for HER2-positive metastatic breast cancer (PTL 3), govitecan) is approved as a treatment for TROP-2-positive metastatic breast cancer, and Blenrep (belantamab ma fodoti n)) is approved as a therapeutic drug for multiple myeloma, Tivdak (tisotumab vedotin) in which monomethyl auristatin E is conjugated to an anti-CD142 antibody is approved as a therapeutic drug for metastatic cervical cancer, and Zynlonta (loncastuximab tesirine) in which a pyrrolobenzodiazepine dimer is conjugated to an anti-CD19 antibody is approved as a therapeutic drug for B-cell lymphoma (NPL 4 to 10). In addition, many novel ADCs are being clinically developed as anti-tumor drugs (NPL 11 to 14).

[0003] At the same time, almost all effective cancer chemotherapy is intended to overcome the differences in drug sensitivity within heterogeneous tumor cell populations, and a combination of multiple drugs is widely used for treatment (NPL 15). This strategy has also been applied to ADC, and currently, a combination of approved unconjugated anticancer agents and ADCs is used for clinical trials (NPL 16). Therefore, it is expected that ADCs in which multiple antitumor drugs with different mechanisms of action are combined with an antibody via a joint will qualitatively show better efficacy and become more useful antitumor drugs. In addition, when multiple antitumor compounds with the same mechanism of action are combined with an antibody via a joint, it is expected that ADC will strongly show better efficacy and become more useful antitumor drugs. [List of cited references] [Patent Document]

[0004] [PTL 1] WO 2003 / 043583 [PTL 2] Japanese Patent Application Publication No. 2016-196484 [PTL 3] WO 2022 / 022649 [PTL 4]CN 113941007 [PTL 5] WO 2021 / 148500 [PTL 6] WO 2021 / 209007 [PTL 7] WO 2021 / 212638 [PTL 8] WO 2022 / 199429 [Non-patent literature]

[0005] [NPL 1] Bioconjugate Chem., 2010, 21, 5-13 [NPL 2]Current Opin.Chem.Biol., 2010, 14, 529-537 [NPL 3]Expert Opin.Biol.Ther.[Expert Opinion on Biological Therapy],2004,4,1445-1452 [NPL 4] Biotechnol Lett. [Biotechnology Communications], 2016, 38, 1655-1664. [NPL 5]Chem Pharm Bull. [Journal of Chemistry and Pharmacology], 2019, 67, 173-185. [NPL 6] N Engl J Med. [New England Journal of Medicine], 2012, 367, 1783-1791 [NPL 7]Expert Opin.Biol.Ther.[Expert Opinion on Biological Therapy],2020,8,871-875 [NPL 8] Drugs Today, 2021, 57, 653-663 [NPL 9] Drugs, 2021, 81, 2141-2147 [NPL 10] Drugs, 2021, 81, 1229-1233 [NPL 11] Clin Cancer Res., 2019, 25, 5441-5448. [NPL 12]Molecules.2020,25,4764 [NPL 13] Methods Mol Biol. [Molecular Biology Methods], 2020, 2078, 1-22 [NPL 14]Nat.Rev.Drug Discov.[Review of drug discovery],2017,16,315 [NPL 15] Nat. Biotecnol. [Nature Biotechnology], 2015, 33, 733-736 [NPL 16] N Engl J Med. [New England Journal of Medicine], 2018, 378, 331-344. [NPL 17] Bioconjugate Chem. 2016, 27, 1030-1039 [NPL 18]Org.Biomol.Chem.[Organic Chemistry and Biomolecular Chemistry]2016,14,6165-6178 [NPL 19]Nat. Commun. [Nature Communications] 2015, 6, 6645 [NPL 20]Angew.Chem.Int.Ed.[Applied Chemistry International Edition],2017,56,733-737 [NPL 21] Bioorg.Med.Chem.Lett. [Bioorganic and Medicinal Chemistry Communications], 2018, 28, 3617-3621 [NPL 22] Data in Brief, 2018, 21, 2208-2220 [NPL 23] Antib. Ther. 2019 Oct;2(4):71-78 [NPL 24]Nat. Commun. [Nature Communications] 2018, 9, 2512 [Summary of the invention] [Technical issues]

[0006] The present invention provides an ADC having a linker modified with at least one modifying group (such as a lactone group and a phosphoryl group) and connected to two or more drugs. [Solution to the problem]

[0007] In order to develop useful anti-tumor drugs, the inventors have designed an "antibody-multidrug conjugate (antibody multi-drugs conjugate; AMDC), in which an antibody is bound to multiple anti-tumor drugs via a branched (e.g., bibranched or Y-shaped) linker", and designed a useful conjugate precursor (a precursor compound that reacts with a functional group present in an antibody to form an antibody-multidrug conjugate) for obtaining the AMDC, and successfully synthesized the conjugate precursor, and clarified the characteristics that the AMDC exhibits excellent pharmacokinetics (especially blood retention). In addition, the inventors have designed and successfully synthesized a conjugate precursor having one or both of a lactone group or a phosphoryl group in the Y-shaped AMDC linker, or an anti-tumor drug as a conjugate precursor, to obtain a "highly hydrophilic Y-shaped AMDC that is stable in the blood", and clarified the characteristics that the AMDC exhibits excellent pharmacokinetics (particularly high stability in the blood compared to the stability of AMDC without the said groups). In addition, the inventors have found that Y-type AMDC synthesized using the precursor is effective in both in vitro and in vivo tests, thereby confirming the usefulness of the conjugated precursor of the present invention. The present invention also includes a "conjugated precursor synthetic intermediate" for synthesizing the conjugate precursor.

[0008] AMDCs in which multiple drugs are bound to one antibody via linkers are disclosed in PTLs 3 to 8 and NPLs 17 to 24, some of which disclose Y-shaped linkers, but none discloses both lactone groups and phosphoryl groups in linkers or antitumor drugs.

[0009] The present invention provides the following [1] to

[35] . [1] The antibody-multi-drug conjugate precursor (hereinafter also referred to as conjugate precursor (I)) is represented by the following general formula (I): [C1] [In this formula, Z is a reactive group (hereinafter also referred to simply as a "reactive group") that can react with a functional group present in an antibody (hereinafter also referred to as a "functional group in the antibody"), G is a group represented by the following formula (i), (ii), (iii) or (iv), [C2] [C3] [C4] [C5] [in the formula, R is a hydrogen atom, a hydroxyl group, an amino group, an alkyl group or an alkyloxy group, and Cy is a cycloalkyl ring, a cycloalkenyl ring, an aryl ring, a heteroaryl ring or a heterocyclyl ring], L 1 It connects G and D 1 The connector, L 2 It connects G and D 2 The connector, L 3 It is the connector that connects G and Z. L 1 , L 2 and L 3 may be the same or different from each other (hereinafter, L 1 , L 2 and L 3 Also collectively referred to as "joint portion"), D 1 and D 2is a residue in which a hydrogen atom or a hydroxyl group is removed from any position of an antitumor drug molecule or an analog thereof (hereinafter also referred to as "antitumor drug residue"), or a derivative thereof, and these residues may be the same as or different from each other, One or more lactone groups and one or more phosphoryl groups independently exist as substituents or protecting groups at any position of the antitumor drug residue or linker portion, the total number of the lactone groups is 1 to 10, when the number of these lactone groups is two or more, these lactone groups may be the same as or different from each other, and the total number of the phosphoryl groups is 1 to 10] or its salt. [2] The conjugate precursor (I) as described in [1], or a salt thereof, wherein Z is a maleimido group (formula (v) below), an α-halomethylcarbonyl group (formula (vi) below), an ethynylphosphonamide group (formula (vii) below), a carboxyl group, an active ester of a carboxyl group, a thiol group, a hydroxyl group, an amino group, an alkynyl group, a cycloalkynyl group or an azide group (-N 3 Group), Formula (v) [C6] Formula (vi) [C7] Hal-CH 2 -C(=O)-* Formula (vii) [C8] [In this formula, * is related to L 3 The point of attachment, Hal is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, and R 16 is a methyl group, an ethyl group or -CH 2 CH 2 OCH 2 CH 2 OH group]. [3] The conjugate precursor (I) as described in [1] or [2], or a salt thereof, wherein Z is a maleimido group (formula (v)), an α-halomethylcarbonyl group (formula (vi)), an ethynylphosphonamide group (formula (vii)), a carboxyl group or an active ester of a carboxyl group. [4] The conjugate precursor (I) or a salt thereof as described in any one of [1] to [3], wherein Z is a maleimido group (formula (v)), an α-halomethylcarbonyl group (formula (vi)), a carboxyl group or an active ester of a carboxyl group. [5] The conjugate precursor (I) or a salt thereof as described in any one of [1] to [4], wherein G is a group represented by formula (i), formula (ii) or formula (iii). [6] The conjugate precursor (I) or a salt thereof as described in any one of [1] to [5], wherein G is a group represented by formula (i). [7] The antibody multi-drug conjugate precursor (I) or a salt thereof as described in any one of [1] to [6], wherein L 1 , L 2 and L 3 each independently is an optionally substituted alkylene group; One or more methylene groups in the chain of the alkylene group are optionally replaced by one or more divalent groups independently selected from the group consisting of: -C(R 1 )(R 2 )-;-O-;-N(R 3 )-;-N(R 3 )-N(R 3 )-;-S-;-Se-;-Si(R 4 )(R 5 )-;-SS-;-Se-Se-;-SOm-;-SeOn-;-C(=C(R 6 )(R 7 ))-;-C(=O)-;-C(=S)-;-C(=N(R 8 ))-;-C(=N-OR 9 )-;-C(=NN(R 10 )(R 11 ))-;-P(=O)(R 12 )-;-P(=O)(OR 13 )-;-OP(=O)(R 12 )-O-;-OP(=O)(OR 13 )-O-;-C(R 14 )=;=C(R 14 )-;-C(R 14 )=C(R 14 )-;-N=;=N-;-C≡C-;-(OC(R 1 )(R 2 )-C(R 1 )(R 2 )) 1-30 -;-(C(R 1 )(R 2 )-C(R1 )(R 2 )-0) 1-30 -; an optionally substituted alkenylene group, an optionally substituted alkynylene group, an optionally substituted cycloalkylene group; an optionally substituted cycloalkenylene group; an arylene group; an optionally substituted heteroarylene group; and an optionally substituted heterocyclylene group; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 and R 14 each independently is a group selected from the group consisting of a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkenyl group, an aryl group, an optionally substituted heteroaryl group, and an optionally substituted heterocyclyl group, When R 3 When it is an alkyl group, the alkyl group is optionally combined with the alkyl group in the adjacent methylene group to form a ring structure; and m and n are each independently an integer from 0 to 2. [8] The antibody multi-drug conjugate precursor (I) as described in [7], or a salt thereof, Where L 1 , L 2 and L 3 are each independently an optionally substituted alkylene group; and One or more methylene groups in the chain of the alkylene group are replaced by one or more divalent groups independently selected from the following formulae: Formula Group -C(R 1 )(alkyl)-; -C(R 14 )=; -O-; -N(R 3 )-; -N=; -N(R 3 )-C(R 1 )(R 2 )-(where R 3 With R 1 or R2 When it is an alkyl group, R 3 With R 1 or R 2 optionally combined to form a ring structure); -N(R 3 )-C(R 1 )(R 2 )-C(=O)-(wherein, when R 3 With R 1 or R 2 When it is an alkyl group, R 3 With R 1 or R 2 optionally combined to form a ring structure); -OC(R 1 )(R 2 )-; -SC(R 1 )(R 2 )-; -N(R 3 )-N(R 3 )-; -N(R 3 )-OC(R 1 )(R 2 )-; -S-; -Si(R 4 )(R 5 )-; -SS-; -SOm-; -C(=O)-; -C(R 1 )(R 2 )-C(=O)-; -C(=C(R 6 )(R 7 ))-; -C(=N(R 8 ))-; -C(=N-OR 9 )-; -C(=NN(R 10 )(R 11 ))-; -P(=O)(R 12 )-; -P(=O)(R 12 )-O-; -OP(=O)(R 12 )-O-; -P(=O)(OR 13)-O-; -P(=O)(OR 13 )-N(R 3 )-; -OP(=O)(OR 13 )-O-; -C(R 14 )=C(R 14 )-; -C(R 14 )=C(R 14 )-P(=O)(OR 13 )-N(R 3 )-; -C(R 14 )=N-; -C(R 14 )=NN(R 3 )-; -C≡C-; -OC(R 1 )(R 2 )-C(R 1 )(R 2 )-; -OC(R 1 )(R 2 )-C(R 1 )(R 2 )-O-; -(OC(R 1 )(R 2 )-C(R 1 )(R 2 )) 2-30 -; -C(=O)-O-; -C(=O)-S-; -C(=O)-N(R 3 )-; -C(=O)-N(R 3 )-O-; -C(=O)-N(R 3 )-C(R 1 )(R 2 )-(where R 3 With R 1 or R 2 When it is an alkyl group, R 3 With R 1 or R 2 optionally combined to form a ring structure); -C(=S)-O-; -C(=S)-S-; -OC(=O)-O-; -OC(=O)-N(R 3 )-; -SC(=O)-N(R 3 )-; -N(R 3 )-C(=O)-N(R 3 )-; an optionally substituted arylene group; optionally substituted heteroarylene groups; and Optionally substituted heterocyclylene groups. [9] The antibody multi-drug conjugate precursor (I) or a salt thereof as described in [7], wherein L 1 , L 2 and L 3 are each independently an optionally substituted alkylene group; and One or more methylene groups in the chain of the alkylene group are replaced by one or more divalent groups independently selected from the following formulae: Formula Group -C(H or C 1 -C 4 Alkyl)=; -O-; -N(H or C 1 -C 4 Alkyl) = -; -N=; -S-; -C(=O)-; -O-Si(CH 3 )(CH 3 )-O-; -CH 2 -C(=O)-; -C(=O)-NH-; -C(=O)-O-; -C(=O)-S-; -OC(=O)-O-; -N(H or H or C 1 -C 4 alkyl)-C(═O)-O-; -NH-NH-; -N(H or C 1 -C 4 Alkyl)-O-CH 2 -; -C(=O)-(CH 2 )1-20 -C(=O)-; -C(=O)-(CH 2 ) 1-10 -O-(CH 2 ) 1-10 -C(=O)-; -C(=O)-CH 2 -(O-CH 2 CH 2 ) 1-20 -O-CH 2 -C(=O)-; -(O-CH 2 CH 2 ) 1-20 -; -C(=O)-N(H or H or C 1 -C 4 Alkyl)-CH 2 CH 2 -N(H or H or C 1 -C 4 alkyl)-C(═O)-; [C9] [where * is the point of attachment to the adjacent group] -C(=O)-N(H or C 1 -C 4 Alkyl)-CH 2 -; -P(=O)(OH)-O-; -OP(=O)(OH)-O-; -OP(=O)(OH)-OP(=O)(OH)-O-; -OP(=O)(OH)-OP(=O)(OH)-OP(=O)(OH)-O-; -CH(CH 2 -NH 2 )-; -CH(CH 2 -NH-C(=O))-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -CH 3 )-; -CH(CH 2 -NH-C(=O)-(CH 2 ) 0-20 -lactone)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -CH 2 -lactone)-; -CH(CH 2 -NH-C(=O)-(CH 2 ) 1-20 -phosphoryl)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -CH 2 -phosphoryl)-; -CH(CH 2 -NH-(CH 2 ) 1-20 -phosphoryl)-; -(cis)-CH=CH-P(=O)(O-CH 2 CH 3 or O-CH 2 CH 2 -OH)-NH-(phenylene)-C(=O)-; -C(=O)-(cyclohexylene)-; -(succinimidyl)-; -Gly-; -Ala-; -Val-; -Leu-; -Ile-; -Phe-; -Ser-; -Cys-; -Asp-; -Glu-; -Orn-; -Lys-; -Cit-; -Arg-; -His-; -Pro-; -GlyGly-; -PheLys-; -ValLys-; -ValCit-; -ValAla-; -AspValCit-; -GluValCit-; -LysValCit-; -SerValCit-; -AspValAla-; -GluValAla-; -LysValAla-; -SerValAla-; -GlyGlyPheGly-; -AspGlyGlyPheGly-; -GluGlyGlyPheGly-; -LysGlyGlyPheGly-; -SerGlyGlyPheGly-; -AspAspAspAspAsp- (Among the amino acid residues and the amino acid residues in the peptide, One or more carboxyl groups in one or more side chains of Asp and Glu may be converted into lactone esters, lactone alkyl esters or phosphoryl alkyl esters, or may be converted into unsubstituted amides, monoalkyl amides or dialkyl amides, and the amino group in the amide portion may have one or more lactone groups, one or more lactone alkyl groups or phosphoryl alkyl groups as one or more substituents, One or more amino groups in one or more side chains of Lys and Orn may have, as one or more substituents, one or more lactone groups, one or more lactone alkyl groups, one or more lactone carbonyl groups, one or more lactone alkylcarbonyl groups, one or more phosphoryl groups, one or more phosphoryl alkyl groups or one or more phosphoryl alkylcarbonyl groups, and The hydroxyl group in the side chain of Ser and the thiol group in the side chain of Cys may optionally have as one or more substituents one or more lactone groups, one or more lactone alkyl groups, one or more lactone carbonyl groups, one or more lactone alkylcarbonyl groups, one or more phosphoryl groups, one or more phosphoryl alkyl groups or one or more phosphoryl alkylcarbonyl groups); -N(H or C 1 -C 4 alkyl)-(optionally substituted phenylene)-CH 2 -OC(=O)-; -O-(optionally substituted phenylene)-CH 2 -OC(=O)-; -N(H or C 1 -C 4alkyl)-(optionally substituted pyridinyl)-CH 2 -OC(=O)-; [C10] [C11] [C12] [C13] as well as [C14] [In this formula, * is the point of attachment to the adjacent group].

[10] The conjugate precursor (I) or a salt thereof as described in [7], wherein L 1 , L 2 and L 3 are each independently an optionally substituted alkylene group; and One or more methylene groups in the chain of the alkylene group are substituted by one or more divalent groups, the one or more divalent groups being independently selected from the following formula group, Formula Group -CH 2 -N(CH 3 )-CH 2 -; -CH 2 -C(=O)-; -C(=O)-NH-CH 2 -; -C(=O)-(CH 2 ) 1-10 -(O-CH 2 CH 2 ) 1-20 -O-(CH 2 ) 1-10 -C(=O)-; -C(=O)-(CH 2 ) 1-10 -(O-CH 2 CH 2 ) 1-20 -O-(CH 2 ) 1-10 -CH 2 -NH-; -NH-CH 2 -(CH 2 ) 1-10-(O-CH 2 CH 2 ) 1-20 -O-(CH 2 ) 1-10 -CH 2 -NH-; -C(=O)-N(CH 3 )-CH 2 CH 2 -N(CH 3 )-C(=O)-; [C15] [In this formula, * is the point of attachment to the adjacent group]; -P(=O)(OH)-O-; -OP(=O)(OH)-O-; -OP(=O)(OH)-OP(=O)(OH)-O-; -OP(=O)(OH)-OP(=O)(OH)-OP(=O)(OH)-O-; -CH(CH 2 -NH 2 )-; -CH(CH 2 -NH(CH 3 ))-; -CH(CH 2 -N(CH 3 ) 2 )-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 0-20 -CH 3 )-; -CH(CH 2 -NH-C(=O)-(CH 2 ) 0-20 -lactone)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -(CH 2 ) 1-10 -CH 2 -lactone)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2-O-) 1-20 -(CH 2 ) 1-10 -CH 2 -NH-lactone)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -(CH 2 ) 1-10 -CH 2 -NH-C(=O)-lactone)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -(CH 2 ) 1-10 -C(=O)-NH-lactone)-; -CH(CH 2 -NH-(CH 2 ) 1-20 -(O) 0-1 -phosphoryl)-; -CH(CH 2 -NH-C(=O)-(CH 2 ) 1-20 -phosphoryl)-; -CH(CH 2 -NH-C(=O)-(CH 2 ) 1-20 -C(=O)-NH-(CH 2 ) 1-10 -phosphoryl)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -(CH 2 ) 1-10 -CH 2 -phosphoryl)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -(CH 2 ) 1-10 -C(=O)-NH-(CH 2 ) 1-10 -phosphoryl)-; -CH(CH 2-NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -(CH 2 ) 1-10 -C(=O)-NH-(CH 2 ) 1-10 -C(H, OH, Cl, NH 2 or C 1 -C 4 Alkyl)(P(=O)(OH) 2 ) 2 )-; -(cis)-CH=CH-P(=O)(O-CH 2 CH 3 )-NH-(phenylene)-C(=O)-; -C(=O)-(cyclohexylene)-; -(succinimidyl)-; -Ser-; -Cys-; -Asp-; -Glu-; -Orn-; -Lys-; -ValLys-; -ValCit-; -ValAla-; -GlyGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -PheLys-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -ValLys-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -ValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -ValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -AspValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -GluValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -LysValCit-C(=O)-NH-(optionally substituted phenylene)-CH2 -; -SerValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -AspValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -GluValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -LysValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -SerValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -GlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -AspGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -GluGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -LysGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -SerGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -AspAspAspAspAsp-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -GlyGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -PheLys-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -ValLys-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -ValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -ValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -AspValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -GluValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -LysValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -SerValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -AspValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -GluValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -LysValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -SerValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -GlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -AspGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -GluGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -LysGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -SerGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -AspAspAspAspAsp-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -GlyGlyPheGly-C(=O)-NH-CH 2 -; -AspGlyGlyPheGly-C(=O)-NH-CH 2 - (Among the amino acid residues and the amino acid residues in the peptide, One or more carboxyl groups in one or more side chains of Asp and Glu are converted into O-(lactonyl)esters, O-(lactonylalkyl)esters, O-(phosphorylalkyl)esters, N-(lactonyl)amides, N-(lactonylalkyl)amides or N-(phosphorylalkyl)amides, One or more amino groups in one or more side chains of Lys and Orn have, as one or more substituents, one or more lactone groups, one or more lactone alkyl groups, one or more lactone carbonyl groups, one or more lactone alkylcarbonyl groups, one or more phosphoryl groups, one or more phosphoryl alkyl groups, or one or more phosphoryl alkylcarbonyl groups, and The hydroxyl group in the side chain of Ser and the thiol group in the side chain of Cys optionally have, as one or more substituents, one or more lactone groups, one or more lactone alkyl groups, one or more lactone carbonyl groups, one or more lactone alkylcarbonyl groups, one or more phosphoryl groups, one or more phosphoryl alkyl groups or one or more phosphoryl alkylcarbonyl groups); [C16] [C17] [C18] [C19] as well as [C20] [In this formula, * is the point of attachment to the adjacent group].

[11] The conjugate precursor (I) or a salt thereof as described in any one of [1] to

[10] , wherein D 1 and D 2is a residue of an antitumor drug molecule independently selected from the group consisting of: camptothecin; MMAE; maytansine; PBD (parabenzodiazepine ) dimer; Eribulin; 5-fluorouracil (5-FU); 5-bromo-N-(2,3-dihydroxypropyloxy)-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide (PD-318088); pimasertib (AS-703026); 3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3- d] pyrimidine-4,7-dione (TAK-733); samotolisib (LY-3023414); calicheamicin; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; Aplysia 10; superdox; ciprofloxacin; and caderfloxacin hydrochloride (CS-940); or an analog or derivative thereof; or a derivative of said analog.

[12] The conjugate precursor (I) or a salt thereof as described in any one of [1] to

[11] , wherein D 1 and D 2 is a residue of an antitumor drug molecule independently selected from the group consisting of: camptothecin; MMAE; maytansine; PBD (parabenzodiazepine ) dimer; eribulin; 5-FU; PD-318088; AS-703026; TAK-733; LY-3023414; calicheamicin; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; Aplysia 10; and superdox; or an analog or derivative thereof; or a derivative of said analog.

[13] The conjugate precursor (I) or a salt thereof as described in any one of [1] to

[12] , wherein D 1 and D 2 is a residue of an antitumor drug molecule independently selected from the group consisting of: camptothecin; MMAE; maytansine; PBD (parabenzodiazepine ) dimer; and eribulin; or an analog or derivative thereof; or a derivative of said analog.

[14] The conjugate precursor (I) or a salt thereof as described in any one of [1] to

[13] , wherein D 1 and D 2 is the residue of: the same antitumor drug or an analog or derivative of these antitumor drugs; or a derivative of the analog.

[15] The conjugate precursor (I) or a salt thereof as described in any one of [1] to

[13] , wherein D 1 and D 2 is the residue of: a different anti-tumor drug or an analog or derivative thereof; or a derivative of the analog.

[16] The conjugate precursor (I) or a salt thereof as described in any one of [1] to

[15] , wherein D 1 and D 2 At least one of the residues is an antitumor drug or an analog of the antitumor drug having a hydroxyl group in the molecule and wherein at least one hydroxyl group is phosphorylated; or a derivative of the analog.

[17] The conjugate precursor (I) or a salt thereof as described in any one of [1] to

[16] , wherein one or more lactone groups and one or more phosphoryl groups are independently present as substituents or protecting groups at any position of the antitumor drug residues or the linker portions, the total number of the lactone groups is 1 to 8, when the number of the lactone groups is two or more, the lactone groups may be the same as or different from each other, and the total number of the phosphoryl groups is 1 to 4.

[18] The conjugate precursor (I) or a salt thereof as described in any one of [1] to

[17] , wherein one or more lactone groups and one or more phosphoryl groups are independently present as substituents or protecting groups at any position of the antitumor drug residues or the linker moieties, and In addition to the above, when at least any one of the antitumor drug residues and the linker moieties independently has at any position one or more phosphorylalkylcarbonyl groups (-C(=O)-alkylene-P(=O)(OH) 2 ); a dialkylamino group; and a group of a cyclic amino group which forms a ring together with the dialkyl group as a substituent or a protecting group and when a plurality of such groups are present in total, these groups may be the same as or different from each other.

[19] A conjugate precursor (I) selected from the group consisting of: Example 1 [C21] Example 2 [C22] Example 3 [C23] Example 4 [C24] Example 5 [C25] Example 6 [C26] Example 7 [C27] [In this formula, the spatial configuration of the amino acid residues in the linker is all L-type], or a salt thereof.

[20] A synthetic intermediate (II-1) of a conjugate precursor (I), which is represented by the following general formula (II-1) (hereinafter also referred to as a conjugate precursor synthetic intermediate (II-1)): [C28] [In this formula, Z 1 is a "reactive group" as defined in [1] above; or a group for bonding the "reactive group" or the antitumor drug residue as defined in [1] above to a linker (hereinafter also referred to as a "bonding group"), and the bonding group may be a protected body protected by a protecting group (hereinafter also referred to as a "protected body"), G 1 is a group represented by formula (i), (ii), (iii) or (iv), L 1-1 It is connected to G 1 and D 1-1 The connector, L 2-1 It is connected to G 1 and D 2-1 The connector, L 3-1 It is connected to G 1 and Z 1 The connector, L 1-1 , L 2-1 and L 3-1 may be the same or different from each other (hereinafter, L 1-1 , L 2-1 and L 3-1 Also collectively referred to as "joint portion"), D 1-1 and D 2-1is an anti-tumor drug residue as defined in [1] above or A bonding group or a protective body thereof, D 1-1 and D 2-1 can be the same or different from each other, When there are one or more independently selected from lactone groups; phosphoryl groups; phosphoryl alkylcarbonyl groups (-C(=O)-alkylene-P(=O)(OH)) at any one or more positions of these antitumor drug residues or these linker moieties, 2 ); a dialkylamino group; and a group of a cyclic amino group that forms a ring together with the dialkyl group and when there are a plurality of such groups in total, these groups may be the same as or different from each other, and When Z 1 When D is a reactive group, 1-1 and D 2-1 at least one of which is a bonding group], or a salt thereof. [twenty one] The conjugate precursor synthetic intermediate (II-1) as described in

[20] , or a salt thereof, wherein G 1 is a group selected from the group consisting of the formula described in [5] or [6] above. [twenty two] The conjugate precursor synthetic intermediate (II-1) as described in

[20] or

[21] , or a salt thereof, wherein L 1-1 , L 2-1 and L 3-1 are each independently an optionally substituted alkylene group; and One or more methylene groups in the chain of the alkylene group are each independently substituted with one or more groups selected from the divalent groups described in any one of [7] to

[10] above. [twenty three] The conjugate precursor synthetic intermediate (II-1) as described in any one of

[20] to

[22] , or a salt thereof, wherein Z 1 is a bonding group, which is a hydroxyl group, a nitro group, a cyano group, an amide group, an oxo group, an azide group, an amino group, a monoalkylamino group which may have a substituent, an imino group (also including -N= and the imino group of a cyclic amine), a carboxyl group, a phosphoryl group, an alkynyl group, a cycloalkynyl group or a thiol group; or a protective body thereof. [twenty four] The conjugate precursor synthetic intermediate (II-1) as described in any one of

[20] to

[23] , or a salt thereof, wherein Z 1is a bonding group, which is a hydroxyl group, a nitro group, a cyano group, an oxo group, an azide group, an amino group, a monoalkylamino group which may have a substituent, an imino group (also including -N= and the imino group of a cyclic amine), a carboxyl group, a phosphoryl group, an alkynyl group, a cycloalkynyl group or a thiol group; or a protective body thereof.

[25] The conjugate precursor synthetic intermediate (II-1) as described in any one of

[20] to

[24] , or a salt thereof, wherein Z 1 is a bonding group, which is a hydroxyl group, a nitro group, an oxo group, an azide group, an amino group, a monoalkylamino group which may have a substituent, an imino group (also including -N= and the imino group of a cyclic amine), a carboxyl group, a phosphoryl group, an alkynyl group, a cycloalkynyl group or a thiol group; or a protective body thereof.

[26] The conjugate precursor synthetic intermediate (II-1) as described in any one of

[20] to

[25] , or a salt thereof, wherein Z 1 is a bonding group, which is a hydroxyl group, a nitro group, an oxo group, an azide group, an amino group, a monoalkylamino group which may have a substituent, an imino group (also including -N= and the imino group of a cyclic amine), a carboxyl group, a phosphoryl group, an alkynyl group or a cycloalkynyl group; or a protective body thereof.

[27] The conjugate precursor synthetic intermediate (II-1) as described in any one of

[20] to

[26] , or a salt thereof, wherein Z 1 is a group selected from the bonding groups described in any one of

[23] to

[26] above, and D 1-1 and D 2-1 One of them is a group selected from the antitumor drug residues described in any one of

[11] to

[16] , and the other is a group selected from the bonding groups described in any one of

[23] to

[26] above.

[28] The conjugate precursor synthetic intermediate (II-1) as described in any one of

[20] to

[26] , or a salt thereof, wherein Z 1 is a group selected from the bonding groups described in any one of

[23] to

[26] above, and D 1-1 and D 2-1 Both are independently selected from the group of antitumor drug residues described in any one of

[11] to

[16] above.

[29] The conjugate precursor synthetic intermediate (II-1) as described in any one of

[20] to

[26] , or a salt thereof, wherein Z 1, D 1 -1 and D 2-1 All are each independently a group selected from the bonding groups described in any one of

[23] to

[26] above.

[30] The conjugate precursor synthetic intermediate (II-1) as described in any one of

[20] to

[22] , or a salt thereof, wherein Z 1 is a reactive group as defined in [1] above, and D 1-1 and D 2-1 One of them is a group selected from the antitumor drug residues described in any one of

[11] to

[16] , and the other is a group selected from the bonding groups described in any one of

[23] to

[26] above.

[31] The conjugate precursor synthetic intermediate (II-1) as described in any one of

[20] to

[22] , or a salt thereof, wherein Z 1 is a reactive group as defined in [1] above, and D 1-1 and D 2-1 Both are each independently a group selected from the bonding groups described in any one of

[23] to

[26] above.

[32] The conjugate precursor synthetic intermediate (II-1) as described in any one of

[20] to

[31] , or a salt thereof, wherein one or more lactone groups and one or more phosphoryl groups are independently present as substituents or protecting groups at any position of these antitumor drug residues or these linker parts, the total number of the lactone groups is 1 to 8, when the number of these lactone groups is two or more, these lactone groups may be the same as or different from each other, and the total number of the phosphoryl groups is 1 to 4.

[33] The conjugate precursor synthetic intermediate (II-1) as described in any one of

[20] to

[32] , or a salt thereof, wherein one or more lactone groups and one or more phosphoryl groups are independently present as substituents or protecting groups at any position of the antitumor drug residues or the linker moieties, and In addition to the above, when there are one or more independently selected from phosphorylalkylcarbonyl groups (-C(=O)-alkylene-P(=O)(OH) at any one or more positions of these antitumor drug residues or these linker moieties, 2 ); a dialkylamino group; and a group of a cyclic amino group which forms a ring together with the dialkyl group and when there are a plurality of such groups in total, these groups may be the same as or different from each other.

[34] A conjugate precursor synthetic intermediate (II-2), which is represented by the following general formula (II-2): [C29] [In this formula, L 1-1 and L 2-1 are each independently an optionally substituted alkylene group, and one or more methylene groups in the chain of the alkylene group are each independently substituted by one or more groups selected from the divalent groups described in any one of [7] to

[10] , D 1-1 and D 2-1 is a group selected from the antitumor drug residues described in any one of

[11] to

[16] above or a group selected from the bonding groups described in any one of

[23] to

[26] above, and D 1-1 and D 2-1 can be the same or different from each other, When the L 1-1 and L 2-1 or any one or more positions of the antitumor drug residues contain one or more independently selected from lactone groups; phosphoryl groups; phosphoryl alkyl carbonyl groups (-C(=O)-alkylene-P(=O)(OH) 2 ); a dialkylamino group; and a group of a cyclic amino group that forms a ring together with the dialkyl group as a substituent or a protecting group and when there are a plurality of such groups in total, these groups may be the same as or different from each other, and R 17 is a hydrogen atom or a protecting group], or a salt thereof.

[35] A conjugate precursor synthetic intermediate (II-1) and (II-2) selected from the group consisting of: Example 1-15 [C30] Example 2-10 [C31] Example 3-1 [C32] Example 4-3 [C33] Example 4-4 [C34] Example 5-2 [C35] Example 5-3 [C36] Example 6-4 [C37] Example 6-5 [C38] Example 7-6 [C39] Example 7-7 [C40] [In this formula, the spatial configuration of the amino acid residues in the linker is all L-type], or a salt thereof].

[0010] Hereinafter, various aspects of the present invention will be described. Aspects created by optionally selecting and combining the following various aspects and aspects created by optionally combining the following various aspects with any one or more aspects, one or more embodiments, etc. described herein are also encompassed in the present invention. [Aspect A1] A conjugate precursor (I), or a salt thereof, wherein, in the general formula (I): [C41] Z is a reactive group capable of reacting with an antibody (hereinafter also simply referred to as a "reactive group"). [Aspect A2] The conjugate precursor (I) as described in [Aspect A1], or a salt thereof, wherein Z is a maleimido group (the following formula (v)), an α-halomethylcarbonyl group (the following formula (vi)), an ethynylphosphonamide group (the following formula (vii)), a carboxyl group, an active ester of a carboxyl group, a thiol group, a hydroxyl group, an amino group, an alkynyl group, a cycloalkynyl group or an azide group (—N 3 group). [Aspect A3] The conjugate precursor (I) as described in [Aspect A1] or [Aspect A2], or a salt thereof, wherein Z is a maleimido group (formula (v) above), an α-halomethylcarbonyl group (formula (vi) above), an ethynylphosphonamide group (formula (vii) above), a carboxyl group or an active ester of a carboxyl group. [Aspect A4] The conjugate precursor (I) as described in any one of [Aspect A1] to [Aspect A3], or a salt thereof, wherein Z is a maleimido group (Formula (v)), an α-halomethylcarbonyl group (Formula (vi)), a carboxyl group or an active ester of a carboxyl group. [Aspect B1] The conjugate precursor (I) as described in any one of [Aspect A1] to [Aspect A4], or a salt thereof, wherein G is a group represented by formula (i), formula (ii) or formula (iii). [Aspect B2] The conjugate precursor (I) as described in any one of [Aspect A1] to [Aspect A4] and [Aspect B1], or a salt thereof, wherein G is a group represented by formula (i). [Aspect C1] The conjugate precursor (I) as described in any one of [Aspect A1] to [Aspect A4], [Aspect B1] and [Aspect B2], or a salt thereof, Where L 1 , L 2 and L 3 each independently is an optionally substituted alkylene group; One or more methylene groups in the chain of the alkylene group are optionally replaced by one or more divalent groups independently selected from the group consisting of: -C(R 1 )(R 2 )-;-O-;-N(R 3 )-;-N(R 3 )-N(R 3 )-;-S-;-Se-;-Si(R 4 )(R 5 )-;-SS-;-Se-Se-;-SOm-;-SeOn-;-C(=C(R 6 )(R 7 ))-;-C(=O)-;-C(=S)-;-C(=N(R 8 ))-;-C(=N-OR 9 )-;-C(=NN(R 10 )(R 11 ))-;-P(=O)(R 12 )-;-P(=O)(OR 13 )-;-OP(=O)(R 12 )-O-;-OP(=O)(OR 13 )-O-;-C(R 14 )=;=C(R 14 )-;-C(R 14 )=C(R14 )-;-N=;=N-;-C≡C-;-(OC(R 1 )(R 2 )-C(R 1 )(R 2 )) 1-30 -;-(C(R 1 )(R 2 )-C(R 1 )(R 2 )-0) 1-30 -; an optionally substituted alkenylene group, an optionally substituted alkynylene group, and an optionally substituted cycloalkylene group; an optionally substituted cycloalkenylene group; an optionally substituted arylene group; an optionally substituted heteroarylene group; and an optionally substituted heterocyclylene group, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 and R 14 are each independently a group selected from the group consisting of a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkenyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, and an optionally substituted heterocyclyl group, and when R 3 When is an alkyl group, the alkyl group is optionally combined with an alkyl group in an adjacent methylene group to form a cyclic structure, and m and n are each independently an integer from 0 to 2. [Aspect C2] The conjugate precursor (I) as described in [Aspect C1], or a salt thereof, wherein L 1 , L 2 and L 3 are each independently an optionally substituted alkylene group; and One or more methylene groups in the chain of the alkylene group are substituted by one or more divalent groups, the one or more divalent groups being independently selected from the following formula group, Formula Group -C(R 1 )(alkyl)-; -C(R 14 )=; -O-; -N(R 3 )-; -N=; -N(R 3 )-C(R 1 )(R 2 )-(where R 3 With R 1 or R 2 When it is an alkyl group, R 3 With R 1 or R 2 optionally combined to form a ring structure); -N(R 3 )-C(R 1 )(R 2 )-C(=O)-(wherein, when R 3 With R 1 or R 2 When it is an alkyl group, R 3 With R 1 or R 2 optionally combined to form a ring structure); -OC(R 1 )(R 2 )-; -SC(R 1 )(R 2 )-; -N(R 3 )-N(R 3 )-; -N(R 3 )-OC(R 1 )(R 2 )-; -S-; -Si(R 4 )(R 5 )-; -SS-; -SOm-; -C(=O)-; -C(R 1 )(R 2 )-C(=O)-; -C(=C(R 6 )(R 7 ))-; -C(=N(R 8 ))-; -C(=N-OR 9 )-; -C(=NN(R 10 )(R 11 ))-; -P(=O)(R 12 )-; -P(=O)(R 12 )-O-; -O-P(=O)(R 12 )-O-; -P(=O)(OR 13 )-O-; -P(=O)(OR 13 )-N(R 3 )-; -O-P(=O)(OR 13 )-O-; -C(R 14 )=C(R 14 )-; -C(R 14 )=C(R 14 )-P(=O)(OR 13 )-N(R 3 )-; -C(R 14 )=N-; -C(R 14 )=N-N(R 3 )-; -C≡C-; -O-C(R 1 )(R 2 )-C(R 1 )(R 2 )-; -O-C(R 1 )(R 2 )-C(R 1 )(R 2 )-O-; -(O-C(R 1 )(R 2 )-C(R 1 )(R 2 )) 2-30 -; -C(=O)-O-; -C(=O)-S-; -C(=O)-N(R 3 )-; -C(=O)-N(R 3 )-O-; -C(=O)-N(R 3 )-C(R 1 )(R 2 )(wherein, when R 3 and R 1 or R2 When it is an alkyl group, R 3 With R 1 or R 2 optionally combined to form a ring structure); -C(=S)-O-; -C(=S)-S-; -OC(=O)-O-; -OC(=O)-N(R 3 )-; -SC(=O)-N(R 3 )-; -N(R 3 )-C(=O)-N(R 3 )-; an optionally substituted arylene group; optionally substituted heteroarylene groups; and Optionally substituted heterocyclylene groups. [Aspect C3] The conjugate precursor (I) as described in [Aspect C1], or a salt thereof, wherein L 1 , L 2 and L 3 are each independently an optionally substituted alkylene group; and One or more methylene groups in the chain of the alkylene group are substituted by one or more divalent groups, the one or more divalent groups being independently selected from the following formula group, Formula Group -C(H or C 1- C 4 Alkyl)=; -O-; N(H or C 1- C 4 alkyl)-; -N=; -S-; -C(=O)-; -O-Si(CH 3 )(CH 3 )-O-; -CH 2 -C(=O)-; -C(=O)-NH-; -C(=O)-O-; -C(=O)-S-; -OC(=O)-O-; -N(H or C 1- C 4 alkyl)-C(═O)-O-; -NH-NH-; -N(H or C 1- C 4 Alkyl)-O-CH 2 -; -C(=O)-(CH 2 ) 1-20 -C(=O)-; -C(=O)-(CH 2 ) 1-10 -O-(CH 2 ) 1-10 -C(=O)-; -C(=O)-CH 2 -(O-CH 2 CH 2 ) 1-20 -O-CH 2 -C(=O)-; -(O-CH 2 CH 2 ) 1-20 -; -C(=O)-N(H or C 1- C 4 Alkyl)-CH 2 CH 2 -N(H or H or C 1- C 4 alkyl)-C(═O)-; [C42] [where * is the point of attachment to the adjacent group]; -C(=O)-N(H or H or C 1- C 4 Alkyl)-CH 2 -; -P(=O)(OH)-O-; -OP(=O)(OH)-O-; -OP(=O)(OH)-OP(=O)(OH)-O-; -OP(=O)(OH)-OP(=O)(OH)-OP(=O)(OH)-O-; -CH(CH 2 -NH 2 )-; -CH(CH 2 -NH-C(=O)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-)1-20 -CH 3 )-; -CH(CH 2 -NH-C(=O)-(CH 2 ) 0-20 -lactone)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -CH 2 -lactone)-; -CH(CH 2 -NH-C(=O)-(CH 2 ) 1-20 -phosphoryl)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -CH 2 -phosphoryl)-; -CH(CH 2 -NH-(CH 2 ) 1-20 -phosphoryl)-; -(cis)-CH=CH-P(=O)(O-CH 2 CH 3 or O-CH 2 CH 2 -OH)-NH-(phenylene)-C(=O)-; -C(=O)-(cyclohexylene)-; -(succinimidyl)-; -Gly-; -Ala-; -Val-; -Leu-; -Ile-; -Phe-; -Ser-; -Cys-; -Asp-; -Glu-; -Orn-; -Lys-; -Cit-; -Arg-; -His-; -Pro-; -GlyGly-; -PheLys-; -ValLys-; -ValCit-; -ValAla-; -AspValCit-; -GluValCit-; -LysValCit-; -SerValCit-; -AspValAla-; -GluValAla-; -LysValAla-; -SerValAla-; -GlyGlyPheGly-; -AspGlyGlyPheGly-; -GluGlyGlyPheGly-; -LysGlyGlyPheGly-; -SerGlyGlyPheGly-; -AspAspAspAspAsp- (Among the amino acid residues and the amino acid residues in the peptide, One or more carboxyl groups in one or more side chains of Asp and Glu may be converted into lactone esters, lactone alkyl esters or phosphoryl alkyl esters, or may be converted into unsubstituted amides, monoalkyl amides or dialkyl amides, and the amino group in the amide portion may have one or more lactone groups, one or more lactone alkyl groups or phosphoryl alkyl groups as one or more substituents, One or more amino groups in one or more side chains of Lys and Orn may have, as one or more substituents, one or more lactone groups, one or more lactone alkyl groups, one or more lactone carbonyl groups, one or more lactone alkylcarbonyl groups, one or more phosphoryl groups, one or more phosphoryl alkyl groups or one or more phosphoryl alkylcarbonyl groups, and The hydroxyl group in the side chain of Ser and the thiol group in the side chain of Cys may optionally have as one or more substituents one or more lactone groups, one or more lactone alkyl groups, one or more lactone carbonyl groups, one or more lactone alkylcarbonyl groups, one or more phosphoryl groups, one or more phosphoryl alkyl groups or one or more phosphoryl alkylcarbonyl groups); -N(H or C 1 -C 4 alkyl)-(optionally substituted phenylene)-CH2 -OC(=O)-; -O-(optionally substituted phenylene)-CH 2 -OC(=O)-; -N(H or C1-C4 alkyl)-(optionally substituted pyridinylene)-CH 2 -OC(=O)-; [C43] [C44] [C45] [C46] as well as [C47] [In this formula, * is the point of attachment to the adjacent group]. [Aspect C4] The conjugate precursor (I) as described in [Aspect C1], or a salt thereof, wherein L 1 , L 2 and L 3 are each independently an optionally substituted alkylene group; and One or more methylene groups in the chain of the alkylene group are substituted by one or more divalent groups, the one or more divalent groups being independently selected from the following formula group, Formula Group -CH 2 -N(CH 3 )-CH 2 -; -CH 2 -C(=O)-; -C(=O)-NH-CH 2 -; -C(=O)-(CH 2 ) 1-10 -(O-CH 2 CH 2 ) 1-20 -O-(CH 2 ) 1-10 -C(=O)-; -C(=O)-(CH 2 ) 1-10 -(O-CH 2 CH 2 ) 1-20 -O-(CH2 ) 1-10 -CH 2 -NH-; -NH-CH 2 -(CH 2 ) 1-10 -(O-CH 2 CH 2 ) 1-20 -O-(CH 2 ) 1-10 -CH 2 -NH-; -C(=O)-N(CH 3 )-CH 2 CH 2 -N(CH 3 )-C(=O)-; [C48] [In this formula, * is the point of attachment to the adjacent group]; -P(=O)(OH)-O-; -OP(=O)(OH)-O-; -OP(=O)(OH)-OP(=O)(OH)-O-; -OP(=O)(OH)-OP(=O)(OH)-OP(=O)(OH)-O-; -CH(CH 2 -NH 2 )-; -CH(CH 2 -NH(CH 3 ))-; -CH(CH 2 -N(CH 3 ) 2 )-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 0-20 -CH 3 )-; -CH(CH 2 -NH-C(=O)-(CH 2 ) 0-20 -lactone)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -(CH 2) 1-10 -CH 2 -lactone)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -(CH 2 ) 1-10 -CH 2 -NH-lactone)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -(CH 2 ) 1-10 -CH 2 -NH-C(=O)-lactone)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -(CH 2 ) 1-10 -C(=O)-NH-lactone)-; -CH(CH 2 -NH-(CH 2 ) 1-20 -(O) 0-1 -phosphoryl)-; -CH(CH 2 -NH-C(=O)-(CH 2 ) 1-20 -phosphoryl)-; -CH(CH 2 -NH-C(=O)-(CH 2 ) 1-20 -C(=O)-NH-(CH 2 ) 1-10 -phosphoryl)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -(CH 2 ) 1-10 -CH 2 -phosphoryl)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -(CH2 ) 1-10 -C(=O)-NH-(CH 2 ) 1-10 -phosphoryl)-; -CH(CH 2 -NH-C(=O)-(CH 2 CH 2 -O-) 1-20 -(CH 2 ) 1-10 -C(=O)-NH-(CH 2 ) 1-10 -C(H, OH, Cl, NH 2 or C 1 -C 4 Alkyl)(P(=O)(OH) 2 ) 2 )-; -(cis)-CH=CH-P(=O)(O-CH 2 CH 3 )-NH-(phenylene)-C(=O)-; -C(=O)-(cyclohexylene)-; -(succinimidyl)-; -Ser-; -Cys-; -Asp-; -Glu-; -Orn-; -Lys-; -ValLys-; -ValCit-; -ValAla-; -GlyGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -PheLys-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -ValLys-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -ValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -ValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -AspValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -GluValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -LysValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -SerValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -AspValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -GluValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -LysValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -SerValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -GlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -AspGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -GluGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -LysGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -SerGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -AspAspAspAspAsp-C(=O)-NH-(optionally substituted phenylene)-CH 2 -; -GlyGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -PheLys-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -ValLys-C(=O)-NH-(optionally substituted phenylene)-CH2 -OC(=O)-; -ValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -ValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -AspValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -GluValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -LysValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -SerValCit-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -AspValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -GluValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -LysValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -SerValAla-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -GlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -AspGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -GluGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -LysGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2-OC(=O)-; -SerGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -AspAspAspAspAsp-C(=O)-NH-(optionally substituted phenylene)-CH 2 -OC(=O)-; -GlyGlyPheGly-C(=O)-NH-CH 2 -; -AspGlyGlyPheGly-C(=O)-NH-CH 2 - (Among the amino acid residues and the amino acid residues in the peptide, One or more carboxyl groups in one or more side chains of Asp and Glu are converted into O-(lactonyl)esters, O-(lactonylalkyl)esters, O-(phosphorylalkyl)esters, N-(lactonyl)amides, N-(lactonylalkyl)amides or N-(phosphorylalkyl)amides, One or more amino groups in one or more side chains of Lys and Orn have, as one or more substituents, one or more lactone groups, one or more lactone alkyl groups, one or more lactone carbonyl groups, one or more lactone alkylcarbonyl groups, one or more phosphoryl groups, one or more phosphoryl alkyl groups, or one or more phosphoryl alkylcarbonyl groups, and The hydroxyl group in the side chain of Ser and the thiol group in the side chain of Cys optionally have, as one or more substituents, one or more lactone groups, one or more lactone alkyl groups, one or more lactone carbonyl groups, one or more lactone alkylcarbonyl groups, one or more phosphoryl groups, one or more phosphoryl alkyl groups or one or more phosphoryl alkylcarbonyl groups); [C49] [C50] [C51] [C52] as well as [C53] [In this formula, * is the point of attachment to the adjacent group]. [Aspect D1] The conjugate precursor (I) as described in any one of [Aspect A1] to [Aspect A4], [Aspect B1], [Aspect B2] and [Aspect C1] to [Aspect C4], or a salt thereof, wherein D 1 and D 2 is a residue of an antitumor drug molecule independently selected from the group consisting of: camptothecin; MMAE; maytansine; PBD (parabenzodiazepine ) dimer; eribulin; 5-FU; PD-318088; AS-703026; TAK-733; LY-3023414; calicheamicin; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; Aplysia 10; superdox; ciprofloxacin; and caderfloxacin hydrochloride (CS-940); or its analogs or derivatives; or derivatives of said analogs. [Aspect D2] The conjugate precursor (I) as described in any one of [Aspect A1] to [Aspect A4], [Aspect B1], [Aspect B2], [Aspect C1] to [Aspect C4] and [Aspect D1], or a salt thereof, wherein D 1 and D 2 is a residue of an antitumor drug molecule independently selected from the group consisting of: camptothecin; MMAE; maytansine; PBD (parabenzodiazepine ) dimer; eribulin; 5-FU; PD-318088; AS-703026; TAK-733; LY-3023414; calicheamicin; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; Aplysia 10; and superdox; or an analog or derivative thereof; or a derivative of said analog. [Aspect D3] The conjugate precursor (I) of any one of [Aspect A1] to [Aspect A4], [Aspect B1], [Aspect B2], [Aspect C1] to [Aspect C4], [Aspect D1] and [Aspect D2], or a salt thereof, wherein D 1 and D 2 is a residue of an antitumor drug molecule independently selected from the group consisting of: camptothecin; MMAE; maytansine; PBD (parabenzodiazepine ) dimer; and eribulin; or an analog or derivative thereof; or a derivative of said analog. [Aspect D4] The conjugate precursor (I) as described in any one of [Aspect A1] to [Aspect A4], [Aspect B1], [Aspect B2], [Aspect C1] to [Aspect C4] and [Aspect D1] to [Aspect D3], or a salt thereof, wherein D1 and D 2 is the residue of: the same antitumor drug or an analog or derivative of these antitumor drugs; or a derivative of the analog. [Aspect D5] The conjugate precursor (I) as described in any one of [Aspect A1] to [Aspect A4], [Aspect B1], [Aspect B2], [Aspect C1] to [Aspect C4] and [Aspect D1] to [Aspect D3], or a salt thereof, wherein D 1 and D 2 is the residue of: a different anti-tumor drug or an analog or derivative thereof; or a derivative of the analog. [Aspect D6] The conjugate precursor (I) as described in any one of [Aspect A1] to [Aspect A4], [Aspect B1], [Aspect B2], [Aspect C1] to [Aspect C4] and [Aspect D1] to [Aspect D3], or a salt thereof, wherein D 1 and D 2 At least one of the residues is “an anti-tumor drug or an analog of the anti-tumor drug, the anti-tumor drug having a hydroxyl group in the molecule and at least one hydroxyl group of which is phosphorylated; or a derivative of the analog”. [Aspect E1] A conjugate precursor (I) as described in any one of [Aspect A1] to [Aspect A4], [Aspect B1], [Aspect B2], [Aspect C1] to [Aspect C4] and [Aspect D1] to [Aspect D6], or a salt thereof, wherein one or more lactone groups and one or more phosphoryl groups are independently present as substituents or protecting groups at any position of the anti-tumor drug residues or the linker portions, the total number of the lactone groups is 1 to 10, and when the number of the lactone groups is two or more, the lactone groups may be the same as or different from each other, and the total number of the phosphoryl groups is 1 to 10. [Aspect E2] A conjugate precursor (I) as described in any one of [Aspect A1] to [Aspect A4], [Aspect B1], [Aspect B2], [Aspect C1] to [Aspect C4] and [Aspect D1] to [Aspect D6], or a salt thereof, wherein one or more lactone groups and one or more phosphoryl groups are independently present as substituents or protecting groups at any position of the anti-tumor drug residues or the linker portions, the total number of the lactone groups is 1 to 8, and when the number of the lactone groups is two or more, the lactone groups may be the same as or different from each other, and the total number of the phosphoryl groups is 1 to 4. [Aspect E3] The conjugate precursor (I) as described in any one of [Aspect A1] to [Aspect A4], [Aspect B1], [Aspect B2], [Aspect C1] to [Aspect C4], [Aspect D1] to [Aspect D6], [Aspect E1] and [Aspect E2], or a salt thereof, wherein one or more lactone groups and one or more phosphoryl groups are independently present as substituents or protecting groups at any position of the anti-tumor drug residues or the linker moieties, and In addition to the above, when there are one or more independently selected from lactone groups; phosphoryl groups; phosphoryl alkyl carbonyl groups (-C (= O) -alkylene -P (= O) (OH) at any one or more positions of these anti-tumor drug residues or these linker moieties, 2 ); a dialkylamino group; and a group of a cyclic amino group which forms a ring together with the dialkyl group and when there are a plurality of such groups in total, these groups may be the same as or different from each other. [Aspect F1] A conjugate precursor synthetic intermediate (II-1), or a salt thereof, wherein, in the following general formula (II-1): [C54] G 1 is a group selected from the formula as described in [Aspect B1] or [Aspect B2] above. [Aspect F2] The conjugate precursor synthetic intermediate (II-1) as described in [Aspect F1], or a salt thereof, wherein L 1-1 , L 2-1 and L 3-1 are each independently an optionally substituted alkylene group; and One or more methylene groups in the chain of the alkylene group are each independently substituted with one or more groups selected from the divalent groups described in [Aspect C1] to [Aspect C4] above. [Aspect G1] The conjugate precursor synthetic intermediate (II-1) as described in [Aspect F1] or [Aspect F2], or a salt thereof, wherein Z 1 is a bonding group, which is a hydroxyl group, a nitro group, a cyano group, an amide group, an oxo group, an azide group, an amino group, a monoalkylamino group which may have a substituent, an imino group (also including -N= and the imino group of a cyclic amine), a carboxyl group, a phosphoryl group, an alkynyl group, a cycloalkynyl group or a thiol group; or a protective body thereof. [Aspect G2] The conjugate precursor synthetic intermediate (II-1) as described in any one of [Aspect F1], [Aspect F2] and [Aspect G1], or a salt thereof, wherein Z 1 is a bonding group, which is a hydroxyl group, a nitro group, a cyano group, an oxo group, an azide group, an amino group, a monoalkylamino group which may have a substituent, an imino group (also including -N= and the imino group of a cyclic amine), a carboxyl group, a phosphoryl group, an alkynyl group, a cycloalkynyl group or a thiol group; or a protective body thereof. [Aspect G3] The conjugate precursor synthetic intermediate (II-1) as described in any one of [Aspect F1], [Aspect F2], [Aspect G1] and [Aspect G2], or a salt thereof, wherein Z 1 is a bonding group, which is a hydroxyl group, a nitro group, an oxo group, an azide group, an amino group, a monoalkylamino group which may have a substituent, an imino group (also including -N= and the imino group of a cyclic amine), a carboxyl group, a phosphoryl group, an alkynyl group, a cycloalkynyl group or a thiol group; or a protective body thereof. [Aspect G4] The conjugate precursor synthetic intermediate (II-1) as described in any one of [Aspect F1], [Aspect F2] and [Aspect G1] to [Aspect G3], or a salt thereof, wherein Z 1 is a bonding group, which is a hydroxyl group, a nitro group, an oxo group, an azide group, an amino group, a monoalkylamino group which may have a substituent, an imino group (also including -N= and the imino group of a cyclic amine), a carboxyl group, a phosphoryl group, an alkynyl group or a cycloalkynyl group; or a protective body thereof. [Aspect H1] The conjugate precursor synthetic intermediate (II-1) as described in any one of [Aspect F1], [Aspect F2] and [Aspect G1] to [Aspect G4], or a salt thereof, wherein Z 1 is a group selected from the bonding groups described in [Aspect G1] to [Aspect G4] above, and D 1-1 or D 2-1 Any one of them is a group selected from the antitumor drug residues described in [Aspect D1] to [Aspect D6] above, and the other is a group selected from the bonding groups described in [Aspect G1] to [Aspect G4] above. [Aspect H2] The conjugate precursor synthetic intermediate (II-1) as described in any one of [Aspect F1], [Aspect F2] and [Aspect G1] to [Aspect G4], or a salt thereof, wherein Z 1 is a group selected from the bonding groups described in [Aspect G1] to [Aspect G4] above, and D1-1 and D 2-1 Both are independently selected from the group of anti-tumor drug residues as described in [Aspect D1] to [Aspect D6] above. [Aspect H3] The conjugate precursor synthetic intermediate (II-1) as described in any one of [Aspect F1], [Aspect F2] and [Aspect G1] to [Aspect G4], or a salt thereof, wherein Z 1 , D 1-1 and D 2-1 All are each independently a group selected from the bonding groups described in [Aspect G1] to [Aspect G4] above. [Aspect H4] The conjugate precursor synthetic intermediate (II-1) as described in any one of [Aspect F1], [Aspect F2] and [Aspect G1] to [Aspect G4], or a salt thereof, wherein Z 1 is a reactive group as defined above in [Aspect A1], and D 1-1 or D 2-1 Any one of them is a group selected from the antitumor drug residues described in [Aspect D1] to [Aspect D6] above, and the other is a group selected from the bonding groups described in [Aspect G1] to [Aspect G4] above. [Aspect H5] The conjugate precursor synthetic intermediate (II-1) as described in any one of [Aspect F1], [Aspect F2] and [Aspect G1] to [Aspect G4], or a salt thereof, wherein Z 1 is a reactive group as defined above in [Aspect A1], and D 1-1 and D 2-1 Both are each independently a group selected from the bonding groups described in [Aspect G1] to [Aspect G4] above. [Aspect I1] The conjugate precursor intermediate (II-1) as described in any one of [Aspect F1], [Aspect F2], [Aspect G1] to [Aspect G4] and [Aspect H1] to [Aspect H5], or a salt thereof, wherein when there is one or more independently selected from a lactone group; a phosphoryl group; a phosphorylalkylcarbonyl group (-C(=O)-alkylene-P(=O)(OH) at any one or more positions of the anti-tumor drug residues or the linker moieties, 2 ); a dialkylamino group; and a group of a cyclic amino group which forms a ring together with the dialkyl group and when there are a plurality of such groups in total, these groups may be the same as or different from each other. [Aspect I2] A conjugate precursor intermediate (II-1) as described in any one of [Aspect F1], [Aspect F2], [Aspect G1] to [Aspect G4], [Aspect H1] to [Aspect H5] and [Aspect I1], or a salt thereof, wherein one or more lactone groups and one or more phosphoryl groups are independently present as substituents or protecting groups at any position of these anti-tumor drug residues or these linker portions, the total number of the lactone groups is 1 to 8, when the number of these lactone groups is two or more, these lactone groups may be the same as or different from each other, and the total number of the phosphoryl groups is 1 to 4. [Aspect I3] The conjugate precursor intermediate (II-1) as described in any one of [Aspect F1], [Aspect F2], [Aspect G1] to [Aspect G4], [Aspect H1] to [Aspect H5], [Aspect I1] and [Aspect I2], or a salt thereof, wherein one or more lactone groups and one or more phosphoryl groups are independently present as substituents or protecting groups at any position of the anti-tumor drug residues or the linker moieties, and In addition to the above, when there are one or more independently selected from lactone groups; phosphoryl groups; phosphoryl alkyl carbonyl groups (-C (= O) -alkylene -P (= O) (OH) at any one or more positions of these anti-tumor drug residues or these linker moieties, 2 ); a dialkylamino group; and a group of a cyclic amino group which forms a ring together with the dialkyl group and when there are a plurality of such groups in total, these groups may be the same as or different from each other. [Aspect J1] A conjugate precursor intermediate (II-2), which is represented by the following general formula (II-2): [C55] [In this formula, L 1-1 and L 2-1 are each independently an optionally substituted alkylene group, and one or more methylene groups in the chain of the alkylene group are each independently substituted by one or more groups selected from the divalent groups described in any one of [Aspect C1] to [Aspect C4], D 1-1 and D 2-1 is a group selected from the antitumor drug residues described in [Aspect D1] to [Aspect D6] above or a group selected from the bonding groups described in [Aspect G1] to [Aspect G4], and these D 1-1 and D 2-1 can be the same or different from each other, when the L 1-1 and L 2-1or any one or more positions of the anti-tumor drug residues contain one or more independently selected from lactone groups; phosphoryl groups (-P(=O)(OH) 2 ); phosphorylalkylcarbonyl group (-C(=O)-alkylene-P(=O)(OH) 2 ); a dialkylamino group; and a group of a cyclic amino group that forms a ring together with the dialkyl group, and when there are a plurality of such groups in total, these groups may be the same as or different from each other, and R 17 is a hydrogen atom or a protecting group], or a salt thereof.

[0011] In the above divalent groups, if L of the general formula (I) and (II) 1 , L 2 , L 3 , L 1-1 , L 2-1 and L 3-1 The divalent group may face the left, right, top or bottom direction of the paper surface. 3 )-C(R 1 )(R 2 )-as L 1 When part of -N(R 3 )- can be located on the B side, and -C(R 1 )(R 2 )- can be located on the D side, or -C(R 1 )(R 2 )-can be located on the B side and-N(R 3 )-can be located on the D side.

[0012] In addition, the "three-letter alphabet" is a symbol representing the following amino acids, and in particular, in the present specification, it represents the divalent residue (-NH-CH(R 15 )-C(=O)-). In the formula, R 15 is a hydrogen atom (Gly), a methyl group (Ala), an isopropyl group (Val), an isobutyl group (Leu), a (butyl-2-yl) group (Ile), a phenylmethyl group (Phe), a hydroxymethyl group (Ser), a mercaptomethyl group (Cys), a carboxymethyl group (Asp), a 2-carboxyethyl group (Glu), a 3-aminopropyl group (Orn), a 4-aminobutyl group (Lys), a 3-(ureido)propyl group (Cit), a 3-guanidinopropyl group (Arg), or a (1H-imidazol-4-yl)methyl group (His) (wherein each amino acid in brackets represents a corresponding amino acid). In addition, in the above formula (-NH-CH(R 15 )-C(=O)-), when R 15When it is a propyl group and the propyl group combines with the nitrogen atom of "-NH-" in the formula to form a 5-membered ring, a cyclic amino acid (Pro; proline) is formed. Gly; glycine Ala; Alanine Val; valine Leu; leucine Ile; isoleucine Phe; phenylalanine Ser; serine Cys: Cysteine Asp; Aspartic acid Glu; glutamate Orn; Ornithine Lys; lysine Citrulline Arg; Arginine His; Histidine Pro; Proline When the "linker part" or "anti-tumor drug residue" of the conjugate precursor represented by the general formula (I) of the present invention and the conjugate precursor synthetic intermediate represented by the general formulas (II-1) and (II-2) of the present invention includes one or more amino acid residues having one or more asymmetric centers and can produce one or more optical isomers, both D-type and L-type optical isomers are encompassed by the present invention.

[0013] [Aspect K1] A precursor of an antibody-drug conjugate (ADC) containing an antibody and a drug, or a salt thereof, wherein The ADC is one in which the antibody is linked to the drug directly or indirectly via a linker, The precursor has a linker and a drug (eg, an anti-tumor drug molecule, an analog or derivative thereof, and a derivative of the analog), and The linker has a reactive group (the reactive group is the connecting part to the antibody), which can react with a functional group (e.g., a thiol group) in the antibody, and is modified with a solubilizing group, which is, for example, a group selected from the group consisting of a lactone group, an optionally substituted C 1 -C 6 Aminoalkyl groups and phosphoryl groups (particularly solubilizing groups). [Aspect K2] The precursor or a salt thereof as described in [Aspect K1], Wherein the linker is modified with a lactone group and a phosphoryl group. [Aspect K3] The precursor or salt thereof as described in [Aspect K1] or [Aspect K2], wherein the joint is a branch joint, and The branched joint has at least one branch, at least a first joint portion (L 1 )、The second joint part (L 2 ) and the third joint portion L 3 ), the third linker is inserted between the antibody and the branch, The first linker portion and the second linker portion are each connected to the branch via a covalent bond at one end, and are each connected to the first anti-tumor drug molecule or its analog or derivative; the derivative of the analog and the second anti-tumor drug molecule or its analog or derivative; or the derivative of the analog via a covalent bond at the other end, {Here, the first linker moiety and the second linker moiety are the same as or different from each other, and the first anti-tumor drug molecule and the second anti-tumor drug molecule are the same as or different from each other}. [Aspect K4] The precursor or a salt thereof as described in any one of [Aspect K1] to [Aspect K3], Wherein the first linker moiety, the second linker moiety and the third linker moiety each contain a polyalkylene glycol (preferably, polyethylene glycol) block. [Aspect K5] The precursor or a salt thereof according to any one of [Aspect K1] to [Aspect K4] Wherein the third linker portion is modified with a lactone group and / or a phosphoryl group. [Aspect K6] The precursor or a salt thereof as described in any one of [Aspect K1] to [Aspect K5], Wherein one or both of the first linker moiety and the second linker moiety are modified with a lactone group and / or a phosphoryl group. [Aspect K7] The precursor or a salt thereof as described in any one of [Aspect K1] to [Aspect K5], Wherein the first linker moiety and the second linker moiety are modified with a lactone group and a phosphoryl group. [Aspect K8] The precursor or a salt thereof as described in any one of [Aspect K1] to [Aspect K7], The first linker part or the second linker part and the anti-tumor drug molecule or its analog or derivative; or the derivative of the analog is covalently linked through -OP(=O)(OH)-O-. [Aspect K9] The precursor or a salt thereof according to any one of [Aspect K1] to [Aspect K8] The first linker part and the second linker part and the anti-tumor drug molecule, its analog or derivative thereof bound thereto; or the derivative of the analog is covalently linked via -OP(=O)(OH)-O-. [Aspect K10] The precursor or salt thereof as described in [Aspect K8] or [Aspect K9], The anti-tumor drug molecule or its analog or derivative; or the derivative of the analog has a secondary amine, and the secondary amine is covalently linked to the second linker part via -OP(=O)(OH)-O-. [Aspect K11] The precursor or a salt thereof as described in any one of [Aspect K1] to [Aspect K10], Wherein the second linker portion and the third linker portion have oligopeptide portions that are cleaved in the tumor tissue. [Aspect K12] The precursor or a salt thereof as described in [Aspect K11], The oligopeptide portion contains a valine-citrulline (Val-Cit) dipeptide. [Aspect K13] The precursor or a salt thereof as described in any one of [Aspect K1] to [Aspect K12], wherein one, two or all of the group consisting of the first linker moiety, the second linker moiety and the third linker moiety contain a polyalkylene glycol block (preferably a polyethylene glycol block), The second linker moiety and the third linker moiety contain a valine-citrulline (Val-Cit) dipeptide, and One, two or all selected from the group consisting of the first linker moiety, the second linker moiety and the third linker moiety are modified with a phosphoryl group and / or a lactone group. [Aspect K14] The precursor or a salt thereof as described in any one of [Aspect K1] to [Aspect K13], The anti-tumor drug molecule is modified by a phosphoryl group or a phosphate group, or has a phosphoryl group or a phosphate group. [Aspect K15] The precursor or salt thereof as described in any one of [Aspect K1] to [Aspect K14], when linked to the same antibody, exhibits superior long-term blood retention compared to the precursor with MC-Val-Cit-PAB-MMAE. [Aspect K16] The precursor or salt thereof as described in any one of the above items, wherein when linked to the antibody, the blood concentration 3 days after administration is 10% or more higher than the blood concentration 5 minutes after administration. [Aspect K17] The precursor or salt thereof as described in any one of the above items, wherein when linked to the antibody, the blood concentration 3 days after administration is 20% or more higher than the blood concentration 5 minutes after administration. [Aspect K18] The precursor or salt thereof as described in any one of the above items, wherein when linked to the antibody, the blood concentration 3 days after administration is 25% or more higher than the blood concentration 5 minutes after administration. [Aspect K19] The precursor or salt thereof as described in any one of the above items, wherein when linked to the antibody, the blood concentration 3 days after administration is 30% or more higher than the blood concentration 5 minutes after administration. [Aspect K20] The precursor or salt thereof as described in any one of the above items, wherein when linked to the antibody, the blood concentration 3 days after administration is 14% or more higher than the blood concentration 5 minutes after administration. [Aspect K21] The precursor or salt thereof as described in any one of the above items, wherein the linker comprises a linking portion to an antibody, a polyethylene glycol portion, a cleavable portion, a portion linking the cleavable portion to a drug portion, and a drug. [Aspect K22] The precursor or salt thereof as described in any one of the above items, wherein the linking portion to the antibody contains a maleimido group. [Aspect K23] The precursor or salt thereof as described in any one of the above items, wherein the polyethylene glycol portion contains 3 to 20 (preferably 3 to 10, such as 3 to 6) ethylene glycol units. [Aspect K24] The precursor or salt thereof as described in any one of the above items, wherein the cleavable portion contains a valine-citrulline dipeptide. [Aspect K25] A precursor or a salt thereof as described in any one of the above items, wherein the linking portion to the antibody contains a maleimido group, The polyethylene glycol block contains 3 to 20 (preferably 3 to 10, such as 3 to 6) ethylene glycol units, and The cleavable moiety contains a valine-citrulline dipeptide. [Aspect K26] The precursor or salt thereof as described in any one of the above items, wherein the linking portion to the antibody has an additional solubilizing group. [Aspect K27] The precursor or salt thereof as described in any one of the above items, wherein the cleavable part has a solubilizing group in the side chain. [Aspect K28] The precursor or salt thereof as described in any one of the above items, wherein the part linking the cleavable part to the drug has an additional solubilizing group. [Aspect K29] A precursor or salt thereof as described in any one of the above items, wherein the drug moiety has an additional solubilizing group. [Aspect K30] The precursor or a salt thereof as described in [Aspect K26] above, wherein the additional solubilizing group is a group having a phosphonic acid in a side chain. [Aspect K31] The precursor or a salt thereof as described in [Aspect K27] above, wherein the solubilizing group is an amino group, a phosphonic acid or a lactone group. [Aspect K32] A precursor or a salt thereof as described in [Aspect K28] above, wherein the additional solubilizing group is a phosphate ester (including a phosphodiester). [Aspect K33] Use of the various moieties specified in [Aspect K21] to [Aspect K32] above (particularly the moiety having a solubilizing group) in the production of a precursor or a salt thereof as described in any one of the above items.

[0014] [Aspect L1] A compound having the above formula (I), or a salt thereof, wherein the formula has 1 and D 2 R 18 and R 19 , and R 18 and R 19 are independently a hydrogen atom, a protecting group or a bonding group {each group in the formula is as defined above}. [Aspect L2] A compound having the above formula (II-1), or a salt thereof, wherein the formula has 1-1 and D 2-1 R 18 and R 19 , and R 18 and R 19 are independently a hydrogen atom, a protecting group or a bonding group {each group in the formula is as defined above}. [Aspect L3] A compound having the above formula (II-2), or a salt thereof, wherein the formula has 1-1 and D 2-1 R18 and R 19 , and R 18 and R 19 are independently a hydrogen atom, a protecting group or a bonding group {each group in the formula is as defined above}. [Aspect L4] A method for producing an antibody-drug conjugate (ADC) comprising an antibody and a drug, the method comprising: The compound or a salt thereof as described in any one of [Aspect L1] to [Aspect L3] is reacted with an antibody and an anti-tumor drug molecule, an analog or derivative thereof, and a derivative of the analog to obtain ADC. [Beneficial effects of the present invention]

[0015] The antibody-multi-drug conjugate obtained by reacting the conjugate precursor of the present invention (e.g., precursor (I)) or a salt thereof with an antibody has high stability in the blood compared to the antibody-multi-drug conjugate without the modification, and is therefore expected to exhibit a sustained anti-tumor effect, which is preferred. The antibody-multi-drug conjugate obtained by reacting the conjugate of the present invention (e.g., precursor (I)) or a salt thereof with an antibody can be used as a cancer therapeutic agent having superior anti-tumor effect and safety by being selectively delivered to target tumor cells after administration to a living body to release anti-tumor drugs in the cells. [Drawings]

[0016] [ Figure 1 ] Figure 1 The anti-tumor effect of AMDC (1 mg / kg body weight) of AMDC Production Example 2 is shown. [ Figure 2 ] Figure 2 The anti-tumor effect of AMDC (1 mg / kg body weight) of AMDC Production Example 3 is shown. [ Figure 3 ] Figure 3 The anti-tumor effect of AMDC (1 mg / kg body weight) of AMDC Production Example 4 is shown. [ Figure 4 ] Figure 4 The anti-tumor effect of AMDC (1 mg / kg body weight) of AMDC Production Example 5 is shown. [ Figure 5 ] Figure 5 The anti-tumor effect of AMDC (1 mg / kg body weight) of AMDC Production Example 6 is shown. [ Figure 6 ] Figure 6 The anti-tumor effect of AMDC (3 mg / kg body weight) of AMDC Production Example 4 is shown. [ Figure 7] Figure 7 The anti-tumor effect of AMDC (3 mg / kg body weight) of AMDC Production Example 5 is shown. [ Figure 8 ] Figure 8 The SEC analysis HPLC profile of AMDC of AMDC Production Example 2 is shown. [Specific implementation method]

[0017] Hereinafter, the definitions of the terms used herein are described and each of them is specifically explained, but the present invention is not limited thereto. In addition, various compounds (antibodies and intermediates), drug molecules, substituents, protecting groups, etc. defined or explained below are optionally selected and combined to prepare the conjugate precursor (I) and conjugate precursor synthetic intermediates (II-1) and (II-2) of the present invention, or salts thereof.

[0018] Unless otherwise indicated, the following terms and phrases described herein have the following meanings. In addition, when trade names are used herein, unless otherwise indicated, these trade names include product formulations, generic drugs, and active pharmaceutical ingredients of these trade name products. In addition, terms mentioned in the singular do not exclude plural forms. In addition, the term "comprising" has both the meanings of "consisting of" and "containing".

[0019] As described herein, the term "antibody" refers to intact monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), modified antibodies, unmodified antibodies, unaltered antibodies, full-length antibodies, intact antibodies, and antibody fragments that exhibit desired biological activity (e.g., antigen-binding fragments of antibodies, particularly fragments thereof that exhibit the same binding characteristics as antibodies; however, antibody fragments have the required number of binding sites for the linker to which the drug is attached). Antibodies can bind to antigens expressed on the surface of tumor cells and internalize in the cells, in other words, the antibodies can target tumor cells. In the antibody-multi-drug conjugate (AMDC) produced by reacting the conjugate precursor (I) of the present invention with an antibody, since the antibody is bound to a cytotoxic agent (e.g., an anti-tumor active drug) via a linker and the mechanism is such that the anti-tumor drug is released from the AMDC in the cell after being delivered to the tumor cell as an AMDC, preferably, the antibody has one or more properties, including the property of being able to recognize tumor cells, the property of being able to specifically bind to tumor cells, the property of being able to be incorporated and internalized into tumor cells, and the property of being able to damage tumor cells. Natural antibody is a tetramer consisting of two pairs of identical immunoglobulin chains, each pair having a light chain and a heavy chain. In each pair, the light chain and heavy chain variable regions (VL and VH) are primarily responsible for antigen binding together. The light chain and heavy chain variable domains consist of three hypervariable regions called "complementary determining regions" or "CDRs" and a framework region interrupted by four hypervariable regions. The constant region can be recognized by the immune system and can interact with the immune system. Antibodies can belong to any type (e.g., IgG, IgE, IgM, IgD, IgY and IgA), category (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass, and particularly IgG1, IgG2, IgG3 and IgG4. Antibodies can be from any suitable species. In some aspects, antibodies are derived from humans or mice. Antibodies can be, for example, human antibodies, humanized antibodies or chimeric antibodies.

[0020] The term "monoclonal antibody" in this specification refers to an antibody obtained from a substantially homogeneous antibody population. That is, the individual antibodies contained in the population are identical except for a few naturally occurring mutations. Monoclonal antibodies are highly specific and are directed against a single antigen portion. The term "monoclonal" indicates the antibody property of "obtained from a substantially homogeneous antibody population" and does not mean that the antibody should be produced by any particular method.

[0021] "Complete antibodies" include antigen-binding variable regions, and light chain constant domains (CL) and heavy chain constant domains CH1, CH2, CH3 and CH4 that are appropriate for the antibody class. The constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variants thereof.

[0022] "Antibody fragments" include a portion of an intact antibody, including its antigen binding region or variable region. Antibody fragments may be any antigen binding fragment of an antibody, although there is no particular limitation, and examples thereof include Fab, Fab', F(ab') 2 To be used in the present invention, the antibody fragment must have a functional group (eg, a sulfhydryl group and an amino group) or a disulfide bond that can generate a sulfhydryl group by reduction so that it can be bound to a drug moiety via a linker. An "antigen" is a substance to which an antibody binds or specifically binds (eg, a cell surface antigen, particularly a cell surface protein, cell surface glycoprotein, or cell surface glycan).

[0023] "Specific binding" and "specifically bind" mean that the antibody or antibody derivative binds to the corresponding target antigen in a highly selective manner and does not bind to other abundant antigens. Typically, antibodies and antibody derivatives bind to the corresponding target antigen in a highly selective manner with a specificity of at least about 1×10 -7 M, and preferably 10 -8 Up to 10-9 M, 10 -10 M, 10 -11 M or 10 -12 The antibody binds to the predetermined antigen with an affinity that is at least twice as strong as that for a nonspecific antigen (e.g., bovine serum albumin (BSA), casein) other than the predetermined antigen or a closely related antigen.

[0024] In a particular embodiment, known antibodies for cancer therapy can be used. Immunospecific antibodies for cancer cell antigens are commercially available or can be produced by any method known to those skilled in the art (e.g., recombinant expression technology). The nucleotide sequence encoding the immunospecific antibodies for cancer cell antigens can be obtained, for example, from the GenBank database or similar databases or from literature or by conventional cloning and sequencing.

[0025] Examples of antibodies that can be used to treat cancer include, but are not limited to, humanized anti-HER2 monoclonal antibodies Herceptin (registered trademark) (trastuzumab; Genentech) (antibody used to treat patients with metastatic breast cancer); Rituxan (registered trademark) (rituximab; Genentech) (chimeric anti-CD20 monoclonal antibody used to treat patients with non-Hodgkin's lymphoma); OvaRex (AltaRex Corporation, Massachusetts) (mouse antibody / anti-MUC16 (CA125) antibody used to treat ovarian cancer); Panorex (Glaxo Wellcome Inc., North Carolina) (mouse antibody / anti-EPCAM antibody used to treat colorectal cancer); Cetuximab Erbitux (Imclone Systems, Inc.) =Inc., New York) (IgG chimeric antibody / anti-EGFR antibody for the treatment of epidermal growth factor-positive cancers (such as head and neck cancer)); Vitaxin (MedImmune, Inc., Maryland) (anti-integrin αvβ3 antibody for the treatment of breast cancer, lung cancer, etc.); Campath (Leukosite, Massachusetts) (anti-CD52 antibody for the treatment of chronic lymphocytic leukemia (CLL)); Smart M195 (Protein Design Labs, Inc., California) (humanized anti-CD33 IgG antibody for the treatment of acute myeloid leukemia (AML)); LymphoCide (Immunomedics, Inc., New Jersey) (humanized anti-CD22 IgG antibody for the treatment of non-Hodgkin's lymphoma); Smart ID10 (Protein Design Labs, Inc., Labs, Inc., California) (humanized anti-HLA-DR antibody for the treatment of non-Hodgkin's lymphoma); Oncolym (Techniclone, Inc.), (a radiolabeled murine anti-HLA-Dr10 antibody for the treatment of non-Hodgkin's lymphoma); Allomune (BioTransplant, California) (a humanized anti-CD2 mAb for the treatment of Hodgkin's disease and non-Hodgkin's lymphoma); Avastin (Genentech, California) (a humanized anti-VEGF antibody for the treatment of lung and colorectal cancer); Epratuzamab (ImmunoMedical, New Jersey and Amgen, California) (a humanized anti-CD22 antibody for the treatment of non-Hodgkin's lymphoma); Patritumab (Daiichi Sankyo Co., Ltd.) Co., Ltd.) (humanized anti-HER3 antibody for the treatment of lung cancer and breast cancer); and CEA-Cide (Labetuzumab ImmunoMedical, Inc., New Jersey) (humanized anti-CEA antibody for the treatment of colorectal cancer).

[0026] Examples of other antibodies that can be used to treat cancer include, but are not limited to, antibodies against the following antigens. Examples include testicular cancer antigens, such as MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, NY-ESO-1, PRAME, CT83, BAGE, XAGE, GAGE-1, and SSX2, differentiation antigens, such as gp100, Melan A, tyrosinase, CD20, CD22, CD33, CD79b, PSA, and PAP, overexpressed antigens, such as HER2, MUC-1, PSMA, CEA, survivin, and WT-1, viral antigens, such as HPV viral proteins (E6, E7, etc.) and Epstein-Barr virus (EBV) proteins (EBV-LMP2, etc.), mutated gene product antigens (neoantigens), such as p53, K-ras, and BCR-ABL, as well as CEA and alpha-fetoprotein (AFP) carcinoembryonic antigens.

[0027] Specific examples of antibodies for use in the reaction with the conjugate precursor (I) of the present invention are given below, but the present invention is not limited thereto.

[0028] These antibodies include anti-HER2 antibody, anti-EGFR antibody, anti-lymphocyte antigen 6E (Ly-6E) antibody, anti-hepatocyte growth factor receptor (HGFR) antibody, anti-CD22 antibody, anti-folate receptor α (FRα) antibody, anti-PSMA (FOLH1) antibody, anti-CD30 (TNFRSF8) antibody, anti-TROP-2 antibody, anti-CD19 antibody, anti-5T4 antibody, anti-mesothelin antibody, anti-CD20 antibody, anti-CD33 antibody, anti-CDB7-H3 antibody, anti-CD269 (BCMA) antibody, and anti-CD142 antibody. , anti-CD70 antibody, anti-CD123 antibody, anti-TAG-72 antibody, anti-TFRC antibody, anti-EPHA2 antibody, anti-EPHA3 antibody, anti-c-KIT antibody, anti-PD-L1 antibody, anti-epithelial cell adhesion molecule (EPCAM) antibody, anti-AXL antibody, anti-interleukin-1 receptor accessory protein antibody, anti-mucin-16 (CA125) antibody, anti-MUC1 antibody, anti-GPC3 antibody, anti-CLEC12A (CLL1) antibody, anti-LRRC15 antibody, anti-ADAM9 antibody, anti-sodium-dependent phosphate transporter 2B (SLC34A2) antibody, anti-CD25 antibody, anti-ROR1 antibody, anti-TweakR antibody, anti-CD74 antibody, anti-CEACAM5 antibody, anti-CD105 antibody, anti-CD79b antibody, anti-CD147 antibody, anti-sialyl-Tn antibody, anti-GCC antibody, anti-HER3 antibody, anti-integrin antibody, anti-EGFR variant III antibody, anti-claudin 6 antibody, anti-leucine-rich repeat-containing G protein-coupled receptor 5 antibody, anti-PTK7 antibody, anti-LYPD3 antibody, anti-ASCT2 antibody, anti-ASPH antibody, anti-GP C1 antibody, anti-CD174 antibody, anti-CD38 antibody, anti-ANGPT2 antibody, anti-CD44 antibody, anti-DDL3 antibody, anti-FGFR2 antibody, anti-KAAG1 antibody, anti-CD73 antibody, anti-CLDN18.2 antibody, anti-PRLR antibody, anti-SEZ6 antibody, anti-neprilysin antibody, anti-neural cell adhesion molecule 1 antibody, anti-CD166 (ALCAM) antibody, anti-CD24 antibody, anti-CD27 antibody, anti-CDH3 antibody, anti-EPHA4 antibody, anti-FGFR3 antibody, anti-GFRAL antibody, anti-GloboH antibody, anti-IL-13Ra2 antibody, anti-STEAP-1 antibody, anti-TMCC3 antibody, anti-CD209 antibody, anti-CD37 antibody, anti-CD48 antibody, anti-CDCP1 antibody, anti-CD46 antibody, anti-CD200 antibody, anti-CTLA4 antibody, anti-CXCR5 antibody, anti-FLT3 antibody, anti-SDC1 (CD138) antibody, anti-CLDN6 / 9 antibody, anti-CEACAM6 antibody, anti-CA9 antibody, anti-EDNRB antibody, anti-GD3 ganglioside antibody, anti-MICA / B antibody, anti-JAG1 / 2 antibody, anti-TM4SF1 antibody, anti-uPAR antibody, anti-carbonic anhydrase IX antibody, anti-ALK1 antibody, anti-I GF-1R antibody, anti-KDR antibody, anti-CEACAM8 antibody, anti-IL5R antibody, anti-CD205 (Ly75) antibody, anti-MSR1 antibody, anti-KREMEN2 antibody, anti-SSEA-4 antibody, anti-CD228 antibody, anti-CD5 antibody, anti-DLL4 antibody, anti-FAP antibody, anti-Notch3 antibody, anti-AG7 antibody, anti-guanylate cyclase antibody, anti-nectin-4 antibody, anti-CD226 (DNAM-1) antibody, anti-FcRL5 antibody, anti-HLA-DR antibody, anti-ITGB3 antibody, anti-DLK1 antibody, anti-CD157 (BST1) antibody, anti-CD56 (NCAM1) antibody, anti-MICA (MHCClass I polypeptide-related sequence A) antibody, anti-SSEA-1 antibody, anti-TRAIL-R2 (DR5) antibody, anti-GPNMB antibody, anti-CCR5 antibody, anti-LAMP1 antibody, anti-LGALS3BP antibody, anti-ROR2 antibody, anti-DLL3 antibody, anti-ETBR antibody, anti-LIV-1 antibody, anti-integrin αvβ6 antibody, anti-TIM-1 antibody, anti-AGS-16 (ENPP3) antibody, anti-SLITRK6 antibody, anti-GD2 antibody, anti-CD52 antibody, anti-CCR4 antibody, anti-VEGFR2 antibody, anti-PDGFR antibody, anti-FGFR antibody, anti-SLAMF7 antibody, anti-GD2 ganglioside antibody, anti-EPHA3 antibody, anti-integrin αvβ3 antibody, anti-AGS-5 antibody, anti-CA19-9 antibody, anti-PSA antibody, anti-MAGE3 antibody, anti-transferrin receptor 1 (CD71) antibody, anti-CEAC AM1 antibody, anti-SLC3A2 (CD98) antibody, anti-ACVR1 antibody, anti-AG-7 antibody, anti-AMHR2 antibody, anti-ABCB1 antibody, anti-C16orf54 antibody, anti-cathepsin D antibody, anti-CCR7 antibody, anti-SLC44A4 antibody, anti-CD300LF antibody, anti-DPEP3 antibody, anti-FucGM1 antibody, anti-GPR20 antibody, anti-ITGB6 antibody, anti-Lewis-A-like carbohydrate antibody, anti-prolactin receptor antibody, anti-sialyl Tn antibody, anti-SLAMF6 antibody, anti-SLAMF7 antibody, anti-TRA-1-60 antibody, anti-membrane serine protease antibody, anti-B7-H4 antibody, anti-Cripto antibody, anti-CD99 antibody, anti-CanAg antibody, anti-A33 antibody, anti-α10β1 integrin antibody, anti-ALPP antibody, anti-CD248 antibody, and anti-GPRC5D antibody.

[0029] In addition, examples of antibodies represented by common names include trastuzumab, rituximab, palivizumab, infliximab, basiliximab, tocilizumab, bevacizumab, adalimumab, cetuximab, ranibizumab, omalizumab, eculizumab, ustekinumab, golimumab, canakinumab, denosumab, mogalizumab, natalizumab, nivolumab, secukinumab, ipilimumab, elocumab, mepolizumab, amorobumab, acegeizumab, brolumab, idarucizumab, pembrolizumab, samarituzumab, belotosuzumab, belimumab, avelumab, dupilumab, atelizumab, benlelizumab, emicizumab, gosekumab , durvalumab, vedolizumab, lomosotuzumab, risankizumab, eculizumab, brosutuzumab, brolucizumab, tetragizumab, satelizumab, ganezumab, remanezumab, efavirenzumab, dactuximab, aniluzumab, sotovetumumab, bimegyzumab, farcitumumab, nemolizumab, lanalizumab monoclonal antibody, ibritumomab tiuxetan, brentuximab, ituzumab, polotuzumab, enroku, panitumumab, ofatumumab, pertuzumab, alemtuzumab, ramucirumab, elotuzumab, daratumumab, obinutuzumab, blinatumomab, necituzumab, isatuximab, inelizumab, datuximab, gemtuzumab, lovo tocilizumab, promiximab, talinutuzumab, taquitozumab, cofetozumab, berantuzumab, taquitozumab, enatuximab, fezetozumab, mazetozumab, naratuximab, oletuzumab, rilotuzumab, tetumumab, ganitazumab, dalotuzumab, citumumab, rotuximab, estuzumab, fentolumab, sibotuzumab, mecbotamab, tevituzumab, mipatuzumab, enapotamab, ogavuzumab, abavotumab, ubatuzumab, sofituzumab, levitra, rifatuzumab, dasutuzumab iximab, daclizumab, ipilimumab, camidanlumab, acitumomab, atumomab, tecetumomab, labetuzumab, cerbituximab, pertuzumab, duligotumab, zenoculumab, seribantumab, baricitumomab, lumretuzumab, efegnumab, vedicitutumab, makituximab, zenidatuzumab, culotuzumab, initutumab, gantuzumab, anitutumomab, zenoculumab, ertuinomab, rufatumomab, ertuinomab, ertuinomab, ertuinomab, nimotuzumab, zalutumab, vortuximab, zatuximab,depatuxizumab, duligotumab, tomatuximab, imgatuzumab, matuzumab, tosenoside, pesentozumab, isatuximab, etirituzumab, sucizumab, epratuzumab, betumomab, pinatuximab, somituximab, farletuzumab, rosopetuzumab, caprotumab, itumumab, gosartuzumab, dedabruzumab, cotuximab, dinutuzumab, durotoxin, lontuzumab, obelizumab, tancitumomab, talitumomab, urituximab, tositumomab, ocletuzumab, okatuzumab ocaratuzumab), zebetozumab, divolizumab, involumab, icoretuzumab, gefituzumab, onitumab, paramatuzumab, motuzumab, ametuzumab, anetumab, berantuzumab, anukatuzumab, enatuzumab, rivositantumab, pacanatuzumab, pavoretuzumab, terituzumab, victorumab, tatuzumab, pivekimab, vortuzumab, tucotuzumab, catumaxomab, solitonumab, mootuzumab, edrecolomab, sitatuzumab, and adelimumab, and antibodies having one to six (preferably six) complementary determining regions (CDRs) of any of these antibodies.

[0030] Antibodies described herein also include modified antibodies. Modified antibodies refer to antibodies that have been chemically or biologically modified. Chemical modification includes the combination of chemical moieties with amino acid frameworks, chemical modification of N-connected or O-connected carbohydrate chains, etc. Examples of biological modifications include modification through post-translational modification (e.g., glycosylation to N-connect or O-connect, N-terminal or C-terminal processing, deamidation, aspartic acid isomerization and methionine oxidation) and addition of methionine residues at the N-terminal by using prokaryotic host cell expression. In addition, such modifications also include labels that allow detection or separation of antibodies or antigens, such as enzyme labels, fluorescent labels and affinity labels. Such modified antibodies of the present invention can be used to improve the stability and blood retention of the original antibody, reduce antigenicity, and detect or separate such antibodies or antigens. As used herein, the term "modified antibody" refers to a chemically or biologically modified antibody, wherein a linker is extended from a functional group (e.g., a hydroxyl group, a sulfhydryl group, an amino group, or a carboxyl group) present in the original antibody, and a "sulfhydryl group, a hydroxyl group, an amino group, a maleimido group (formula (v) above), an α-halomethylcarbonyl group (formula (vi) above), an ethynylphosphonamide group (formula (vii) above), a carboxyl group, an active ester of a carboxyl group, an azide group (-N-3 In the present specification, the “antibody” defined above and the “modified antibody” defined above are optionally collectively referred to as “antibody”.

[0031] In addition, the antibody-dependent cellular toxicity activity can be enhanced by regulating (glycosylation, defucosylation, etc.) the glycan modifications associated with the antibodies described herein. Known techniques for regulating the glycan modifications of antibodies include, but are not limited to, those in WO99 / 54342, WO 00 / 61739, and WO 02 / 31140. Antibodies for use in reactions with the conjugate precursor (I) of the present invention also include antibodies that have been modified by glycosylation. As described herein, the term "functional group in an antibody" refers to a group present in the above-defined "antibody" and "modified antibody", which reacts with a reactive group present in the conjugate precursor (I) and the conjugate precursor synthetic intermediate (II-1) of the present invention to form an antibody-multi-drug conjugate. Specific examples thereof include a thiol group, a hydroxyl group, an amino group, a maleimido group (formula (v) above), an α-halomethylcarbonyl group (formula (vi) above), an ethynylphosphonamide group (formula (vii) above), a carboxyl group, an active ester of a carboxyl group, an azide group (-N 3 group), alkynyl group and cycloalkynyl group. As described herein, the term "reactive group" refers to a group present in the conjugate precursor (I) of the present invention and the conjugate precursor intermediate (II-1) of the present invention, which reacts with the "functional group in the antibody" defined above to form an antibody-multi-drug conjugate. Specific examples thereof include a maleimido group (formula (v) above), an α-halomethylcarbonyl group (formula (vi) above), an ethynylphosphonamide group (formula (vii) above), a carboxyl group, an active ester of a carboxyl group, a thiol group, a hydroxyl group, an amino group, an alkynyl group, a cycloalkynyl group, and an azide group (-N 3 group). As described herein, the term "bonding group" refers to a group present at the terminal of the linker component of the conjugate precursor synthetic intermediate (II-1) and (II-2) of the present invention, and the bonding group is used to bond the "reactive group" or the "anti-tumor drug residue" described below to the "linker part" through the following: etherification reaction, thioetherification reaction, carboxyl esterification reaction, phosphate (mono- or di-) esterification reaction, amidation reaction, reductive amination reaction, disulfide reaction, click reaction, etc. Specific examples thereof include a hydroxyl group, a nitro group, a cyano group, an amide group, an oxo group, an azide group, an amino group, a monoalkylamino group which may have a substituent, an imino group (also including -N= and an imino group of a cyclic amine), a carboxyl group, a phosphoryl group, an alkynyl group, a cycloalkynyl group or a thiol group; and their protective bodies. Among these groups, a nitro group can be a precursor of an amino group, a cyano group can be a precursor of an amino group and an amide group, and an amide group can be a precursor of an amino group and a carboxyl group, and therefore, they are also regarded as “bonding groups” herein. As used herein, the term "anti-tumor drug molecule" refers to any drug that has an anti-tumor effect or cytotoxicity regardless of its mechanism of action and has a structure that can be combined with a linker (L in the conjugate precursor (I)). 1 and L 2 and L in the conjugate precursor synthetic intermediates (II-1) and (II-2) 1-1 and L 2-1 ) is a drug molecule that is not particularly limited to a substituent or a partial structure of the drug molecule. The anti-tumor drug molecule is preferably released by cleavage of some or all of the linkers in tumor cells to exert its anti-tumor effect. As described herein, the term "antitumor drug residue" refers to a residue in which a hydrogen atom or a hydroxyl group is removed from any position of the "antitumor drug molecule or its analog, or its derivative". Those skilled in the art can appropriately select the atom or residue to be removed.

[0032] Examples of the antitumor drug molecules include antitumor drug molecules independently selected from the group consisting of: camptothecin; MMAE; maytansine; para-benzodiazepine (PBD) dimer; Eribulin; 5-FU; PD-318088; AS-703026; TAK-733; LY-3023414; calicheamicin; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; Aplysia 10; superdox; ciprofloxacin; caderfloxacin hydrochloride (CS-940); and their analogs or derivatives, or derivatives of these analogs.

[0033] The term "analog" of "antitumor drug molecule or its analog, or derivative thereof" in the specification herein refers to a compound having a chemical structure and activity similar to that of each antitumor drug molecule (i.e., the antitumor activity of the antitumor drug molecule), and for example, "analog of camptothecin" refers to a compound having a chemical structure similar to that of camptothecin and having the same type I topoisomerase inhibitory effect as camptothecin. Examples of analogs include antitumor drug molecules modified with solubilizing groups.

[0034] In this specification, a "solubilizing group" refers to a group that ionizes or forms hydrogen bonds with water molecules and improves the water solubility of a compound (i.e., improves the water solubility of a compound relative to a compound without a solubilizing group). Examples of solubilizing groups include lactone groups (which may be, for example, β-propiolactone, γ-butyrolactone, or δ-valerolactone, and preferably γ-butyrolactone), phosphoryl groups (-OP 3 H 2 ), phosphonic acid group (-PO 3 H 2 ), carboxyl group, sulfonic acid group (-SO 3 H), nitrate group (-OSO 3 H) and C having one or more optionally substituted heteroatoms (e.g., O, S or N) 1 -C 6 An alkyl group. A C 1 -C 6 Examples of alkyl groups include aminohexyl groups, aminopentyl groups, aminobutyl groups, aminopropyl groups, aminoethyl groups, and aminomethyl groups. In addition, C having one or more heteroatoms (e.g., O, S, or N) may be present. 1 -C 6 The alkyl group may be substituted, and in particular, is optionally substituted with one, two, three or more optionally substituted methyl groups. C having one or more optionally substituted heteroatoms (e.g., O, S or N) 1 -C 6 The example of alkyl group comprises aminohexyl group, aminopentyl group, aminobutyl group, aminopropyl group, aminoethyl group and aminomethyl group, and these groups are replaced by one, two, three or more methyl groups, and for example, dimethylaminobutyl group can be illustrated. The example of the replacement of methyl group comprises hydroxyl group and halogen (for example, Cr, F and Br). In preferred aspect, the solubilizing group is phosphoryl group (-OPO 3 H 2 ) or phosphonic acid group (-PO 3 H 2 ).

[0035] As described herein, the term "derivative" in the term "anti-tumor drug molecule or its analogs, or derivatives thereof" refers to a functional group (such as a hydroxyl group, a thiol group (-SH), an amino group (-NH 2 The invention relates to a derivative in which -NH- and -NH- (including -NH- in an amide group and -NH- in a heteroaryl group or a heterocyclyl group ring) and a carboxyl group) are protected by a "protecting group", or a glycoside derivative generated by the reaction of the functional group with a saccharide. The protecting group of the derivative can be deprotected in vivo by various chemical reactions, biochemical reactions or metabolic reactions (e.g., pH fluctuations, hydrolysis reactions and oxidation-reduction reactions), converted into a parent compound (original antitumor drug molecule), and exhibits antitumor activity in some cases, or is not deprotected and exhibits antitumor activity in an intact form in other cases.

[0036] The “protecting group” is optionally selected from the protecting groups disclosed in, for example, Greene's Protective Groups in Organic Synthesis 5th Edition, PGM Wuts, John Wiley & Sons Inc. (2014) and the like.

[0037] Examples of the protective group for the hydroxyl group as a functional group include alkyloxyalkyl groups such as a methoxymethyl group, a methoxyethoxymethyl group and an ethoxy-2-ethyl group; arylalkyloxymethyl groups such as a benzyloxymethyl group; aryloxymethyl groups such as a phenyloxymethyl group; alkylthiomethyl groups such as a methylthiomethyl group; arylalkylthiomethyl groups such as a benzylthiomethyl group; arylthiomethyl groups such as a phenylthiomethyl group; an aminomethyl group in which the N atom is optionally replaced by an alkyl group or the following "amino group" alkylcarbonyl groups, for example, methylcarbonyl groups and ethylcarbonyl groups; alkenylcarbonyl groups, for example, allylcarbonyl groups; alkynylcarbonyl groups, for example, propargylcarbonyl groups; arylcarbonyl groups, for example, phenylcarbonyl groups; heteroarylcarbonyl groups, for example, pyridin-2, 3 or 4-ylcarbonyl groups; heterocyclylcarbonyl groups, for example, tetrahydrofuran-2 or 3-ylcarbonyl groups, and 5-oxotetrahydrofuran-2-ylcarbonyl groups; alkyloxycarbonyl groups, for example Such as tert-butyloxycarbonyl group, methyloxycarbonyl group, and ethyloxycarbonyl group; allyloxycarbonyl group; allyloxycarbonyl group, such as phenyloxycarbonyl group, 4-nitrophenyloxycarbonyl group and 4-methoxyphenyloxycarbonyl group; arylmethyloxycarbonyl group, such as 9-fluorenylmethyloxycarbonyl group, benzyloxycarbonyl group, 4-methoxybenzyloxycarbonyl group, 4 (or 2) -nitrobenzyloxycarbonyl group, 4 (or 2) -aminobenzyloxycarbonyl group or N-alkylcarbonylated or N-arylcarbonylated derivatives thereof, and 4 (or 2) -hydroxybenzyloxycarbonyl group or its O-alkylcarbonyl or O-arylcarbonyl derivative; alkylaminocarbonyl group, such as tert-butylaminocarbonyl group, methylaminocarbonyl group, ethylaminocarbonyl group; silyl group, such as trimethylsilyl group, trimethylsilylethoxymethyl group, triisopropylsilyl group, triisopropylsilyl group, tert-butyldimethylsilyl group and tert-butyldiphenylsilyl group; tetrahydropyranyl group, such as tetrahydropyranyl group and 2 (or 4) -methoxytetrahydropyranyl group. In addition, the hydroxyl group is optionally protected as an ester with formic acid, boric acid, phosphoric acid, phosphonic acid, phosphinic acid, sulfuric acid, sulfonic acid, sulfinic acid, sulfenic acid, amino acid or peptide. In one embodiment, the protecting group of the hydroxyl group is an alkyloxyalkyl group; an arylalkyloxymethyl group; an aminomethyl group in which the N atom is optionally protected by an alkyl group or a "protecting group for an amino group" described later; an alkylcarbonyl group; an alkenylcarbonyl group; an alkynylcarbonyl group: an arylcarbonyl group; an alkyloxycarbonyl group; an allyloxycarbonyl group; an allyloxycarbonyl group; an arylmethyloxycarbonyl group; an alkylaminocarbonyl group; a tetrahydropyranyl group; a tetrahydrofuranyl group; a silyl group, a lactone group; a lactone alkyl group; a lactone carbonyl group; a lactone alkylcarbonyl group; a phosphoryl group; a phosphorylalkyl group; or a phosphorylalkylcarbonyl group.

[0038] Examples of the protecting group for the mercapto group as a functional group include the protecting groups described as the protecting group for the hydroxyl group, but in addition, a disulfide bond (—SS—) may also be a protecting group.

[0039] Examples of protective groups of carboxyl groups as functional groups include alkyl groups, such as methyl groups, ethyl groups and tert-butyl groups; allyl groups; arylmethyl groups, such as benzyl groups; lactone groups; and silyl groups, such as trimethylsilyl groups, trimethylsilylethoxymethyl groups, tert-butyldimethylsilyl groups, tert-butyldiphenylsilyl groups. In addition, the carboxyl group can also be protected as an amide component (for example, an amide component with ammonia, alkylamines, dialkylamines, lactone amines, amino acid esters, amino acid amides, etc.), and the amino group of the amide moiety can have a lactone group, a lactone alkyl group or a phosphoryl alkyl group as a substituent. In one embodiment, the protecting group of the carboxyl group is an alkyl group; an allyl group; an arylmethyl group; a lactonyl group; a lactonylalkyl group; or a phosphorylalkyl group.

[0040] The functional groups, such as sulfenic acid group, sulfinic acid group, sulfonic acid group, phosphinic acid group, phosphonic acid group and boronic acid group, can also use the same protecting groups as those for the carboxyl group.

[0041] Examples of the protective group for the amino group as a functional group include an alkyloxycarbonyl group such as a tert-butyloxycarbonyl group, a methyloxycarbonyl group, and an ethyloxycarbonyl group; an allyloxycarbonyl group; an allyloxycarbonyl group such as a phenyloxycarbonyl group, a 4-nitrophenyloxycarbonyl group, and a 4-methoxyphenyloxycarbonyl group; an aryloxycarbonyl group such as a phenyloxycarbonyl group, a 4-nitrophenyloxycarbonyl group, and a 4-methoxyphenyloxycarbonyl group; an arylmethyloxycarbonyl group such as a 9-fluorenylmethyloxycarbonyl group, a benzyloxycarbonyl group, and a 4-methoxyphenyloxycarbonyl group. a 4-methoxybenzyloxycarbonyl group, a 4(or 2)-nitrobenzyloxycarbonyl group, a 4(or 2)-aminobenzyloxycarbonyl group or an N-alkylcarbonylated or N-arylcarbonylated derivative thereof, a 4(or 2)-hydroxybenzyloxycarbonyl group or an O-alkylcarbonylated or O-arylcarbonylated derivative thereof; an arylmethyl group such as a benzyl group and a triphenylmethyl group; an alkyloxyalkyl group such as a methyloxymethyl group, a methoxyethoxymethyl group and an ethoxy-2-ethyl group; an arylalkyloxymethyl group such as a benzyloxymethyl group group; an aryloxymethyl group, for example a phenyloxymethyl group; an alkylthiomethyl group, for example a methylthiomethyl group; an arylalkylthiomethyl group, for example a benzylthiomethyl group; an arylthiomethyl group, for example a phenyloxymethyl group; an aminomethyl group in which the N atom is optionally protected by an alkyl group or by a protecting group of an amino group; an alkylcarbonyl group, for example a methylcarbonyl group and an ethylcarbonyl group; an alkenylcarbonyl group, for example an allylcarbonyl group; an alkynylcarbonyl group, for example a propargylcarbonyl group; an arylcarbonyl group, for example a phenylcarbonyl group; Heteroarylcarbonyl groups, such as pyridin-2,3 or 4-ylcarbonyl groups; heterocyclylcarbonyl groups, such as tetrahydrofuran-2 or 3-ylcarbonyl groups, and 5-oxotetrahydrofuran-2-ylcarbonyl groups; silyl groups, such as trimethylsilyl groups, trimethylsilylethoxymethyl groups, triisopropylsilyl groups, tert-butyldimethylsilyl groups, and tert-butyldiphenylsilyl groups; or arylsulfonyl groups, such as 2,4-dinitrobenzenesulfonyl groups and 4-nitrobenzenesulfonyl groups; and protecting groups of amino groups commonly used in peptide synthesis. In addition, the amino group is optionally protected as an amide with formic acid, phosphoric acid, phosphonic acid, phosphinic acid, sulfuric acid, sulfonic acid, sulfinic acid, sulfenic acid, amino acid or peptide. In one embodiment, the protecting group of the amino group is an alkyloxycarbonyl group; an allyloxycarbonyl group; an arylmethyloxycarbonyl group; an alkylcarbonyl group; an alkenylcarbonyl group; an arylcarbonyl group; a silyl group, a lactone group; a lactonealkyl group; a lactonecarbonyl group; a lactonealkylcarbonyl group; a phosphoryl group; a phosphorylalkyl group; a phosphorylalkylcarbonyl group; a bisphosphorylmethyl group (-C(H, OH, NH2 , Cl or alkyl)(P(=O)(OH) 2 ) 2 ); an aminoalkylcarbonyl group; an alkylaminoalkylcarbonyl group; a dialkylaminoalkylcarbonyl group; a cyclic aminoalkylcarbonyl group formed by combining the dialkyl groups; or a trialkylammoniumalkylcarbonyl group.

[0042] The protection or removal of these protecting groups is carried out according to commonly used methods (for example, see Greene's Protective Groups in Organic Synthesis 5th Edition, PGM Wuts, John Wiley & Sons Inc. (2014)).

[0043] As mentioned above, the functional groups can be protected as glycosides by reacting with various sugars. That is, they can be protected by glycosyl groups. Particular examples of glycosyl groups include D-glucosyl groups, D-galactosyl groups, D-mannosyl groups and D-glucuronic acid groups, and the functional groups (-OH, -SH, -NH 2 , -NH- and -COOH groups, etc.) can also be protected as described above. These glycosides and their protected forms can be produced according to conventional methods commonly used in the field of carbohydrate chemistry (e.g., Comprehensive Glycoscience From Chemistry to Systems Biology, Hans Kamerling (2007)).

[0044] In addition, among the functional groups, hydroxyl groups, thiol groups (-SH) and amino groups (-NH 2 , -NH- (including -NH- in an amide group and -NH- in a heteroaryl group or a heterocyclyl group ring)) are optionally also protected with various sugar acids (e.g., gluconic acid, glucuronic acid and galacturonic acid) as esters, thioesters, amides or imides, respectively. As described herein, the "protecting groups" of various functional groups in the "derivative" in the "antitumor drug molecule or its analogs, or its derivatives" have been described above, and they can also be applied to the linker part, bonding group, protecting group or substituent.

[0045] The methods for selecting, attaching and removing the protecting groups are also applicable to the production of the following compounds having the general formula (I), (II-1) and (II-2) (ie, conjugate precursors and conjugate precursor synthetic intermediates).

[0046] As described herein, a specific example of "anti-tumor drug molecules or analogs thereof, or derivatives thereof" is shown in the following Example 1, but the present invention is not limited thereto.

[0047] Example 1. Example of "anti-tumor drug molecules or their analogs, or their derivatives" [C56] Camptothecin [C57] Topotecan [C58] Lutotecan [C59] Exotecan [C60] SN-38 [C61] DB-67 [C62] BNP-1350 [C63] ST-1481 [C64] CKD-602 [C65] Dxd(N-(2-hydroxyacetyl)exitecan) [C66] U-001 [C67] U-002 [C68] U-003 [C69] U-004 [C70] U-005 [C71] U-006 [C72] U-007 [C73] MMAE (monomethyl auristatin E) [C74] MMAF (monomethyl auristatin F) [C75] MMAQ (monomethyl auristatin Q) [C76] MMAD (monomethyl aplysia 10) [C77] Aplysia 10 [C78] U-008 [C79] U-009 [C80] U-010 [C81] U-011 [C82] U-012 [C83] U-013 [C84] U-014 [C85] U-015 [C86] U-016 [C87] U-017 [C88] U-018 [C89] U-019 [C90] U-020 [C91] U-021 [C92] U-022

[93] U-023 [C94] U-024 [C95] U-025 [C96] U-026 [C97] U-027 [C98] U-028 [C99] U-029 [C100] U-030 [C101] U-031 [C102] U-032 [C103] U-033 [C104] U-034 [C105] U-035 [C106] U-036 [C107] U-037 [C108] U-038 [C109] U-039 [C110] U-040 [C111] U-041 [C112] U-042 [C113] U-043 [C114] U-044 [C115] U-045 [C116] Maytansine [C117] DM-1 (Maytansine) [C118] DM-3 [C119] DM-4 [C120] PBD dimer [C121] Eribulin [C122] 5-FU [C123] PD-318088 [C124] AS-703026 [C125] TAK-733 [C126] LY-3023414 [C127] Calcheamicin γ1 [C128] Paclitaxel [C129] Docetaxel [C130] Mitomycin C [C131] Bleomycin A2 [C132] Cyclocytidine [C133] Vincristine [C134] Vinblastine [C135] Daunocin [C136] Doxorubicin [C137] superdox [C138] Ciprofloxacin [C139] Caderfloxacin Hydrochloride (CS-940) [C140] U-046 [C141] U-047 [C142] U-048 [C143] U-049 [C144] U-050 [C145] U-051 [C146] U-052 [C147] U-053 [C148] U-054 [C149] U-055 [C150] U-056 [C151] U-057 [C152] U-058 [C153] U-059 [C154] U-060 [C155] U-061 [C156] U-062 [C157] U-063 [C158] U-064 [C159] U-065 [C160] U-066 [C161] U-067 [C162] U-068 [C163] U-069 [C164] U-070 [C165] U-071 [C166] U-072 [C167] U-073 [C168] U-074 [C169] U-075 [C170] U-076 [C171] U-077 [C172] U-078 [C173] U-079 [C174] U-080 [C175] U-081 [C176] U-082 [C177] U-083 [C178] U-084 [C179] U-085 [C180] U-086 [C181] U-087 [C182] U-088 [C183] U-089 [C184] U-090 [C185] U-091 [C186] U-092 [C187] U-093 [C188] U-094 [C189] U-095 [C190] U-096 [C191] U-097 [C192] U-098 [C193] U-099 [C194] U-100 [C195] U-101 [C196] U-102 [C197] U-103 [C198] U-104

[0048] As described herein, the term "active ester of a carboxyl group" refers to an ester obtained by making an ester of a carboxyl group with a strongly acidic alcohol to enhance its reactivity, and examples thereof include N-hydroxysuccinimidyl ester, sulfosuccinimidyl ester, N-hydroxyphthalimidyl ester, N-hydroxysulfophthalimidyl ester, o-nitrophenyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, 3-sulfonyl-4-nitrophenyl ester, 3-carboxy-4-nitrophenyl ester, and pentafluorophenyl ester. However, the present invention is not limited thereto.

[0049] As described herein, the term "alkyl group" refers to a group in which one hydrogen atom is removed from a linear or branched saturated hydrocarbon (i.e., alkane) having 1 to 10 carbon atoms. Further, even if not specifically stated, the alkyl group also includes an "optionally substituted alkyl group".

[0050] Examples of the substituent of the optionally substituted alkyl group include one or more substituents independently selected from the following Group A. Group A Selected from the group consisting of: A halogen atom (a fluorine atom, a chlorine atom, a bromine atom or an iodine atom); Alkyloxy groups; Hydroxyl groups; sulfhydryl groups; Amino group; Alkylamino groups; dialkylamino group (wherein two alkyl groups are optionally combined to form a heterocyclyl group containing an N atom); trialkylammonium groups; Carboxyl group; cyano group; Nitro group; Alkylcarbonyl group; alkenylcarbonyl group; Alkynylcarbonyl group; Arylcarbonyl group; heteroarylcarbonyl group; heterocyclylcarbonyl group; lactone carbonyl group; Phosphorylalkylcarbonyl group; Alkyloxycarbonyl group; an aryloxycarbonyl group; heteroaryloxycarbonyl group; aminocarbonyl group; an aminocarbonyl group, wherein the amino moiety is the amino group of any amino acid or peptide; N-alkylaminocarbonyl group; N,N-dialkylaminocarbonyl group (wherein two alkyl groups are optionally combined to form a heterocyclyl group containing an N atom); aminocarbonyloxy group; N-alkylaminocarbonyloxy group; N,N-dialkylaminocarbonyloxy group (wherein two alkyl groups are optionally combined to form a heterocyclyl group containing an N atom); Alkyloxycarbonyloxy group; an aryloxycarbonyloxy group; heteroaryloxycarbonyloxy group; urea group; N-alkylureido groups; N,N-dialkylureido groups (wherein two alkyl groups are optionally combined to form a heterocyclyl group containing an N atom); N,N,N'-trialkylureido groups (wherein two alkyl groups on the same N atom are optionally combined to form a heterocyclyl group containing the N atom); Guanidinyl group; amidino group; hydrazino group; Alkylhydrazine groups; N,N-dialkylhydrazine group; N,N'-dialkylhydrazine group; Alkylthio groups; Alkylsulfinyl groups; Alkylsulfonyl groups; Arylthio groups; arylsulfinyl groups; arylsulfonyl groups; heteroarylthio groups; heteroarylsulfinyl groups; heteroarylsulfonyl groups; Sulfenic acid group; Sulfinic acid group; Sulfonic acid group; Sulfate groups; Sulfenamide group; Sulfonamide group; Phosphine oxide group; Phosphinic acid group; Phosphoryl group (phosphonic acid group -P(=O)(OH) 2 ); Phosphate group (phosphate ester group -OP(=O)(OH) 2 ); Boronic acid group; alkenyl groups; Alkynyl groups; Cycloalkyl groups; Cycloalkenyl groups; Aryl groups; heteroaryl groups; heterocyclyl groups; Lactone group; as well as Y is: Hydrogen atom; Alkyl groups; A halogen atom (a fluorine atom, a chlorine atom, a bromine atom or an iodine atom); Alkyloxy groups; Alkylthio groups; Hydroxyl groups; sulfhydryl groups; Amino group; Alkylamino groups; dialkylamino group (wherein two alkyl groups are optionally combined to form a heterocyclyl group containing an N atom); Carboxyl group; trialkylammonium groups; cyano group; Nitro group; Alkylcarbonyl group; alkenylcarbonyl group; Alkynylcarbonyl group; Arylcarbonyl group; heteroarylcarbonyl group; heterocyclylcarbonyl group; lactone carbonyl group; Phosphorylalkylcarbonyl group; Alkyloxycarbonyl group; an aryloxycarbonyl group; heteroaryloxycarbonyl group; aminocarbonyl group; an aminocarbonyl group, wherein the amino group portion is the amino group of any amino acid or peptide; N-alkylaminocarbonyl group; N,N-dialkylaminocarbonyl group (wherein two alkyl groups are optionally combined to form a heterocyclyl group containing an N atom); aminocarbonyloxy group; N-alkylaminocarbonyloxy group; N,N-dialkylaminocarbonyloxy group (wherein two alkyl groups are optionally combined to form a heterocyclyl group containing an N atom); Alkyloxycarbonyloxy group; an aryloxycarbonyloxy group; heteroaryloxycarbonyloxy group; urea group; N-alkylureido groups; N,N-dialkylureido groups (wherein two alkyl groups are optionally combined to form a heterocyclyl group containing an N atom); N,N,N'-trialkylureido groups (wherein two alkyl groups on the same N atom are optionally combined to form a heterocyclyl group containing the N atom); Guanidinyl group; amidino group; hydrazino group; Alkylhydrazine groups; N,N-dialkylhydrazine group; N,N'-dialkylhydrazine group; Alkylthio groups; Alkylsulfinyl groups; Alkylsulfonyl groups; Arylthio groups; arylsulfinyl groups; arylsulfonyl groups; heteroarylthio groups; heteroarylsulfinyl groups; heteroarylsulfonyl groups; Sulfenic acid group; Sulfinic acid group; Sulfonic acid group; Sulfate groups; Sulfenamide group; Sulfonamide group; Phosphine oxide group; Phosphinic acid group; Phosphoryl group (phosphonic acid group -P(=O)(OH) 2 ); Bisphosphorylmethyl groups (-C(H, OH, NH 2 , Cl or optionally substituted alkyl)(P(=O)(OH) 2 ) 2 ); Phosphate group (phosphate ester group -OP(=O)(OH) 2 ); Boronic acid group; Alkyl groups; alkenyl groups; Alkynyl groups; Cycloalkyl groups; Cycloalkenyl groups; Aryl groups; heteroaryl groups; a heterocyclyl group; or lactone group).

[0051] Specific examples of the alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an n-hexyl group, an n-heptyl group, an n-octyl group, an n-nonyl group and an n-decyl group.

[0052] When the term "alkane" is used in the present specification, the alkane means a "straight-chain or branched saturated hydrocarbon having 1 to 10 carbon atoms" formed by adding one hydrogen atom to the "alkyl group" defined above.

[0053] As used herein, the term "alkenyl group" refers to a straight or branched unsaturated hydrocarbon group containing one or more double bonds (-C=C-) in the chain of the alkyl group defined above.

[0054] Examples of the substituent of the optionally substituted alkenyl group include one or more substituents independently selected from Group A.

[0055] Specific examples of the alkenyl group include a methylene group (=CH 2 group), vinyl group, 1-propenyl group, 2-propenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 1,3-butadienyl group, 1-methyl-2-propenyl group, 1,1-dimethyl-2-propenyl group, 1-pentenyl group, 2-pentenyl group, 3-pentenyl group, 4-pentenyl group, 1-methyl-2-butenyl group, 3-methyl-1-butenyl group, 1-hexenyl group, 2-hexenyl group, 3-hexenyl group, 4-hexenyl group, 5-hexenyl group, 1-methyl-2-pentenyl group, 3-methyl-1-pentenyl group, 2-heptenyl group, 4-octenyl group, 1-nonenyl group, and 2-decenyl group.

[0056] As used herein, the term "alkynyl group" refers to a straight or branched unsaturated hydrocarbon group (provided that the number of carbon atoms is 2 to 10) containing one or more triple bonds (C triple bond C) in the chain of the alkyl group defined above.

[0057] Examples of the substituent of the optionally substituted alkynyl group include one or more substituents independently selected from Group A.

[0058] Specific examples of the alkynyl group include an ethynyl group, a 1-propynyl group, a 2-propynyl group, a 1-butynyl group, a 2-butynyl group, a 3-butynyl group, a 1-methyl-2-propynyl group, a 1,1-dimethyl-2-propynyl group, a 1-pentynyl group, a 2-pentynyl group, a 3-pentynyl group, a 4-pentynyl group, a 1-methyl-2-butynyl group, a 3-methyl-1-butynyl group, a 1-hexynyl group, a 2-hexynyl group, a 3-hexynyl group, a 4-hexynyl group, a 5-hexynyl group, a 1-methyl-2-pentynyl group, a 3-methyl-1-pentynyl group, a 2-heptynyl group, a 4-octynyl group, a 1-nonynyl group, and a 2-decynyl group.

[0059] As used herein, the term "alkyloxy group" refers to a monovalent group (alkyl-O-group) in which an alkyl group as defined above having 1 to 10 carbon atoms is bonded to an oxy group. Specific examples of the alkyloxy group include a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, an n-butoxy group, an isobutoxy group, a sec-butoxy group, a tert-butoxy group, an n-pentoxy group, an n-hexoxy group, an n-heptyloxy group, an n-octyloxy group, an n-nonyloxy group, and an n-decyloxy group.

[0060] As used herein, the term "alkylthio group" refers to a monovalent group in which an alkyl group as defined above having 1 to 10 carbon atoms is bonded to a thio group (alkyl-S-group). Specific examples of the alkylthio group include a methylthio group, an ethylthio group, an n-propylthio group, an isopropylthio group, an n-butylthio group, an isobutylthio group, a sec-butylthio group, a tert-butylthio group, an n-pentylthio group, an n-hexylthio group, an n-heptylthio group, an n-octylthio group, an n-nonylthio group, and an n-decylthio group.

[0061] Examples of the substituent of the optionally substituted alkyloxy group and alkylthio group include one or more substituents independently selected from Group A.

[0062] As used herein, the term "cycloalkyl group" refers to a group in which one hydrogen atom is removed from a monocyclic hydrocarbon (i.e., cycloalkane) having 3 to 10 carbon atoms and a group in which one hydrogen atom is removed from a bicyclic hydrocarbon (i.e., bicyclic cycloalkane) having 4 to 10 carbon atoms.

[0063] Examples of substituents of the optionally substituted cycloalkyl group include one or more substituents independently selected from the following: an oxo group (=O); a thioalkenyl group (=S); an imino group (=N(R 8 )); Oxime group (=N-OR 9 ); hydrazone group (=NN(R 10 )(R 11 )); alkyl group; and Group A (hereinafter referred to as the group consisting of: an oxo group, a thioalkenyl group; an imino group; an oxime group; a hydrazone group; an alkyl group; and Group A is referred to as "Group B") (wherein R 8 , R 9 , R 10 and R 11 are each independently a hydrogen atom, an alkyl group, an alkenyl group, a cycloalkyl group, a cycloalkenyl group, an aryl group, a heteroaryl group or a heterocyclyl group).

[0064] Specific examples of the cycloalkyl group include monocyclic cycloalkyl groups having 3 to 10 carbon atoms, such as a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclononyl group and a cyclodecyl group; and bicyclic cycloalkyl groups having 4 to 10 carbon atoms, such as a bicyclo[1.1.0]butyl group, a bicyclo[2.1.0]pentyl group, a bicyclo[3.1.0]hexyl group, a bicyclo[3.2.0]heptyl group, a bicyclo[2.2.1]heptyl group, a bicyclo[3.3.0]octyl group, a bicyclo[3.2.1]octyl group, a bicyclo[2.2.2]octyl group, a bicyclo[6.1.0]nonyl group and a bicyclo[4.4.0]decyl group.

[0065] When the term "cycloalkane" is used in the present specification, the cycloalkane means "monocyclic hydrocarbons having 3 to 10 carbon atoms and bicyclic hydrocarbons having 4 to 10 carbon atoms" in which one hydrogen atom is added to the above-defined "cycloalkyl group".

[0066] As used herein, the term "cycloalkenyl" refers to a monocyclic or bicyclic unsaturated hydrocarbon group containing one or more double bonds (-C=C-) in the ring of the cycloalkyl group defined above.

[0067] Examples of the substituent of the optionally substituted cycloalkenyl group include one or more substituents independently selected from Group B.

[0068] Specific examples of the cycloalkenyl group include monocyclic cycloalkenyl groups having 3 to 10 carbon atoms, such as a 1-cyclopropenyl group, a 1-cyclobutenyl group, a 1-cyclopentenyl group, a 2-cyclopentenyl group, a 1-cyclohexenyl group, a 2-cyclohexenyl group, a 3-cyclohexenyl group, a 1,3-cyclohexadienyl group, a 1,4-cyclohexadienyl group, a 1-cycloheptenyl group, a 2-cyclooctenyl group, a 3-cyclooctenyl group, a 4-cyclooctenyl group, a 1-cyclononenyl group, and a 1-cyclodecenyl group; and Bicyclic cycloalkenyl groups, for example bicyclo[1.1.0]but-1-enyl groups, bicyclo[2.1.0]pent-2-enyl groups, bicyclo[3.1.0]hex-2-enyl groups, bicyclo[3.2.0]hept-3-enyl groups, bicyclo[2.2.1]hept-2-enyl groups, bicyclo[3.3.0]oct-2-enyl groups, bicyclo[3.2.1]oct-2-enyl groups, bicyclo[2.2.2]oct-2-enyl groups, bicyclo[6.1.0]non-4-enyl groups and bicyclo[4.4.0]dec-3-enyl groups.

[0069] As used herein, the term "aryl group" refers to a group in which one hydrogen atom is removed from a monocyclic or bicyclic aromatic hydrocarbon (ie, arene) having 6 to 11 ring carbon atoms.

[0070] Examples of the substituent of the optionally substituted aryl group include one or more substituents independently selected from the alkyl group and Group A (hereinafter, the group consisting of the alkyl group and Group A is referred to as "Group C").

[0071] Specific examples of the aryl group include monocyclic aryl groups, such as a phenyl group; and aryl groups having 9 to 11 ring carbon atoms (C 9 To C 11 ) is an optionally partially saturated bicyclic aryl group such as a naphthyl group, a tetrahydronaphthyl group, an indenyl group and an indanyl group.

[0072] When the term "arene" is used in the present specification, the aromatic hydrocarbon means a "monocyclic aromatic hydrocarbon having 6 to 11 ring carbon atoms or a bicyclic aromatic hydrocarbon having 9 to 11 ring carbon atoms" formed by adding one hydrogen atom to the above-defined "aryl group".

[0073] As used herein, the term "heteroaryl group" refers to a group in which one hydrogen atom is removed from a 5- to 14-membered monocyclic, bicyclic or tricyclic aromatic heterocyclic ring (i.e., heteroarene) containing, in addition to one or more carbon atoms, 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms and nitrogen atoms.

[0074] Examples of the substituent of the optionally substituted heteroaryl group include one or more substituents independently selected from Group C.

[0075] Specific examples of the heteroaryl group include a 5- to 6-membered monocyclic heteroaryl group containing 1 to 4 hetero atoms selected from oxygen atoms, sulfur atoms and nitrogen atoms in addition to one or more carbon atoms, such as a pyrrolyl group, a furanyl group, a thienyl group, a pyrazolyl group, an imidazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, a thiadiazolyl group, a triazolyl group, a tetrazolyl group, a pyridyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, and a triazinyl group; and an 8- to 11-membered bicyclic heteroaryl group containing 1 to 4 hetero atoms selected from oxygen atoms, sulfur atoms and nitrogen atoms in addition to one or more carbon atoms, such as an indolyl group, an isoindolyl group, an indazolyl group, a tetrahydroindazolyl group, a benzoindolyl group a furanyl group, a dihydrobenzofuranyl group, a dihydroisobenzofuranyl group, a benzothiophenyl group, a dihydrobenzothiophenyl group, a dihydroisobenzothiophenyl group, a benzoxazolyl group, a dihydrobenzoxazolyl group, a benzothiazolyl group, a dihydrobenzothiazolyl group, a quinolyl group, a tetrahydroquinolyl group, an isoquinolyl group, a tetrahydroisoquinolyl group, a naphthyridinyl group, a tetrahydronaphthyridinyl group, a quinoxalinyl group, a tetrahydroquinoxalinyl group, and a quinazolinyl group; and an 11- to 14-membered tricyclic heteroaryl group containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms and nitrogen atoms other than one or more carbon atoms, such as a dibenzofuranyl group, a dibenzopyrrole group, a dibenzothiophene group, and a dibenzopyridine group.

[0076] When the term "heteroarene" is used in the present specification, the heteroarene means a "5- to 14-membered monocyclic, bicyclic or tricyclic aromatic heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms and nitrogen atoms other than one or more carbon atoms" formed by adding one hydrogen atom to the "heteroaryl group" defined above.

[0077] As used herein, the term "heterocyclyl group" refers to a monovalent group (i.e., a heterocyclic ring) formed by removing one hydrogen atom from a 3- to 12-membered monocyclic non-aromatic heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms and nitrogen atoms in addition to one or more carbon atoms.

[0078] Examples of substituents of the optionally substituted heterocyclyl group include one or more substituents independently selected from the following: an oxo group (=O); a thiol group (=S); an imino group (=NR 9 ; where R 9 Same as above definition); hydrazone group (=NN(R 10 )(R 11 );where R 10 and R 11Same as defined above); an alkyl group; and Group A (hereinafter referred to as a group consisting of an oxo group, a thioalkenyl group; an imino group; a hydrazone group; an alkyl group; and Group A is referred to as "Group D").

[0079] Specific examples of the heterocyclic group include an azetidinyl group, an oxetanyl group, a thietanyl group, a pyrrolidinyl group, a piperidinyl group, a piperidinyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, a tetrahydrothiophenyl group, a piperazinyl group, a morpholinyl group, a perhydroazepinyl group, an azacyclooctyl group, an azacyclooct-3-enyl group, an azacyclooct-4-enyl group, an azacyclononyl group, an azacyclodecyl group, a 6- to 12-membered azabicycloalkyl group (e.g., an azabicyclohexyl group, an azabicycloheptyl group, an azabicyclooctyl group, an azabicyclononyl group) , azabicyclodecanyl group, azabicycloundecyl group, or azabicyclododecyl group), a 6- to 12-membered azabicycloalkenyl group (e.g., an azabicyclohexenyl group, an azabicycloheptenyl group, an azabicyclooctenyl group, an azabicyclononenyl group, an azabicyclodecenyl group, an azabicycloundecyl group, or an azabicyclododecyl group), and a 6- to 12-membered azaspiroalkyl group (e.g., an azaspirohexyl group, an azaspiroheptyl group, an azaspirooctyl group, an azaspirononyl group, an azaspirodecanyl group, an azaspiroundecyl group, or an azaspirododecyl group).

[0080] When the term "heterocyclic group" is used in the present specification, the heterocyclic group means a "4- to 12-membered monocyclic non-aromatic heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms and nitrogen atoms other than one or more carbon atoms" formed by adding one hydrogen atom to the "heterocyclic group" defined above.

[0081] The above-mentioned cyclic compounds (i.e., cycloalkanes, arenes, heteroarenes and heterocyclic rings) are each optionally fused with any other one or more cyclic compounds to form bicyclic to tetracyclic compounds, and monovalent groups or divalent groups can be generated by removing one or two hydrogen atoms from these bicyclic to tetracyclic compounds. As described herein, the term "lactone group" refers to a class of heterocyclic groups, wherein the heterocyclic group has an oxygen atom as a heteroatom in the ring and the carbon atom adjacent to the oxygen atom is substituted by an oxo group. Examples of the lactone group include α-acetone lactone groups, β-propiolactone groups, γ-butyrolactone groups, δ-valerolactone groups, ε-caprolactone groups, γ-nonalactone groups, γ-decanolactone groups, γ-undecanolactone groups, glucono-δ-lactone groups, and pantolactone groups (a monovalent residue of pantolactone), and each of which is optionally substituted like the heterocyclic group, and optionally fused with any other one or more cyclic compounds to form a compound of two to four rings. Furthermore, the lactone group may be a substituent bonded to a carbon atom or a heteroatom (e.g., N, O, S, Se or P) present in a linker portion or an antitumor drug residue in the conjugate precursor or conjugate precursor synthetic intermediate of the present invention represented by general formula (I), (II-1) or (II-2).

[0082] As used herein, the term "alkylene group" means a divalent group formed by removing any one hydrogen atom from the above-defined "alkyl group". In addition, when the alkyl group has one or more substituents, the term "alkylene group" means a divalent group formed by removing any one additional hydrogen atom from an alkyl chain carbon atom other than the one or more substituents. Here, in the present invention, in the general formulas (I), (II-1) and (II-2), L 1 , L 2 , L 3 、L1 -1 , L 1-2 and L 3-1 are each independently an optionally substituted alkylene group, One or more methylene groups in the chain of the alkylene group may be replaced by one or more divalent groups independently selected from the group consisting of: -C(R 1 )(R 2 )-;-O-;-N(R 3 )-;-N(R 3 )-N(R 3 )-;-S-;-Se-;-Si(R 4 )(R 5 )-;-SS-;-Se-Se-;-SOm-;-SeOn-;-C(=C(R 6 )(R 7 ))-;-C(=O)-;-C(=S)-;-C(=N(R 8))-;-C(=N-OR 9 )-;-C(=NN(R 10 )(R 11 ))-;-P(=O)(R 12 )-;-P(=O)(OR 13 )-;-OP(=O)(R 12 )-O-;-OP(=O)(OR 13 )-O-;-C(R 14 )=;=C(R 14 )-;-C(R 14 )=C(R 14 )-;-N=;=N-;-C≡C-;-(OC(R 1 )(R 2 )-C(R 1 )(R 2 )) 1-30 -;-(C(R 1 )(R 2 )-C(R 1 )(R 2 )-0) 1-30 -(where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 and R 14 is independently a group selected from the group consisting of a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, an aryl group, a heteroaryl group, and a heterocyclyl group, and when R 3 when it is an alkyl group, the alkyl group is optionally combined with the alkyl group on the adjacent methylene group to form a cyclic structure, and m and n are independently an integer from 0 to 2); an optionally substituted alkenylene group, an optionally substituted alkynylene group, an optionally substituted cycloalkylene group; an optionally substituted cycloalkenylene group; an optionally substituted arylene group; an optionally substituted heteroarylene group; and an optionally substituted heterocyclylene group.

[0083] Examples of the substituent of the optionally substituted alkylene group include one or more substituents independently selected from Group A.

[0084] Specific examples of the alkylene group include a methylene group, an ethylene group, a methylmethylene group, a trimethylene group, an ethylmethylene group, a dimethylmethylene group, an n-propylene group, an n-butylene group, an n-pentylene group, an n-hexylene group, an n-heptylene group, an n-octylene group, an n-nonylene group, an n-decylene group, an n-undecylene group, an n-dodecylene group, an n-tridecylene group, an n-tetradecylene group, an n-pentadecylene group, an n-hexadecylene group, an n-heptadecynylene group, an n-octadecylene group, an n-nonadecylene group, an n-eicosylene group, an n-triacontylene group, an n-tetracontylene group, and an n-pentacontylene group.

[0085] As used herein, the term "alkenylene group" refers to a group consisting of L in the above general formula (II-1) and (II-2). 1 , L 2 , L 3 , L 1-1 , L 2-1 and L 3-1 The term "alkenylene group" refers to a group of a linker chain, and means a divalent group formed by removing any one hydrogen atom from the "alkenyl group" defined above. In addition, when the alkenyl group has one or more substituents, the term "alkenylene group" means a divalent group formed by removing any one additional hydrogen atom from the alkenyl chain carbon atom other than the one or more substituents.

[0086] Examples of the substituent of the optionally substituted alkenylene group include one or more substituents independently selected from Group A.

[0087] Specific examples of the alkenylene group include a vinylene group, a 1-propenylene group, a 2-propenylene group, a 1-butenylene group, a 2-butenylene group, a 3-butenylene group, a 1,3-butadienylene group, a 1-methyl-2-propenylene group, a 1,1-dimethyl-2-propenylene group, a 1-pentenylene group, a 2-pentenylene group, a 3-pentenylene group, a 4-pentenylene group, a 1-methyl-2-butenylene group, a 3-methyl-1-butenylene group, a 1-hexenylene group, a 2-hexenylene group, The invention also includes but is not limited to 3-(4-(4-(4-decenyl)-2-yl)-1-ylene group, 3-(4-(4-decenyl)-2-yl)-1-ylene group, 3-(4-(4-decenyl)-2-yl)-1-ylene group, 3-(4-(4-decenyl)-2-yl)-1-ylene group, 3-(4-(4-decenyl)-2-yl)-1-ylene group, 3-(4-(4-decenyl)-2-yl)-1-ylene group, 3-(4-decenyl)-2 ...

[0088] As used herein, the term "alkynylene group" refers to a group consisting of L in the above general formula (II-1) and (II-2). 1 , L 2 , L 3 , L 1-1 , L 2-1 and L 3-1 The term "alkynylene group" refers to a group of a linker chain, and means a divalent group formed by removing any one hydrogen atom from the "alkynyl group" defined above. In addition, when the alkynyl group has one or more substituents, the term "alkynylene group" means a divalent group formed by removing any one additional hydrogen atom from one or more alkynyl chain carbon atoms other than the one or more substituents.

[0089] Examples of the substituent of the optionally substituted alkynylene group include one or more substituents independently selected from Group A.

[0090] Specific examples of the alkynylene group include an ethynylene group, a 1-propynylene group, a 2-propynylene group, a 1-butynylene group, a 2-butynylene group, a 3-butynylene group, a 1-methyl-2-propynylene group, a 1,1-dimethyl-2-propynylene group, a 1-pentynylene group, a 2-pentynylene group, a 3-pentynylene group, a 4-pentynylene group, a 1-methyl-2-butynylene group, a 3-methyl-1-butynylene group, a 1-hexynylene group, a 2-hexynylene group, a 3-hexynylene group. group, a 4-hexynylene group, a 5-hexynylene group, a 1-methyl-2-pentynylene group, a 3-methyl-1-pentynylene group, a 2-heptynylene group, a 4-octynylene group, a 1-nonynylene group, a 2-decynylene group, a 1-undecynylene group, a 3-dodecynylene group, a 2-tridecynylene group, a 4-tetradecynylene group, a 1-pentadecinylene group, a 2-hexadecynylene group, a 3-heptadecinylene group, a 2-octadecynylene group, a 1-nonadecinylene group, and a 1-eicosynylene group.

[0091] As used herein, the term "cycloalkylene group" refers to a group consisting of L in the above general formula (II-1) and (II-2). 1 , L 2 , L 3 , L 1-1 , L 2-1 and L 3-1The term "cycloalkylene group" refers to a group of a linker chain, and means a divalent group formed by removing any one hydrogen atom from the "cycloalkyl group" defined above. In addition, when the cycloalkyl group has one or more substituents, the term "cycloalkylene group" means a divalent group formed by removing any one additional hydrogen atom from a cycloalkyl ring carbon atom other than the one or more substituents.

[0092] Examples of the substituent of the optionally substituted cycloalkylene group include one or more substituents independently selected from Group B.

[0093] Specific examples of the cycloalkylene group include monocyclic cycloalkylene groups having 3 to 10 carbon atoms, such as a cyclopropylene group, a cyclobutylene group, a cyclopentylene group, a cyclohexylene group, a cycloheptylene group, a cyclooctylene group, a cyclononylene group and a cyclodecylene group; and bicyclic cycloalkylene groups having 4 to 10 carbon atoms, such as a bicyclo[1.1.0]butylene group, a bicyclo[2.1.0]pentylene group, a bicyclo[3.1.0]hexylene group, a bicyclo[3.2.0]heptylene group, a bicyclo[2.2.1]heptylene group, a bicyclo[3.3.0]octylene group, a bicyclo[3.2.1]octylene group, a bicyclo[2.2.2]octylene group, a bicyclo[6.1.0]nonylene group and a bicyclo[4.4.0]decylene group.

[0094] As used herein, the term "cycloalkenylene group" refers to a group consisting of L in the above general formula (I). 1 , L 2 , L 3 , L 1-1 , L 2-1 and L 3-1 The term "cycloalkenylene group" refers to a group of a linker chain, and means a divalent group formed by removing any one hydrogen atom from the "cycloalkenyl group" defined above. In addition, when the cycloalkenyl group has one or more substituents, the term "cycloalkenylene group" means a divalent group formed by removing any one additional hydrogen atom from a cycloalkenyl ring carbon atom other than the one or more substituents.

[0095] Examples of the substituent of the optionally substituted cycloalkenylene group include one or more substituents independently selected from Group B.

[0096] Specific examples of the cycloalkenylene group include monocyclic cycloalkenylene groups having 3 to 10 carbon atoms, such as a 1-cyclopropenylene group, a 1-cyclobutenylene group, a 1-cyclopentenylene group, a 2-cyclopentenylene group, a 1-cyclohexenylene group, a 2-cyclohexenylene group, a 3-cyclohexenylene group, a 1,3-cyclohexadienylene group, a 1,4-cyclohexadienylene group, a 1-cycloheptenylene group, a 2-cyclooctenylene group, a 3-cyclooctenylene group, a 4-cyclooctenylene group, a 1-cyclononenylene group, and a 1-cyclodecenylene group; and monocyclic cycloalkenylene groups having 4 to 10 carbon atoms, such as a 1-cyclopropenylene group, a 1-cyclobutenylene group, a 1-cyclopentenylene group, a 2-cyclopentenylene group, a 1-cyclohexenylene group, a 2-cyclohexenylene group, a 3-cyclohexenylene group, a 1,3-cyclohexadienylene group, a 1,4-cyclohexadienylene group, a 1-cycloheptenylene group, a 2-cyclooctenylene group, a 3-cyclooctenylene group, a 4-cyclooctenylene group, a 1-cyclononenylene group, and a 1-cyclodecenylene group; A bicyclo[1.1.0]but-1-enylidene group, a bicyclo[2.1.0]pent-2-enylidene group, a bicyclo[3.1.0]hex-2-enylidene group, a bicyclo[3.2.0]hept-3-enylidene group, a bicyclo[2.2.1]hept-2-enylidene group, a bicyclo[3.3.0]oct-2-enylidene group, a bicyclo[3.2.1]oct-2-enylidene group, a bicyclo[2.2.2]oct-2-enylidene group, a bicyclo[6.1.0]non-4-enylidene group and a bicyclo[4.4.0]dec-3-enylidene group.

[0097] As used herein, the term "arylene group" refers to an arylene group consisting of L in the above general formula (I). 1 , L 2 , L 3 , L 1-1 , L 2-1 and L 3-1 The term "arylene group" refers to a group of a linker chain, and means a divalent group formed by removing any one hydrogen atom from the "aryl group" defined above. In addition, when the aryl group has one or more substituents, the term "arylene group" means a divalent group formed by removing any one additional hydrogen atom from an aryl ring carbon atom other than the one or more substituents.

[0098] Examples of the substituent of the optionally substituted arylene group include one or more substituents independently selected from Group C.

[0099] Specific examples of the arylene group include a monocyclic arylene group having 6 to 11 ring carbon atoms, such as a phenylene group; and an optionally partially saturated bicyclic arylene group having 9 to 11 ring carbon atoms, such as a naphthylene group, a tetrahydronaphthylene group, an indenylene group, an indanylene group.

[0100] As used herein, the term "heteroarylene group" refers to a group consisting of L in the above general formula (I): 1 , L 2 , L 3 , L 1-1 , L 2-1 and L3-1 The term "heteroaryl group" refers to a group of a linker chain, and means a divalent group formed by removing any one hydrogen atom from the "heteroaryl group" defined above. In addition, when the heteroarylene group has one or more substituents, the term "heteroarylene group" means a divalent group formed by removing any one additional hydrogen atom from a heteroaryl ring atom other than the one or more substituents.

[0101] Examples of the substituent of the optionally substituted heteroarylene group include one or more substituents independently selected from Group C.

[0102] Specific examples of the heteroarylene group include a 5- to 6-membered monocyclic heteroarylene group containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms and nitrogen atoms in addition to one or more carbon atoms, such as a pyrrolylene group, a furylene group, a thienylene group, a pyrazolylene group, an imidazolylene group, an oxazolylene group, an isoxazolylene group, a thiazolylene group, an isothiazolylene group, a thiadiazolylene group, a triazolylene group, a tetrazolylene group, a pyridylene group, a pyrazinylene group, a pyrimidinylene group, a pyridazinylene group, and a triazinylene group; and an 8- to 10-membered monocyclic heteroarylene group containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms and nitrogen atoms in addition to one or more carbon atoms. A 1-membered bicyclic heteroarylene group such as an indolylene group, an isoindolylene group, an indazolylene group, a tetrahydroindazolylene group, a benzofuranylene group, a dihydrobenzofuranylene group, a dihydroisobenzofuranylene group, a benzothiophenylene group, a dihydrobenzothiophenylene group, a dihydroisobenzothiophenylene group, a benzoxazolylene group, a dihydrobenzoxazolylene group, a benzothiazolylene group, a dihydrobenzothiazolylene group, a quinolylene group, a tetrahydroquinolylene group, an isoquinolylene group, a tetrahydroisoquinolylene group, a naphthyridinylene group, a tetrahydronaphthyridinylene group, a quinoxalinylene group, a tetrahydroquinoxalinylene group, and a quinazolinylene group.

[0103] As used herein, the term "heterocyclylene group" refers to a group consisting of L in the above general formulas (I), (II-1) and (II-2). 1 , L 2 , L 3 , L 1-1 , L 2-1 and L 3-1 The group represents a linker chain, and means a divalent group formed by removing any one hydrogen atom from the above-defined "heterocyclyl group".

[0104] Examples of the substituent of the optionally substituted heterocyclylene group include one or more substituents independently selected from the D group.

[0105] Specific examples of the heterocyclylene group include an azetidinylene group, an oxetanylene group, a thietanylene group, a pyrrolidinylene group, a piperidinylene group, a piperidinylene group, a tetrahydrofuranylene group, a tetrahydropyranylene group, a tetrahydrothiophenylene group, a piperazinylene group, a morpholinylene group, a perhydroazepinylene group, an azacyclooctylene group, an azacyclooct-3-enylidene group, an azacyclooct-4-enylidene group, an azacyclononylene group, an azacyclodecylene group, a 6- to 12-membered azabicycloalkylene group (e.g., azabicyclohexylene group, azabicycloheptylene group, azabicyclooctylene group, azabicyclononylene group), The invention further comprises a 6- to 12-membered azabicycloalkenyl group (for example, azabicyclohexenyl group, azabicycloheptenyl group, azabicyclooctenyl group, azabicyclononenyl group, azabicyclodecenyl group, azabicycloundecenyl group, or azabicyclododecenyl group), a 6- to 12-membered azabicycloalkenyl group (for example, azabicyclohexenyl group, azabicycloheptenyl group, azabicyclooctenyl group, azabicyclononenyl group, azabicyclodecenyl group, azabicycloundecenyl group, or azabicyclododecenyl group), a 6- to 12-membered azabicyclospiroalkyl group (for example, azabicyclohexyl group, azabicycloheptyl group, azabicyclooctyl group, azabicyclononyl group, azabicyclodecyl group, azabicycloundecyl group, or azabicyclododecyl group).

[0106] The heterocyclylene group is optionally fused to one or more of the above-mentioned aryl rings and / or the above-mentioned heteroaryl rings to form a bicyclic to tetracyclic heterocyclylene group.

[0107] Furthermore, when the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the cycloalkenyl group, the aryl group, the heteroaryl group, the heterocyclyl group, the alkylene group, the alkenylene group, the alkynylene group, the cycloalkylene group, the cycloalkenylene group, the arylene group, the heteroarylene group, and the heterocyclylene group have one or more functional groups (e.g., a hydroxyl group, a thiol group, an amino group (-NH 2 When one or more substituents are used, the one or more substituents are optionally protected by one or more protecting groups defined in connection with the “anti-tumor drug molecule or its analogs, or its derivatives”.

[0108] Examples of the "salt" described herein include salts with alkali metals such as lithium, sodium and potassium; salts with alkaline earth metals such as magnesium and calcium; salts with aluminum or zinc; salts with amines such as ammonia, choline, diethanolamine, lysine, ethylenediamine, tert-butylamine, tert-octylamine, tris(hydroxymethyl)aminomethane, N-methylglucamine, triethanolamine and dehydroabietylamine; salts with inorganic acids such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, nitric acid and phosphoric acid; salts with organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid and benzenesulfonic acid; and salts with acidic amino acids such as aspartic acid and glutamic acid. Further, the term "salt" also includes intramolecular salts.

[0109] The conjugate precursor (I) and the conjugate precursor synthetic intermediates (II-1) and (II-2) of the present invention, and salts thereof are all available as hydrates or solvates, and the present invention encompasses all of them.

[0110] A specific example of the conjugate precursor (I) of the present invention will be shown in Example 2 below, and specific examples of the conjugate precursor synthetic intermediates (II-1) and (II-2) of the present invention will be shown in Example 3 below, but the present invention is not limited thereto.

[0111] Example 2. Example of "Conjugate Precursor (I)" Example 2-1 [C199] Example 2-2 [C200] Example 2-3 [C201] Example 2-4 [C202] Example 2-5 [C203] Example 2-6 [C204] Example 2-7 [C205]

[0112] Example 3. Example of “Conjugate Precursor Synthetic Intermediates (II-1) and (II-2)” Example 3-1 Example 3-1-(1)-A [C206] Example 3-1-(1)-B [C207] Example 3-1-(1)-C [C208] Example 3-1-(2) [C209] Example 3-1-(3)-A [C210] Example 3-1-(3)-B [C211] Example 3-1-(3)-C [C212] Example 3-2-(1)-A [C213] Example 3-2-(1)-B [C214] Example 3-2-(2) [C215] Example 3-2-(3)-A [C216] Example 3-2-(3)-B [C217] Example 3-3-(1)-A [C218] Example 3-3-(1)-B [C219] Example 3-3-(3) [C220] Example 3-4-(1)-A [C221] Example 3-4-(1)-B [C222] Example 3-4-(3)-A [C223] Example 3-5-(1)-A [C224] Example 3-5-(1)-B [C225] Example 3-5-(1)-C [C226] Example 3-5-(2) [C227] Example 3-5-(3)-A [C228] Example 3-5-(3)-B [C229] Example 3-5-(3)-C [C230] Example 3-6-(1)-A [C231] Example 3-6-(1)-B [C232] Example 3-6-(3)-A [C233] Example 3-7-(1)-A [C234] Example 3-7-(1)-B [C235] Example 3-7-(3)-A [C236]

[0113] A further compound of Example 2 (Example Precursor Compound) can be represented by Formula (X). [C237] {in, Z is the Z in the following table, L 1 Is to choose free L 1-a To L 1-b Any one of the groups, L 2 Is to choose free L 2-a To L 2-d Any one of the groups, L 3 Is to choose free L 3-a To L 3-i Any one of the groups, D 1 Is to choose free D 1-a To D 1-b Any one of the groups, D 2 Is to choose free D 2-aa To D 2-at Any one of the groups consisting of *1 is connected to *1, *1' is connected to *1', *2 is connected to *2, *2' is connected to *2', *3 is connected to *3, *3' is connected to *3'}.

[0114] Additional exemplary precursor compounds are represented by formula (XI). [C238] {in, Z is the Z in the following table, L 1 Is to choose free L 1-a To L 1-b Any one of the groups, L 2 Is to choose free L 2-b To L 2-h Any one of the groups, L 3 Is to choose free L 3-aTo L 3-i Any one of the groups, D 1 Is to choose free D 1-a To D 1-b Any one of the groups, D 2 Is to choose free D 2-ba To D 2-bg Any one of the groups consisting of *1 is connected to *1, *1' is connected to *1', *2 is connected to *2, *2' is connected to *2', *3 is connected to *3, *3' is connected to *3'}.

[0115] Another exemplary precursor compound is represented by formula (XII). [C239] {in, Z is the Z in the following table, L 1 Is to choose free L 1-a To L 1-b Any one of the groups, L 2 Is to choose free L 2-b , L 2-b , L 2-i To L 2-n Any one of the groups, L 3 Is to choose free L 3-a To L 3-i Any one of the groups, D 1 Is to choose free D 1-a To D 1-b Any one of the groups, D 2 Is to choose free D 2-ca To D 2-ch Any one of the groups consisting of *1 is connected to *1, *1' is connected to *1', *2 is connected to *2, *2' is connected to *2', *3 is connected to *3, *3' is connected to *3'}.

[0116] Another exemplary precursor compound is represented by formula (XIII). [C240] {in, Z is the Z in the following table, L 1 Is to choose free L 1-a To L1-b Any one of the groups, L 2 Is to choose free L 2-o To L 2-r Any one of the groups, L 3 Is to choose free L 3-a To L 3-e and L 3-j To L 3-m Any one of the groups, D 1 Is to choose free D 1-a To D 1-b Any one of the groups, D 2 Yes D 2-da ,and *1 is connected to *1, *1' is connected to *1', *2 is connected to *2, *2' is connected to *2', *3 is connected to *3, *3' is connected to *3'}.

[0117] [Table 1]

[0118] The present invention also provides example precursor compounds (Example 4-1 to Example 4-1440) {In the following formula, Z, L 1-a To L 1 -b , L 2-a To L 2-d , L 3-aTo L 3-i , D 1-a To D 1-b and D 2-aa To D 2-at As defined above}. Example 4-1: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-a -D 2-aa ), Example 4-2: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-a -D 2-ab ), Example 4-3: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-a -D 2-ac ), Example 4-4: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-a -D 2-ad ), Example 4-5: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-a -D 2-ae ), Example 4-6: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-a -D 2-af ), Example 4-7: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-a -D 2-ag ), Example 4-8: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-a -D 2-ah ), Example 4-9: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-a -D 2-ai ), Example 4-10: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-a -D 2-aj ), Example 4-11: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-a -D 2-ak ), Example 4-12: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-a -D 2-al ), Example 4-13: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-a -D 2-am ), Example 4-14: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-a -D 2-an ), Example 4-15: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-a -D 2-ao ), Example 4-16: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-a -D 2-ap ), Example 4-17: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-b -D 2-aq ), Example 4-18: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-b -D 2-ar ), Example 4-19: ZL 3-a -N(-L 1-a -D 1-a )(-L2-b -D 2-as ), Example 4-20: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-b -D 2-at ), Example 4-21: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-c -D 2-aa ), Example 4-22: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-c -D 2-ab ), Example 4-23: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-c -D 2-ac ), Example 4-24: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-c -D 2-ad ), Example 4-25: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-c -D 2-ae ), Example 4-26: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-c -D 2-af ), Example 4-27: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-c -D 2-ag ), Example 4-28: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-c -D 2-ah ), Example 4-29: ZL 3-a -N(-L1-a -D 1-a )(-L 2-c -D 2-ai ), Example 4-30: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-c -D 2-aj ), Example 4-31: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-c -D 2-ak ), Example 4-32: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-c -D 2-al ), Example 4-33: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-c -D 2-am ), Example 4-34: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-c -D 2-an ), Example 4-35: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-c -D 2-ao ), Example 4-36: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-c -D 2-ap ), Example 4-37: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-d -D 2-aq ), Example 4-38: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-d -D 2-ar ), Example 4-39: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-d -D 2-as ), Example 4-40: ZL 3-a -N(-L 1-a -D 1-a )(-L 2-d -D 2-at ), Example 4-41: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-a -D 2-aa ), Example 4-42: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-a -D 2-ab ), Example 4-43: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-a -D 2-ac ), Example 4-44: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-a -D 2-ad ), Example 4-45: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-a -D 2-ae ), Example 4-46: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-a -D 2-af ), Example 4-47: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-a -D 2-ag ), Example 4-48: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-a-D 2-ah ), Example 4-49: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-a -D 2-ai ), Example 4-50: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-a -D 2-aj ), Example 4-51: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-a -D 2-ak ), Example 4-52: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-a -D 2-al ), Example 4-53: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-a -D 2-am ), Example 4-54: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-a -D 2-an ), Example 4-55: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-a -D 2-ao ), Example 4-56: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-a -D 2-ap ), Example 4-57: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-b -D 2-aq ), Example 4-58: ZL 3-a -N(-L 1-b -D1-a )(-L 2-b -D 2-ar ), Example 4-59: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-b -D 2-as ), Example 4-60: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-b -D 2-at ), Example 4-61: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-c -D 2-aa ), Example 4-62: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-c -D 2-ab ), Example 4-63: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-c -D 2-ac ), Example 4-64: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-c -D 2-ad ), Example 4-65: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-c -D 2-ae ), Example 4-66: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-c -D 2-af ), Example 4-67: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-c -D 2-ag ), Example 4-68: ZL3-a -N(-L 1-b -D 1-a )(-L 2-c -D 2-ah ), Example 4-69: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-c -D 2-ai ), Example 4-70: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-c -D 2-aj ), Example 4-71: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-c -D 2-ak ), Example 4-72: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-c -D 2-al ), Example 4-73: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-c -D 2-am ), Example 4-74: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-c -D 2-an ), Example 4-75: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-c -D 2-ao ), Example 4-76: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-c -D 2-ap ), Example 4-77: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-d -D 2-aq), Example 4-78: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-d -D 2-ar ), Example 4-79: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-d -D 2-as ), Example 4-80: ZL 3-a -N(-L 1-b -D 1-a )(-L 2-d -D 2-at ), Example 4-81: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-a -D 2-aa ), Example 4-82: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-a -D 2-ab ), Example 4-83: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-a -D 2-ac ), Example 4-84: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-a -D 2-ad ), Example 4-85: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-a -D 2-ae ), Example 4-86: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-a -D 2-af ), Example 4-87: ZL 3-a -N(-L 1-a -D 1-b)(-L 2-a -D 2-ag ), Example 4-88: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-a -D 2-ah ), Example 4-89: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-a -D 2-ai ), Example 4-90: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-a -D 2-aj ), Example 4-91: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-a -D 2-ak ), Example 4-92: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-a -D 2-al ), Example 4-93: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-a -D 2-am ), Example 4-94: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-a -D 2-an ), Example 4-95: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-a -D 2-ao ), Example 4-96: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-a -D 2-ap ), Example 4-97: ZL 3-a-N(-L 1-a -D 1-b )(-L 2-b -D 2-aq ), Example 4-98: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-b -D 2-ar ), Example 4-99: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-b -D 2-as ), Example 4-100: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-b -D 2-at ), Example 4-101: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-c -D 2-aa ), Example 4-102: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-c -D 2-ab ), Example 4-103: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-c -D 2-ac ), Example 4-104: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-c -D 2-ad ), Example 4-105: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-c -D 2-ae ), Example 4-106: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-c -D 2-af ), Example 4-107: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-c -D 2-ag ), Example 4-108: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-c -D 2-ah ), Example 4-109: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-c -D 2-ai ), Example 4-110: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-c -D 2-aj ), Example 4-111: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-c -D 2-ak ), Example 4-112: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-c -D 2-al ), Example 4-113: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-c -D 2-am ), Example 4-114: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-c -D 2-an ), Example 4-115: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-c -D 2-ao ), Example 4-116: ZL 3-a -N(-L 1-a -D1-b )(-L 2-c -D 2-ap ), Example 4-117: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-d -D 2-aq ), Example 4-118: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-d -D 2-ar ), Example 4-119: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-d -D 2-as ), Example 4-120: ZL 3-a -N(-L 1-a -D 1-b )(-L 2-d -D 2-at ), Example 4-121: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-a -D 2-aa ), Example 4-122: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-a -D 2-ab ), Example 4-123: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-a -D 2-ac ), Example 4-124: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-a -D 2-ad ), Example 4-125: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-a -D 2-ae ), Example 4-126: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-a -D 2-af ), Example 4-127: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-a -D 2-ag ), Example 4-128: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-a -D 2-ah ), Example 4-129: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-a -D 2-ai ), Example 4-130: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-a -D 2-aj ), Example 4-131: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-a -D 2-ak ), Example 4-132: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-a -D 2-al ), Example 4-133: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-a -D 2-am ), Example 4-134: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-a -D 2-an ), Example 4-135: ZL 3-a -N(-L 1-b -D 1-b )(-L2-a -D 2-ao ), Example 4-136: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-a -D 2-ap ), Example 4-137: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-b -D 2-aq ), Example 4-138: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-b -D 2-ar ), Example 4-139: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-b -D 2-as ), Example 4-140: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-b -D 2-at ), Example 4-141: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-c -D 2-aa ), Example 4-142: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-c -D 2-ab ), Example 4-143: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-c -D 2-ac ), Example 4-144: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-c -D 2-ad ), Example 4-145: ZL 3-a-N(-L 1-b -D 1-b )(-L 2-c -D 2-ae ), Example 4-146: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-c -D 2-af ), Example 4-147: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-c -D 2-ag ), Example 4-148: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-c -D 2-ah ), Example 4-149: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-c -D 2-ai ), Example 4-150: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-c -D 2-aj ), Example 4-151: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-c -D 2-ak ), Example 4-152: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-c -D 2-al ), Example 4-153: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-c -D 2-am ), Example 4-154: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-c -D 2-an), Example 4-155: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-c -D 2-ao ), Example 4-156: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-c -D 2-ap ), Example 4-157: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-d -D 2-aq ), Example 4-158: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-d -D 2-ar ), Example 4-159: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-d -D 2-as ), Example 4-160: ZL 3-a -N(-L 1-b -D 1-b )(-L 2-d -D 2-at ), Example 4-161: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-a -D 2-aa ), Example 4-162: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-a -D 2-ab ), Example 4-163: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-a -D 2-ac ), Example 4-164: ZL 3-b -N(-L 1-a -D1-a )(-L 2-a -D 2-ad ), Example 4-165: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-a -D 2-ae ), Example 4-166: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-a -D 2-af ), Example 4-167: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-a -D 2-ag ), Example 4-168: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-a -D 2-ah ), Example 4-169: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-a -D 2-ai ), Example 4-170: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-a -D 2-aj ), Example 4-171: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-a -D 2-ak ), Example 4-172: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-a -D 2-al ), Example 4-173: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-a -D 2-am ), Example 4-174: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-a -D 2-an ), Example 4-175: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-a -D 2-ao ), Example 4-176: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-a -D 2-ap ), Example 4-177: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-b -D 2-aq ), Example 4-178: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-b -D 2-ar ), Example 4-179: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-b -D 2-as ), Example 4-180: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-b -D 2-at ), Example 4-181: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-c -D 2-aa ), Example 4-182: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-c -D 2-ab ), Example 4-183: ZL 3-b -N(-L 1-a -D 1-a )(-L2-c -D 2-ac ), Example 4-184: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-c -D 2-ad ), Example 4-185: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-c -D 2-ae ), Example 4-186: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-c -D 2-af ), Example 4-187: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-c -D 2-ag ), Example 4-188: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-c -D 2-ah ), Example 4-189: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-c -D 2-ai ), Example 4-190: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-c -D 2-aj ), Example 4-191: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-c -D 2-ak ), Example 4-192: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-c -D 2-al ), Example 4-193: ZL 3-b-N(-L 1-a -D 1-a )(-L 2-c -D 2-am ), Example 4-194: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-c -D 2-an ), Example 4-195: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-c -D 2-ao ), Example 4-196: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-c -D 2-ap ), Example 4-197: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-d -D 2-aq ), Example 4-198: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-d -D 2-ar ), Example 4-199: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-d -D 2-as ), Example 4-200: ZL 3-b -N(-L 1-a -D 1-a )(-L 2-d -D 2-at ), Example 4-201: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-a -D 2-aa ), Example 4-202: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-a -D 2-ab), Example 4-203: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-a -D 2-ac ), Example 4-204: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-a -D 2-ad ), Example 4-205: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-a -D 2-ae ), Example 4-206: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-a -D 2-af ), Example 4-207: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-a -D 2-ag ), Example 4-208: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-a -D 2-ah ), Example 4-209: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-a -D 2-ai ), Example 4-210: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-a -D 2-aj ), Example 4-211: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-a -D 2-ak ), Example 4-212: ZL 3-b -N(-L 1-b -D1-a )(-L 2-a -D 2-al ), Example 4-213: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-a -D 2-am ), Example 4-214: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-a -D 2-an ), Example 4-215: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-a -D 2-ao ), Example 4-216: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-a -D 2-ap ), Example 4-217: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-b -D 2-aq ), Example 4-218: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-b -D 2-ar ), Example 4-219: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-b -D 2-as ), Example 4-220: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-b -D 2-at ), Example 4-221: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-c -D 2-aa ), Example 4-222: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-c -D 2-ab ), Example 4-223: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-c -D 2-ac ), Example 4-224: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-c -D 2-ad ), Example 4-225: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-c -D 2-ae ), Example 4-226: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-c -D 2-af ), Example 4-227: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-c -D 2-ag ), Example 4-228: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-c -D 2-ah ), Example 4-229: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-c -D 2-ai ), Example 4-230: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-c -D 2-aj ), Example 4-231: ZL 3-b -N(-L 1-b -D 1-a )(-L2-c -D 2-ak ), Example 4-232: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-c -D 2-al ), Example 4-233: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-c -D 2-am ), Example 4-234: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-c -D 2-an ), Example 4-235: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-c -D 2-ao ), Example 4-236: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-c -D 2-ap ), Example 4-237: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-d -D 2-aq ), Example 4-238: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-d -D 2-ar ), Example 4-239: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-d -D 2-as ), Example 4-240: ZL 3-b -N(-L 1-b -D 1-a )(-L 2-d -D 2-at ), Example 4-241: ZL 3-b-N(-L 1-a -D 1-b )(-L 2-a -D 2-aa ), Example 4-242: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-a -D 2-ab ), Example 4-243: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-a -D 2-ac ), Example 4-244: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-a -D 2-ad ), Example 4-245: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-a -D 2-ae ), Example 4-246: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-a -D 2-af ), Example 4-247: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-a -D 2-ag ), Example 4-248: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-a -D 2-ah ), Example 4-249: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-a -D 2-ai ), Example 4-250: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-a -D 2-aj), Example 4-251: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-a -D 2-ak ), Example 4-252: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-a -D 2-al ), Example 4-253: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-a -D 2-am ), Example 4-254: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-a -D 2-an ), Example 4-255: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-a -D 2-ao ), Example 4-256: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-a -D 2-ap ), Example 4-257: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-b -D 2-aq ), Example 4-258: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-b -D 2-ar ), Example 4-259: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-b -D 2-as ), Example 4-260: ZL 3-b -N(-L 1-a -D1-b )(-L 2-b -D 2-at ), Example 4-261: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-c -D 2-aa ), Example 4-262: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-c -D 2-ab ), Example 4-263: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-c -D 2-ac ), Example 4-264: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-c -D 2-ad ), Example 4-265: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-c -D 2-ae ), Example 4-266: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-c -D 2-af ), Example 4-267: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-c -D 2-ag ), Example 4-268: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-c -D 2-ah ), Example 4-269: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-c -D 2-ai ), Example 4-270: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-c -D 2-aj ), Example 4-271: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-c -D 2-ak ), Example 4-272: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-c -D 2-al ), Example 4-273: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-c -D 2-am ), Example 4-274: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-c -D 2-an ), Example 4-275: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-c -D 2-ao ), Example 4-276: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-c -D 2-ap ), Example 4-277: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-d -D 2-aq ), Example 4-278: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-d -D 2-ar ), Example 4-279: ZL 3-b -N(-L 1-a -D 1-b )(-L2-d -D 2-as ), Example 4-280: ZL 3-b -N(-L 1-a -D 1-b )(-L 2-d -D 2-at ), Example 4-281: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-a -D 2-aa ), Example 4-282: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-a -D 2-ab ), Example 4-283: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-a -D 2-ac ), Example 4-284: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-a -D 2-ad ), Example 4-285: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-a -D 2-ae ), Example 4-286: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-a -D 2-af ), Example 4-287: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-a -D 2-ag ), Example 4-288: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-a -D 2-ah ), Example 4-289: ZL 3-b-N(-L 1-b -D 1-b )(-L 2-a -D 2-ai ), Example 4-290: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-a -D 2-aj ), Example 4-291: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-a -D 2-ak ), Example 4-292: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-a -D 2-al ), Example 4-293: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-a -D 2-am ), Example 4-294: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-a -D 2-an ), Example 4-295: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-a -D 2-ao ), Example 4-296: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-a -D 2-ap ), Example 4-297: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-b -D 2-aq ), Example 4-298: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-b -D 2-ar), Example 4-299: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-b -D 2-as ), Example 4-300: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-b -D 2-at ), Example 4-301: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-c -D 2-aa ), Example 4-302: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-c -D 2-ab ), Example 4-303: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-c -D 2-ac ), Example 4-304: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-c -D 2-ad ), Example 4-305: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-c -D 2-ae ), Example 4-306: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-c -D 2-af ), Example 4-307: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-c -D 2-ag ), Example 4-308: ZL 3-b -N(-L 1-b -D1-b )(-L 2-c -D 2-ah ), Example 4-309: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-c -D 2-ai ), Example 4-310: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-c -D 2-aj ), Example 4-311: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-c -D 2-ak ), Example 4-312: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-c -D 2-al ), Example 4-313: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-c -D 2-am ), Example 4-314: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-c -D 2-an ), Example 4-315: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-c -D 2-ao ), Example 4-316: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-c -D 2-ap ), Example 4-317: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-d -D 2-aq ), Example 4-318: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-d -D 2-ar ), Example 4-319: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-d -D 2-as ), Example 4-320: ZL 3-b -N(-L 1-b -D 1-b )(-L 2-d -D 2-at ), Example 4-321: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-a -D 2-aa ), Example 4-322: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-a -D 2-ab ), Example 4-323: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-a -D 2-ac ), Example 4-324: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-a -D 2-ad ), Example 4-325: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-a -D 2-ae ), Example 4-326: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-a -D 2-af ), Example 4-327: ZL 3-c -N(-L 1-a -D 1-a )(-L2-a -D 2-ag ), Example 4-328: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-a -D 2-ah ), Example 4-329: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-a -D 2-ai ), Example 4-330: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-a -D 2-aj ), Example 4-331: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-a -D 2-ak ), Example 4-332: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-a -D 2-al ), Example 4-333: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-a -D 2-am ), Example 4-334: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-a -D 2-an ), Example 4-335: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-a -D 2-ao ), Example 4-336: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-a -D 2-ap ), Example 4-337: ZL 3-c-N(-L 1-a -D 1-a )(-L 2-b -D 2-aq ), Example 4-338: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-b -D 2-ar ), Example 4-339: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-b -D 2-as ), Example 4-340: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-b -D 2-at ), Example 4-341: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-c -D 2-aa ), Example 4-342: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-c -D 2-ab ), Example 4-343: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-c -D 2-ac ), Example 4-344: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-c -D 2-ad ), Example 4-345: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-c -D 2-ae ), Example 4-346: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-c -D 2-af), Example 4-347: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-c -D 2-ag ), Example 4-348: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-c -D 2-ah ), Example 4-349: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-c -D 2-ai ), Example 4-350: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-c -D 2-aj ), Example 4-351: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-c -D 2-ak ), Example 4-352: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-c -D 2-al ), Example 4-353: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-c -D 2-am ), Example 4-354: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-c -D 2-an ), Example 4-355: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-c -D 2-ao ), Example 4-356: ZL 3-c -N(-L 1-a -D1-a )(-L 2-c -D 2-ap ), Example 4-357: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-d -D 2-aq ), Example 4-358: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-d -D 2-ar ), Example 4-359: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-d -D 2-as ), Example 4-360: ZL 3-c -N(-L 1-a -D 1-a )(-L 2-d -D 2-at ), Example 4-361: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-a -D 2-aa ), Example 4-362: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-a -D 2-ab ), Example 4-363: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-a -D 2-ac ), Example 4-364: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-a -D 2-ad ), Example 4-365: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-a -D 2-ae ), Example 4-366: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-a -D 2-af ), Example 4-367: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-a -D 2-ag ), Example 4-368: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-a -D 2-ah ), Example 4-369: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-a -D 2-ai ), Example 4-370: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-a -D 2-aj ), Example 4-371: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-a -D 2-ak ), Example 4-372: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-a -D 2-al ), Example 4-373: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-a -D 2-am ), Example 4-374: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-a -D 2-an ), Example 4-375: ZL 3-c -N(-L 1-b -D 1-a )(-L2-a -D 2-ao ), Example 4-376: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-a -D 2-ap ), Example 4-377: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-b -D 2-aq ), Example 4-378: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-b -D 2-ar ), Example 4-379: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-b -D 2-as ), Example 4-380: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-b -D 2-at ), Example 4-381: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-c -D 2-aa ), Example 4-382: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-c -D 2-ab ), Example 4-383: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-c -D 2-ac ), Example 4-384: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-c -D 2-ad ), Example 4-385: ZL 3-c-N(-L 1-b -D 1-a )(-L 2-c -D 2-ae ), Example 4-386: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-c -D 2-af ), Example 4-387: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-c -D 2-ag ), Example 4-388: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-c -D 2-ah ), Example 4-389: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-c -D 2-ai ), Example 4-390: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-c -D 2-aj ), Example 4-391: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-c -D 2-ak ), Example 4-392: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-c -D 2-al ), Example 4-393: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-c -D 2-am ), Example 4-394: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-c -D 2-an), Example 4-395: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-c -D 2-ao ), Example 4-396: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-c -D 2-ap ), Example 4-397: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-d -D 2-aq ), Example 4-398: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-d -D 2-ar ), Example 4-399: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-d -D 2-as ), Example 4-400: ZL 3-c -N(-L 1-b -D 1-a )(-L 2-d -D 2-at ), Example 4-401: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-a -D 2-aa ), Example 4-402: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-a -D 2-ab ), Example 4-403: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-a -D 2-ac ), Example 4-404: ZL 3-c -N(-L 1-a -D1-b )(-L 2-a -D 2-ad ), Example 4-405: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-a -D 2-ae ), Example 4-406: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-a -D 2-af ), Example 4-407: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-a -D 2-ag ), Example 4-408: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-a -D 2-ah ), Example 4-409: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-a -D 2-ai ), Example 4-410: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-a -D 2-aj ), Example 4-411: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-a -D 2-ak ), Example 4-412: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-a -D 2-al ), Example 4-413: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-a -D 2-am ), Example 4-414: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-a -D 2-an ), Example 4-415: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-a -D 2-ao ), Example 4-416: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-a -D 2-ap ), Example 4-417: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-b -D 2-aq ), Example 4-418: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-b -D 2-ar ), Example 4-419: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-b -D 2-as ), Example 4-420: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-b -D 2-at ), Example 4-421: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-c -D 2-aa ), Example 4-422: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-c -D 2-ab ), Example 4-423: ZL 3-c -N(-L 1-a -D 1-b )(-L2-c -D 2-ac ), Example 4-424: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-c -D 2-ad ), Example 4-425: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-c -D 2-ae ), Example 4-426: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-c -D 2-af ), Example 4-427: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-c -D 2-ag ), Example 4-428: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-c -D 2-ah ), Example 4-429: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-c -D 2-ai ), Example 4-430: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-c -D 2-aj ), Example 4-431: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-c -D 2-ak ), Example 4-432: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-c -D 2-al ), Example 4-433: ZL 3-c-N(-L 1-a -D 1-b )(-L 2-c -D 2-am ), Example 4-434: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-c -D 2-an ), Example 4-435: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-c -D 2-ao ), Example 4-436: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-c -D 2-ap ), Example 4-437: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-d -D 2-aq ), Example 4-438: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-d -D 2-ar ), Example 4-439: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-d -D 2-as ), Example 4-440: ZL 3-c -N(-L 1-a -D 1-b )(-L 2-d -D 2-at ), Example 4-441: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-a -D 2-aa ), Example 4-442: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-a -D 2-ab), Example 4-443: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-a -D 2-ac ), Example 4-444: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-a -D 2-ad ), Example 4-445: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-a -D 2-ae ), Example 4-446: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-a -D 2-af ), Example 4-447: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-a -D 2-ag ), Example 4-448: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-a -D 2-ah ), Example 4-449: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-a -D 2-ai ), Example 4-450: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-a -D 2-aj ), Example 4-451: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-a -D 2-ak ), Example 4-452: ZL 3-c -N(-L 1-b -D1-b )(-L 2-a -D 2-al ), Example 4-453: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-a -D 2-am ), Example 4-454: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-a -D 2-an ), Example 4-455: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-a -D 2-ao ), Example 4-456: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-a -D 2-ap ), Example 4-457: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-b -D 2-aq ), Example 4-458: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-b -D 2-ar ), Example 4-459: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-b -D 2-as ), Example 4-460: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-b -D 2-at ), Example 4-461: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-c -D 2-aa ), Example 4-462: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-c -D 2-ab ), Example 4-463: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-c -D 2-ac ), Example 4-464: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-c -D 2-ad ), Example 4-465: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-c -D 2-ae ), Example 4-466: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-c -D 2-af ), Example 4-467: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-c -D 2-ag ), Example 4-468: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-c -D 2-ah ), Example 4-469: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-c -D 2-ai ), Example 4-470: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-c -D 2-aj ), Example 4-471: ZL 3-c -N(-L 1-b -D 1-b )(-L2-c -D 2-ak ), Example 4-472: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-c -D 2-al ), Example 4-473: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-c -D 2-am ), Example 4-474: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-c -D 2-an ), Example 4-475: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-c -D 2-ao ), Example 4-476: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-c -D 2-ap ), Example 4-477: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-d -D 2-aq ), Example 4-478: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-d -D 2-ar ), Example 4-479: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-d -D 2-as ), Example 4-480: ZL 3-c -N(-L 1-b -D 1-b )(-L 2-d -D 2-at ), Example 4-481: ZL 3-d-N(-L 1-a -D 1-a )(-L 2-a -D 2-aa ), Example 4-482: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-a -D 2-ab ), Example 4-483: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-a -D 2-ac ), Example 4-484: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-a -D 2-ad ), Example 4-485: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-a -D 2-ae ), Example 4-486: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-a -D 2-af ), Example 4-487: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-a -D 2-ag ), Example 4-488: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-a -D 2-ah ), Example 4-489: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-a -D 2-ai ), Example 4-490: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-a -D 2-aj), Example 4-491: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-a -D 2-ak ), Example 4-492: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-a -D 2-al ), Example 4-493: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-a -D 2-am ), Example 4-494: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-a -D 2-an ), Example 4-495: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-a -D 2-ao ), Example 4-496: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-a -D 2-ap ), Example 4-497: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-b -D 2-aq ), Example 4-498: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-b -D 2-ar ), Example 4-499: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-b -D 2-as ), Example 4-500: ZL 3-d -N(-L 1-a -D1-a )(-L 2-b -D 2-at ), Example 4-501: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-c -D 2-aa ), Example 4-502: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-c -D 2-ab ), Example 4-503: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-c -D 2-ac ), Example 4-504: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-c -D 2-ad ), Example 4-505: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-c -D 2-ae ), Example 4-506: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-c -D 2-af ), Example 4-507: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-c -D 2-ag ), Example 4-508: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-c -D 2-ah ), Example 4-509: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-c -D 2-ai ), Example 4-510: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-c -D 2-aj ), Example 4-511: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-c -D 2-ak ), Example 4-512: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-c -D 2-al ), Example 4-513: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-c -D 2-am ), Example 4-514: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-c -D 2-an ), Example 4-515: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-c -D 2-ao ), Example 4-516: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-c -D 2-ap ), Example 4-517: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-d -D 2-aq ), Example 4-518: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-d -D 2-ar ), Example 4-519: ZL 3-d -N(-L 1-a -D 1-a )(-L2-d -D 2-as ), Example 4-520: ZL 3-d -N(-L 1-a -D 1-a )(-L 2-d -D 2-at ), Example 4-521: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-a -D 2-aa ), Example 4-522: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-a -D 2-ab ), Example 4-523: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-a -D 2-ac ), Example 4-524: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-a -D 2-ad ), Example 4-525: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-a -D 2-ae ), Example 4-526: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-a -D 2-af ), Example 4-527: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-a -D 2-ag ), Example 4-528: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-a -D 2-ah ), Example 4-529: ZL 3-d-N(-L 1-b -D 1-a )(-L 2-a -D 2-ai ), Example 4-530: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-a -D 2-aj ), Example 4-531: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-a -D 2-ak ), Example 4-532: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-a -D 2-al ), Example 4-533: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-a -D 2-am ), Example 4-534: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-a -D 2-an ), Example 4-535: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-a -D 2-ao ), Example 4-536: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-a -D 2-ap ), Example 4-537: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-b -D 2-aq ), Example 4-538: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-b -D 2-ar), Example 4-539: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-b -D 2-as ), Example 4-540: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-b -D 2-at ), Example 4-541: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-c -D 2-aa ), Example 4-542: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-c -D 2-ab ), Example 4-543: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-c -D 2-ac ), Example 4-544: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-c -D 2-ad ), Example 4-545: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-c -D 2-ae ), Example 4-546: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-c -D 2-af ), Example 4-547: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-c -D 2-ag ), Example 4-548: ZL 3-d -N(-L 1-b -D1-a )(-L 2-c -D 2-ah ), Example 4-549: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-c -D 2-ai ), Example 4-550: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-c -D 2-aj ), Example 4-551: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-c -D 2-ak ), Example 4-552: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-c -D 2-al ), Example 4-553: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-c -D 2-am ), Example 4-554: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-c -D 2-an ), Example 4-555: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-c -D 2-ao ), Example 4-556: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-c -D 2-ap ), Example 4-557: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-d -D 2-aq ), Example 4-558: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-d -D 2-ar ), Example 4-559: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-d -D 2-as ), Example 4-560: ZL 3-d -N(-L 1-b -D 1-a )(-L 2-d -D 2-at ), Example 4-561: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-a -D 2-aa ), Example 4-562: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-a -D 2-ab ), Example 4-563: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-a -D 2-ac ), Example 4-564: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-a -D 2-ad ), Example 4-565: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-a -D 2-ae ), Example 4-566: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-a -D 2-af ), Example 4-567: ZL 3-d -N(-L 1-a -D 1-b )(-L2-a -D 2-ag ), Example 4-568: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-a -D 2-ah ), Example 4-569: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-a -D 2-ai ), Example 4-570: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-a -D 2-aj ), Example 4-571: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-a -D 2-ak ), Example 4-572: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-a -D 2-al ), Example 4-573: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-a -D 2-am ), Example 4-574: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-a -D 2-an ), Example 4-575: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-a -D 2-ao ), Example 4-576: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-a -D 2-ap ), Example 4-577: ZL 3-d-N(-L 1-a -D 1-b )(-L 2-b -D 2-aq ), Example 4-578: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-b -D 2-ar ), Example 4-579: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-b -D 2-as ), Example 4-580: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-b -D 2-at ), Example 4-581: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-c -D 2-aa ), Example 4-582: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-c -D 2-ab ), Example 4-583: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-c -D 2-ac ), Example 4-584: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-c -D 2-ad ), Example 4-585: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-c -D 2-ae ), Example 4-586: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-c -D 2-af), Example 4-587: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-c -D 2-ag ), Example 4-588: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-c -D 2-ah ), Example 4-589: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-c -D 2-ai ), Example 4-590: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-c -D 2-aj ), Example 4-591: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-c -D 2-ak ), Example 4-592: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-c -D 2-al ), Example 4-593: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-c -D 2-am ), Example 4-594: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-c -D 2-an ), Example 4-595: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-c -D 2-ao ), Example 4-596: ZL 3-d -N(-L 1-a -D1-b )(-L 2-c -D 2-ap ), Example 4-597: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-d -D 2-aq ), Example 4-598: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-d -D 2-ar ), Example 4-599: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-d -D 2-as ), Example 4-600: ZL 3-d -N(-L 1-a -D 1-b )(-L 2-d -D 2-at ), Example 4-601: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-a -D 2-aa ), Example 4-602: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-a -D 2-ab ), Example 4-603: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-a -D 2-ac ), Example 4-604: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-a -D 2-ad ), Example 4-605: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-a -D 2-ae ), Example 4-606: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-a -D 2-af ), Example 4-607: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-a -D 2-ag ), Example 4-608: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-a -D 2-ah ), Example 4-609: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-a -D 2-ai ), Example 4-610: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-a -D 2-aj ), Example 4-611: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-a -D 2-ak ), Example 4-612: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-a -D 2-al ), Example 4-613: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-a -D 2-am ), Example 4-614: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-a -D 2-an ), Example 4-615: ZL 3-d -N(-L 1-b -D 1-b )(-L2-a -D 2-ao ), Example 4-616: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-a -D 2-ap ), Example 4-617: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-b -D 2-aq ), Example 4-618: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-b -D 2-ar ), Example 4-619: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-b -D 2-as ), Example 4-620: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-b -D 2-at ), Example 4-621: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-c -D 2-aa ), Example 4-622: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-c -D 2-ab ), Example 4-623: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-c -D 2-ac ), Example 4-624: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-c -D 2-ad ), Example 4-625: ZL 3-d-N(-L 1-b -D 1-b )(-L 2-c -D 2-ae ), Example 4-626: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-c -D 2-af ), Example 4-627: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-c -D 2-ag ), Example 4-628: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-c -D 2-ah ), Example 4-629: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-c -D 2-ai ), Example 4-630: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-c -D 2-aj ), Example 4-631: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-c -D 2-ak ), Example 4-632: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-c -D 2-al ), Example 4-633: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-c -D 2-am ), Example 4-634: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-c -D 2-an), Example 4-635: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-c -D 2-ao ), Example 4-636: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-c -D 2-ap ), Example 4-637: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-d -D 2-aq ), Example 4-638: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-d -D 2-ar ), Example 4-639: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-d -D 2-as ), Example 4-640: ZL 3-d -N(-L 1-b -D 1-b )(-L 2-d -D 2-at ), Example 4-641: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-a -D 2-aa ), Example 4-642: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-a -D 2-ab ), Example 4-643: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-a -D 2-ac ), Example 4-644: ZL 3-e -N(-L 1-a -D1-a )(-L 2-a -D 2-ad ), Example 4-645: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-a -D 2-ae ), Example 4-646: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-a -D 2-af ), Example 4-647: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-a -D 2-ag ), Example 4-648: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-a -D 2-ah ), Example 4-649: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-a -D 2-ai ), Example 4-650: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-a -D 2-aj ), Example 4-651: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-a -D 2-ak ), Example 4-652: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-a -D 2-al ), Example 4-653: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-a -D 2-am ), Example 4-654: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-a -D 2-an ), Example 4-655: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-a -D 2-ao ), Example 4-656: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-a -D 2-ap ), Example 4-657: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-b -D 2-aq ), Example 4-658: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-b -D 2-ar ), Example 4-659: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-b -D 2-as ), Example 4-660: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-b -D 2-at ), Example 4-661: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-c -D 2-aa ), Example 4-662: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-c -D 2-ab ), Example 4-663: ZL 3-e -N(-L 1-a -D 1-a )(-L2-c -D 2-ac ), Example 4-664: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-c -D 2-ad ), Example 4-665: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-c -D 2-ae ), Example 4-666: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-c -D 2-af ), Example 4-667: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-c -D 2-ag ), Example 4-668: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-c -D 2-ah ), Example 4-669: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-c -D 2-ai ), Example 4-670: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-c -D 2-aj ), Example 4-671: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-c -D 2-ak ), Example 4-672: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-c -D 2-al ), Example 4-673: ZL 3-e-N(-L 1-a -D 1-a )(-L 2-c -D 2-am ), Example 4-674: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-c -D 2-an ), Example 4-675: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-c -D 2-ao ), Example 4-676: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-c -D 2-ap ), Example 4-677: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-d -D 2-aq ), Example 4-678: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-d -D 2-ar ), Example 4-679: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-d -D 2-as ), Example 4-680: ZL 3-e -N(-L 1-a -D 1-a )(-L 2-d -D 2-at ), Example 4-681: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-a -D 2-aa ), Example 4-682: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-a -D 2-ab), Example 4-683: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-a -D 2-ac ), Example 4-684: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-a -D 2-ad ), Example 4-685: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-a -D 2-ae ), Example 4-686: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-a -D 2-af ), Example 4-687: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-a -D 2-ag ), Example 4-688: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-a -D 2-ah ), Example 4-689: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-a -D 2-ai ), Example 4-690: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-a -D 2-aj ), Example 4-691: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-a -D 2-ak ), Example 4-692: ZL 3-e -N(-L 1-b -D1-a )(-L 2-a -D 2-al ), Example 4-693: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-a -D 2-am ), Example 4-694: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-a -D 2-an ), Example 4-695: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-a -D 2-ao ), Example 4-696: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-a -D 2-ap ), Example 4-697: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-b -D 2-aq ), Example 4-698: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-b -D 2-ar ), Example 4-699: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-b -D 2-as ), Example 4-700: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-b -D 2-at ), Example 4-701: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-c -D 2-aa ), Example 4-702: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-c -D 2-ab ), Example 4-703: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-c -D 2-ac ), Example 4-704: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-c -D 2-ad ), Example 4-705: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-c -D 2-ae ), Example 4-706: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-c -D 2-af ), Example 4-707: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-c -D 2-ag ), Example 4-708: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-c -D 2-ah ), Example 4-709: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-c -D 2-ai ), Example 4-710: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-c -D 2-aj ), Example 4-711: ZL 3-e -N(-L 1-b -D 1-a )(-L2-c -D 2-ak ), Example 4-712: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-c -D 2-al ), Example 4-713: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-c -D 2-am ), Example 4-714: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-c -D 2-an ), Example 4-715: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-c -D 2-ao ), Example 4-716: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-c -D 2-ap ), Example 4-717: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-d -D 2-aq ), Example 4-718: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-d -D 2-ar ), Example 4-719: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-d -D 2-as ), Example 4-720: ZL 3-e -N(-L 1-b -D 1-a )(-L 2-d -D 2-at ), Example 4-721: ZL 3-e-N(-L 1-a -D 1-b )(-L 2-a -D 2-aa ), Example 4-722: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-a -D 2-ab ), Example 4-723: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-a -D 2-ac ), Example 4-724: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-a -D 2-ad ), Example 4-725: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-a -D 2-ae ), Example 4-726: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-a -D 2-af ), Example 4-727: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-a -D 2-ag ), Example 4-728: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-a -D 2-ah ), Example 4-729: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-a -D 2-ai ), Example 4-730: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-a -D 2-aj), Example 4-731: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-a -D 2-ak ), Example 4-732: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-a -D 2-al ), Example 4-733: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-a -D 2-am ), Example 4-734: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-a -D 2-an ), Example 4-735: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-a -D 2-ao ), Example 4-736: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-a -D 2-ap ), Example 4-737: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-b -D 2-aq ), Example 4-738: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-b -D 2-ar ), Example 4-739: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-b -D 2-as ), Example 4-740: ZL 3-e -N(-L 1-a -D1-b )(-L 2-b -D 2-at ), Example 4-741: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-c -D 2-aa ), Example 4-742: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-c -D 2-ab ), Example 4-743: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-c -D 2-ac ), Example 4-744: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-c -D 2-ad ), Example 4-745: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-c -D 2-ae ), Example 4-746: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-c -D 2-af ), Example 4-747: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-c -D 2-ag ), Example 4-748: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-c -D 2-ah ), Example 4-749: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-c -D 2-ai ), Example 4-750: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-c -D 2-aj ), Example 4-751: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-c -D 2-ak ), Example 4-752: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-c -D 2-al ), Example 4-753: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-c -D 2-am ), Example 4-754: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-c -D 2-an ), Example 4-755: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-c -D 2-ao ), Example 4-756: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-c -D 2-ap ), Example 4-757: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-d -D 2-aq ), Example 4-758: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-d -D 2-ar ), Example 4-759: ZL 3-e -N(-L 1-a -D 1-b )(-L2-d -D 2-as ), Example 4-760: ZL 3-e -N(-L 1-a -D 1-b )(-L 2-d -D 2-at ), Example 4-761: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-a -D 2-aa ), Example 4-762: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-a -D 2-ab ), Example 4-763: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-a -D 2-ac ), Example 4-764: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-a -D 2-ad ), Example 4-765: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-a -D 2-ae ), Example 4-766: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-a -D 2-af ), Example 4-767: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-a -D 2-ag ), Example 4-768: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-a -D 2-ah ), Example 4-769: ZL 3-e-N(-L 1-b -D 1-b )(-L 2-a -D 2-ai ), Example 4-770: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-a -D 2-aj ), Example 4-771: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-a -D 2-ak ), Example 4-772: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-a -D 2-al ), Example 4-773: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-a -D 2-am ), Example 4-774: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-a -D 2-an ), Example 4-775: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-a -D 2-ao ), Example 4-776: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-a -D 2-ap ), Example 4-777: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-b -D 2-aq ), Example 4-778: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-b -D 2-ar), Example 4-779: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-b -D 2-as ), Example 4-780: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-b -D 2-at ), Example 4-781: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-c -D 2-aa ), Example 4-782: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-c -D 2-ab ), Example 4-783: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-c -D 2-ac ), Example 4-784: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-c -D 2-ad ), Example 4-785: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-c -D 2-ae ), Example 4-786: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-c -D 2-af ), Example 4-787: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-c -D 2-ag ), Example 4-788: ZL 3-e -N(-L 1-b -D1-b )(-L 2-c -D 2-ah ), Example 4-789: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-c -D 2-ai ), Example 4-790: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-c -D 2-aj ), Example 4-791: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-c -D 2-ak ), Example 4-792: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-c -D 2-al ), Example 4-793: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-c -D 2-am ), Example 4-794: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-c -D 2-an ), Example 4-795: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-c -D 2-ao ), Example 4-796: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-c -D 2-ap ), Example 4-797: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-d -D 2-aq ), Example 4-798: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-d -D 2-ar ), Example 4-799: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-d -D 2-as ), Example 4-800: ZL 3-e -N(-L 1-b -D 1-b )(-L 2-d -D 2-at ), Example 4-801: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-a -D 2-aa ), Example 4-802: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-a -D 2-ab ), Example 4-803: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-a -D 2-ac ), Example 4-804: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-a -D 2-ad ), Example 4-805: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-a -D 2-ae ), Example 4-806: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-a -D 2-af ), Example 4-807: ZL 3-f -N(-L 1-a -D 1-a )(-L2-a -D 2-ag ), Example 4-808: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-a -D 2-ah ), Example 4-809: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-a -D 2-ai ), Example 4-810: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-a -D 2-aj ), Example 4-811: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-a -D 2-ak ), Example 4-812: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-a -D 2-al ), Example 4-813: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-a -D 2-am ), Example 4-814: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-a -D 2-an ), Example 4-815: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-a -D 2-ao ), Example 4-816: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-a -D 2-ap ), Example 4-817: ZL 3-f-N(-L 1-a -D 1-a )(-L 2-b -D 2-aq ), Example 4-818: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-b -D 2-ar ), Example 4-819: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-b -D 2-as ), Example 4-820: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-b -D 2-at ), Example 4-821: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-c -D 2-aa ), Example 4-822: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-c -D 2-ab ), Example 4-823: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-c -D 2-ac ), Example 4-824: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-c -D 2-ad ), Example 4-825: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-c -D 2-ae ), Example 4-826: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-c -D 2-af), Example 4-827: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-c -D 2-ag ), Example 4-828: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-c -D 2-ah ), Example 4-829: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-c -D 2-ai ), Example 4-830: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-c -D 2-aj ), Example 4-831: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-c -D 2-ak ), Example 4-832: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-c -D 2-al ), Example 4-833: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-c -D 2-am ), Example 4-834: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-c -D 2-an ), Example 4-835: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-c -D 2-ao ), Example 4-836: ZL 3-f -N(-L 1-a -D1-a )(-L 2-c -D 2-ap ), Example 4-837: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-d -D 2-aq ), Example 4-838: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-d -D 2-ar ), Example 4-839: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-d -D 2-as ), Example 4-840: ZL 3-f -N(-L 1-a -D 1-a )(-L 2-d -D 2-at ), Example 4-841: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-a -D 2-aa ), Example 4-842: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-a -D 2-ab ), Example 4-843: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-a -D 2-ac ), Example 4-844: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-a -D 2-ad ), Example 4-845: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-a -D 2-ae ), Example 4-846: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-a -D 2-af ), Example 4-847: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-a -D 2-ag ), Example 4-848: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-a -D 2-ah ), Example 4-849: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-a -D 2-ai ), Example 4-850: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-a -D 2-aj ), Example 4-851: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-a -D 2-ak ), Example 4-852: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-a -D 2-al ), Example 4-853: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-a -D 2-am ), Example 4-854: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-a -D 2-an ), Example 4-855: ZL 3-f -N(-L 1-b -D 1-a )(-L2-a -D 2-ao ), Example 4-856: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-a -D 2-ap ), Example 4-857: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-b -D 2-aq ), Example 4-858: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-b -D 2-ar ), Example 4-859: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-b -D 2-as ), Example 4-860: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-b -D 2-at ), Example 4-861: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-c -D 2-aa ), Example 4-862: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-c -D 2-ab ), Example 4-863: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-c -D 2-ac ), Example 4-864: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-c -D 2-ad ), Example 4-865: ZL 3-f-N(-L 1-b -D 1-a )(-L 2-c -D 2-ae ), Example 4-866: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-c -D 2-af ), Example 4-867: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-c -D 2-ag ), Example 4-868: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-c -D 2-ah ), Example 4-869: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-c -D 2-ai ), Example 4-870: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-c -D 2-aj ), Example 4-871: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-c -D 2-ak ), Example 4-872: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-c -D 2-al ), Example 4-873: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-c -D 2-am ), Example 4-874: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-c -D 2-an), Example 4-875: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-c -D 2-ao ), Example 4-876: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-c -D 2-ap ), Example 4-877: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-d -D 2-aq ), Example 4-878: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-d -D 2-ar ), Example 4-879: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-d -D 2-as ), Example 4-880: ZL 3-f -N(-L 1-b -D 1-a )(-L 2-d -D 2-at ), Example 4-881: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-a -D 2-aa ), Example 4-882: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-a -D 2-ab ), Example 4-883: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-a -D 2-ac ), Example 4-884: ZL 3-f -N(-L 1-a -D1-b )(-L 2-a -D 2-ad ), Example 4-885: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-a -D 2-ae ), Example 4-886: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-a -D 2-af ), Example 4-887: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-a -D 2-ag ), Example 4-888: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-a -D 2-ah ), Example 4-889: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-a -D 2-ai ), Example 4-890: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-a -D 2-aj ), Example 4-891: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-a -D 2-ak ), Example 4-892: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-a -D 2-al ), Example 4-893: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-a -D 2-am ), Example 4-894: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-a -D 2-an ), Example 4-895: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-a -D 2-ao ), Example 4-896: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-a -D 2-ap ), Example 4-897: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-b -D 2-aq ), Example 4-898: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-b -D 2-ar ), Example 4-899: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-b -D 2-as ), Example 4-900: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-b -D 2-at ), Example 4-901: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-c -D 2-aa ), Example 4-902: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-c -D 2-ab ), Example 4-903: ZL 3-f -N(-L 1-a -D 1-b )(-L2-c -D 2-ac ), Example 4-904: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-c -D 2-ad ), Example 4-905: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-c -D 2-ae ), Example 4-906: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-c -D 2-af ), Example 4-907: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-c -D 2-ag ), Example 4-908: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-c -D 2-ah ), Example 4-909: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-c -D 2-ai ), Example 4-910: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-c -D 2-aj ), Example 4-911: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-c -D 2-ak ), Example 4-912: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-c -D 2-al ), Example 4-913: ZL 3-f-N(-L 1-a -D 1-b )(-L 2-c -D 2-am ), Example 4-914: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-c -D 2-an ), Example 4-915: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-c -D 2-ao ), Example 4-916: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-c -D 2-ap ), Example 4-917: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-d -D 2-aq ), Example 4-918: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-d -D 2-ar ), Example 4-919: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-d -D 2-as ), Example 4-920: ZL 3-f -N(-L 1-a -D 1-b )(-L 2-d -D 2-at ), Example 4-921: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-a -D 2-aa ), Example 4-922: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-a -D 2-ab), Example 4-923: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-a -D 2-ac ), Example 4-924: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-a -D 2-ad ), Example 4-925: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-a -D 2-ae ), Example 4-926: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-a -D 2-af ), Example 4-927: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-a -D 2-ag ), Example 4-928: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-a -D 2-ah ), Example 4-929: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-a -D 2-ai ), Example 4-930: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-a -D 2-aj ), Example 4-931: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-a -D 2-ak ), Example 4-932: ZL 3-f -N(-L 1-b -D1-b )(-L 2-a -D 2-al ), Example 4-933: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-a -D 2-am ), Example 4-934: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-a -D 2-an ), Example 4-935: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-a -D 2-ao ), Example 4-936: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-a -D 2-ap ), Example 4-937: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-b -D 2-aq ), Example 4-938: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-b -D 2-ar ), Example 4-939: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-b -D 2-as ), Example 4-940: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-b -D 2-at ), Example 4-941: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-c -D 2-aa ), Example 4-942: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-c -D 2-ab ), Example 4-943: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-c -D 2-ac ), Example 4-944: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-c -D 2-ad ), Example 4-945: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-c -D 2-ae ), Example 4-946: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-c -D 2-af ), Example 4-947: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-c -D 2-ag ), Example 4-948: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-c -D 2-ah ), Example 4-949: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-c -D 2-ai ), Example 4-950: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-c -D 2-aj ), Example 4-951: ZL 3-f -N(-L 1-b -D 1-b )(-L2-c -D 2-ak ), Example 4-952: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-c -D 2-al ), Example 4-953: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-c -D 2-am ), Example 4-954: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-c -D 2-an ), Example 4-955: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-c -D 2-ao ), Example 4-956: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-c -D 2-ap ), Example 4-957: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-d -D 2-aq ), Example 4-958: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-d -D 2-ar ), Example 4-959: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-d -D 2-as ), Example 4-960: ZL 3-f -N(-L 1-b -D 1-b )(-L 2-d -D 2-at ), Example 4-961: ZL 3-g-N(-L 1-a -D 1-a )(-L 2-a -D 2-aa ), Example 4-962: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-a -D 2-ab ), Example 4-963: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-a -D 2-ac ), Example 4-964: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-a -D 2-ad ), Example 4-965: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-a -D 2-ae ), Example 4-966: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-a -D 2-af ), Example 4-967: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-a -D 2-ag ), Example 4-968: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-a -D 2-ah ), Example 4-969: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-a -D 2-ai ), Example 4-970: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-a -D 2-aj), Example 4-971: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-a -D 2-ak ), Example 4-972: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-a -D 2-al ), Example 4-973: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-a -D 2-am ), Example 4-974: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-a -D 2-an ), Example 4-975: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-a -D 2-ao ), Example 4-976: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-a -D 2-ap ), Example 4-977: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-b -D 2-aq ), Example 4-978: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-b -D 2-ar ), Example 4-979: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-b -D 2-as ), Example 4-980: ZL 3-g -N(-L 1-a -D1-a )(-L 2-b -D 2-at ), Example 4-981: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-c -D 2-aa ), Example 4-982: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-c -D 2-ab ), Example 4-983: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-c -D 2-ac ), Example 4-984: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-c -D 2-ad ), Example 4-985: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-c -D 2-ae ), Example 4-986: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-c -D 2-af ), Example 4-987: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-c -D 2-ag ), Example 4-988: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-c -D 2-ah ), Example 4-989: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-c -D 2-ai ), Example 4-990: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-c -D 2-aj ), Example 4-991: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-c -D 2-ak ), Example 4-992: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-c -D 2-al ), Example 4-993: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-c -D 2-am ), Example 4-994: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-c -D 2-an ), Example 4-995: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-c -D 2-ao ), Example 4-996: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-c -D 2-ap ), Example 4-997: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-d -D 2-aq ), Example 4-998: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-d -D 2-ar ), Example 4-999: ZL 3-g -N(-L 1-a -D 1-a )(-L2-d -D 2-as ), Example 4-1000: ZL 3-g -N(-L 1-a -D 1-a )(-L 2-d -D 2-at ), Example 4-1001: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-a -D 2-aa ), Example 4-1002: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-a -D 2-ab ), Example 4-1003: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-a -D 2-ac ), Example 4-1004: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-a -D 2-ad ), Example 4-1005: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-a -D 2-ae ), Example 4-1006: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-a -D 2-af ), Example 4-1007: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-a -D 2-ag ), Example 4-1008: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-a -D 2-ah ), Example 4-1009: ZL3-g -N(-L 1-b -D 1-a )(-L 2-a -D 2-ai ), Example 4-1010: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-a -D 2-aj ), Example 4-1011: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-a -D 2-ak ), Example 4-1012: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-a -D 2-al ), Example 4-1013: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-a -D 2-am ), Example 4-1014: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-a -D 2-an ), Example 4-1015: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-a -D 2-ao ), Example 4-1016: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-a -D 2-ap ), Example 4-1017: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-b -D 2-aq ), Example 4-1018: ZL 3-g -N(-L 1-b -D 1-a )(-L2-b -D 2-ar ), Example 4-1019: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-b -D 2-as ), Example 4-1020: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-b -D 2-at ), Example 4-1021: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-c -D 2-aa ), Example 4-1022: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-c -D 2-ab ), Example 4-1023: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-c -D 2-ac ), Example 4-1024: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-c -D 2-ad ), Example 4-1025: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-c -D 2-ae ), Example 4-1026: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-c -D 2-af ), Example 4-1027: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-c -D 2-ag ), Example 4-1028: ZL3-g -N(-L 1-b -D 1-a )(-L 2-c -D 2-ah ), Example 4-1029: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-c -D 2-ai ), Example 4-1030: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-c -D 2-aj ), Example 4-1031: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-c -D 2-ak ), Example 4-1032: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-c -D 2-al ), Example 4-1033: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-c -D 2-am ), Example 4-1034: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-c -D 2-an ), Example 4-1035: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-c -D 2-ao ), Example 4-1036: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-c -D 2-ap ), Example 4-1037: ZL 3-g -N(-L 1-b -D 1-a )(-L2-d -D 2-aq ), Example 4-1038: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-d -D 2-ar ), Example 4-1039: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-d -D 2-as ), Example 4-1040: ZL 3-g -N(-L 1-b -D 1-a )(-L 2-d -D 2-at ), Example 4-1041: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-a -D 2-aa ), Example 4-1042: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-a -D 2-ab ), Example 4-1043: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-a -D 2-ac ), Example 4-1044: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-a -D 2-ad ), Example 4-1045: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-a -D 2-ae ), Example 4-1046: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-a -D 2-af ), Example 4-1047: ZL3-g -N(-L 1-a -D 1-b )(-L 2-a -D 2-ag ), Example 4-1048: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-a -D 2-ah ), Example 4-1049: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-a -D 2-ai ), Example 4-1050: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-a -D 2-aj ), Example 4-1051: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-a -D 2-ak ), Example 4-1052: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-a -D 2-al ), Example 4-1053: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-a -D 2-am ), Example 4-1054: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-a -D 2-an ), Example 4-1055: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-a -D 2-ao ), Example 4-1056: ZL 3-g -N(-L 1-a -D 1-b )(-L2-a -D 2-ap ), Example 4-1057: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-b -D 2-aq ), Example 4-1058: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-b -D 2-ar ), Example 4-1059: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-b -D 2-as ), Example 4-1060: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-b -D 2-at ), Example 4-1061: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-c -D 2-aa ), Example 4-1062: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-c -D 2-ab ), Example 4-1063: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-c -D 2-ac ), Example 4-1064: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-c -D 2-ad ), Example 4-1065: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-c -D 2-ae ), Example 4-1066: ZL3-g -N(-L 1-a -D 1-b )(-L 2-c -D 2-af ), Example 4-1067: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-c -D 2-ag ), Example 4-1068: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-c -D 2-ah ), Example 4-1069: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-c -D 2-ai ), Example 4-1070: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-c -D 2-aj ), Example 4-1071: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-c -D 2-ak ), Example 4-1072: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-c -D 2-al ), Example 4-1073: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-c -D 2-am ), Example 4-1074: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-c -D 2-an ), Example 4-1075: ZL 3-g -N(-L 1-a -D 1-b )(-L2-c -D 2-ao ), Example 4-1076: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-c -D 2-ap ), Example 4-1077: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-d -D 2-aq ), Example 4-1078: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-d -D 2-ar ), Example 4-1079: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-d -D 2-as ), Example 4-1080: ZL 3-g -N(-L 1-a -D 1-b )(-L 2-d -D 2-at ), Example 4-1081: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-a -D 2-aa ), Example 4-1082: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-a -D 2-ab ), Example 4-1083: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-a -D 2-ac ), Example 4-1084: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-a -D 2-ad ), Example 4-1085: ZL3-g -N(-L 1-b -D 1-b )(-L 2-a -D 2-ae ), Example 4-1086: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-a -D 2-af ), Example 4-1087: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-a -D 2-ag ), Example 4-1088: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-a -D 2-ah ), Example 4-1089: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-a -D 2-ai ), Example 4-1090: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-a -D 2-aj ), Example 4-1091: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-a -D 2-ak ), Example 4-1092: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-a -D 2-al ), Example 4-1093: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-a -D 2-am ), Example 4-1094: ZL 3-g -N(-L 1-b -D 1-b )(-L2-a -D 2-an ), Example 4-1095: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-a -D 2-ao ), Example 4-1096: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-a -D 2-ap ), Example 4-1097: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-b -D 2-aq ), Example 4-1098: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-b -D 2-ar ), Example 4-1099: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-b -D 2-as ), Example 4-1100: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-b -D 2-at ), Example 4-1101: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-c -D 2-aa ), Example 4-1102: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-c -D 2-ab ), Example 4-1103: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-c -D 2-ac ), Example 4-1104: ZL3-g -N(-L 1-b -D 1-b )(-L 2-c -D 2-ad ), Example 4-1105: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-c -D 2-ae ), Example 4-1106: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-c -D 2-af ), Example 4-1107: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-c -D 2-ag ), Example 4-1108: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-c -D 2-ah ), Example 4-1109: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-c -D 2-ai ), Example 4-1110: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-c -D 2-aj ), Example 4-1111: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-c -D 2-ak ), Example 4-1112: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-c -D 2-al ), Example 4-1113: ZL 3-g -N(-L 1-b -D 1-b )(-L2-c -D 2-am ), Example 4-1114: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-c -D 2-an ), Example 4-1115: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-c -D 2-ao ), Example 4-1116: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-c -D 2-ap ), Example 4-1117: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-d -D 2-aq ), Example 4-1118: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-d -D 2-ar ), Example 4-1119: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-d -D 2-as ), Example 4-1120: ZL 3-g -N(-L 1-b -D 1-b )(-L 2-d -D 2-at ), Example 4-1121: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-a -D 2-aa ), Example 4-1122: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-a -D 2-ab ), Example 4-1123: ZL3-h -N(-L 1-a -D 1-a )(-L 2-a -D 2-ac ), Example 4-1124: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-a -D 2-ad ), Example 4-1125: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-a -D 2-ae ), Example 4-1126: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-a -D 2-af ), Example 4-1127: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-a -D 2-ag ), Example 4-1128: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-a -D 2-ah ), Example 4-1129: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-a -D 2-ai ), Example 4-1130: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-a -D 2-aj ), Example 4-1131: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-a -D 2-ak ), Example 4-1132: ZL 3-h -N(-L 1-a -D 1-a )(-L2-a -D 2-al ), Example 4-1133: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-a -D 2-am ), Example 4-1134: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-a -D 2-an ), Example 4-1135: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-a -D 2-ao ), Example 4-1136: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-a -D 2-ap ), Example 4-1137: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-b -D 2-aq ), Example 4-1138: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-b -D 2-ar ), Example 4-1139: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-b -D 2-as ), Example 4-1140: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-b -D 2-at ), Example 4-1141: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-c -D 2-aa ), Example 4-1142: ZL3-h -N(-L 1-a -D 1-a )(-L 2-c -D 2-ab ), Example 4-1143: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-c -D 2-ac ), Example 4-1144: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-c -D 2-ad ), Example 4-1145: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-c -D 2-ae ), Example 4-1146: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-c -D 2-af ), Example 4-1147: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-c -D 2-ag ), Example 4-1148: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-c -D 2-ah ), Example 4-1149: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-c -D 2-ai ), Example 4-1150: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-c -D 2-aj ), Example 4-1151: ZL 3-h -N(-L 1-a -D 1-a )(-L2-c -D 2-ak ), Example 4-1152: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-c -D 2-al ), Example 4-1153: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-c -D 2-am ), Example 4-1154: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-c -D 2-an ), Example 4-1155: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-c -D 2-ao ), Example 4-1156: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-c -D 2-ap ), Example 4-1157: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-d -D 2-aq ), Example 4-1158: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-d -D 2-ar ), Example 4-1159: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-d -D 2-as ), Example 4-1160: ZL 3-h -N(-L 1-a -D 1-a )(-L 2-d -D 2-at ), Example 4-1161: ZL3-h -N(-L 1-b -D 1-a )(-L 2-a -D 2-aa ), Example 4-1162: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-a -D 2-ab ), Example 4-1163: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-a -D 2-ac ), Example 4-1164: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-a -D 2-ad ), Example 4-1165: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-a -D 2-ae ), Example 4-1166: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-a -D 2-af ), Example 4-1167: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-a -D 2-ag ), Example 4-1168: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-a -D 2-ah ), Example 4-1169: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-a -D 2-ai ), Example 4-1170: ZL 3-h -N(-L 1-b -D 1-a )(-L2-a -D 2-aj ), Example 4-1171: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-a -D 2-ak ), Example 4-1172: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-a -D 2-al ), Example 4-1173: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-a -D 2-am ), Example 4-1174: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-a -D 2-an ), Example 4-1175: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-a -D 2-ao ), Example 4-1176: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-a -D 2-ap ), Example 4-1177: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-b -D 2-aq ), Example 4-1178: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-b -D 2-ar ), Example 4-1179: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-b -D 2-as ), Example 4-1180: ZL3-h -N(-L 1-b -D 1-a )(-L 2-b -D 2-at ), Example 4-1181: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-c -D 2-aa ), Example 4-1182: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-c -D 2-ab ), Example 4-1183: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-c -D 2-ac ), Example 4-1184: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-c -D 2-ad ), Example 4-1185: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-c -D 2-ae ), Example 4-1186: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-c -D 2-af ), Example 4-1187: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-c -D 2-ag ), Example 4-1188: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-c -D 2-ah ), Example 4-1189: ZL 3-h -N(-L 1-b -D 1-a )(-L2-c -D 2-ai ), Example 4-1190: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-c -D 2-aj ), Example 4-1191: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-c -D 2-ak ), Example 4-1192: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-c -D 2-al ), Example 4-1193: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-c -D 2-am ), Example 4-1194: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-c -D 2-an ), Example 4-1195: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-c -D 2-ao ), Example 4-1196: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-c -D 2-ap ), Example 4-1197: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-d -D 2-aq ), Example 4-1198: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-d -D 2-ar ), Example 4-1199: ZL3-h -N(-L 1-b -D 1-a )(-L 2-d -D 2-as ), Example 4-1200: ZL 3-h -N(-L 1-b -D 1-a )(-L 2-d -D 2-at ), Example 4-1201: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-a -D 2-aa ), Example 4-1202: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-a -D 2-ab ), Example 4-1203: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-a -D 2-ac ), Example 4-1204: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-a -D 2-ad ), Example 4-1205: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-a -D 2-ae ), Example 4-1206: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-a -D 2-af ), Example 4-1207: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-a -D 2-ag ), Example 4-1208: ZL 3-h -N(-L 1-a -D 1-b )(-L2-a -D 2-ah ), Example 4-1209: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-a -D 2-ai ), Example 4-1210: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-a -D 2-aj ), Example 4-1211: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-a -D 2-ak ), Example 4-1212: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-a -D 2-al ), Example 4-1213: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-a -D 2-am ), Example 4-1214: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-a -D 2-an ), Example 4-1215: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-a -D 2-ao ), Example 4-1216: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-a -D 2-ap ), Example 4-1217: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-b -D 2-aq ), Example 4-1218: ZL3-h -N(-L 1-a -D 1-b )(-L 2-b -D 2-ar ), Example 4-1219: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-b -D 2-as ), Example 4-1220: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-b -D 2-at ), Example 4-1221: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-c -D 2-aa ), Example 4-1222: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-c -D 2-ab ), Example 4-1223: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-c -D 2-ac ), Example 4-1224: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-c -D 2-ad ), Example 4-1225: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-c -D 2-ae ), Example 4-1226: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-c -D 2-af ), Example 4-1227: ZL 3-h -N(-L 1-a -D 1-b )(-L2-c -D 2-ag ), Example 4-1228: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-c -D 2-ah ), Example 4-1229: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-c -D 2-ai ), Example 4-1230: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-c -D 2-aj ), Example 4-1231: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-c -D 2-ak ), Example 4-1232: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-c -D 2-al ), Example 4-1233: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-c -D 2-am ), Example 4-1234: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-c -D 2-an ), Example 4-1235: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-c -D 2-ao ), Example 4-1236: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-c -D 2-ap ), Example 4-1237: ZL3-h -N(-L 1-a -D 1-b )(-L 2-d -D 2-aq ), Example 4-1238: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-d -D 2-ar ), Example 4-1239: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-d -D 2-as ), Example 4-1240: ZL 3-h -N(-L 1-a -D 1-b )(-L 2-d -D 2-at ), Example 4-1241: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-a -D 2-aa ), Example 4-1242: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-a -D 2-ab ), Example 4-1243: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-a -D 2-ac ), Example 4-1244: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-a -D 2-ad ), Example 4-1245: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-a -D 2-ae ), Example 4-1246: ZL 3-h -N(-L 1-b -D 1-b )(-L2-a -D 2-af ), Example 4-1247: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-a -D 2-ag ), Example 4-1248: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-a -D 2-ah ), Example 4-1249: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-a -D 2-ai ), Example 4-1250: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-a -D 2-aj ), Example 4-1251: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-a -D 2-ak ), Example 4-1252: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-a -D 2-al ), Example 4-1253: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-a -D 2-am ), Example 4-1254: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-a -D 2-an ), Example 4-1255: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-a -D 2-ao ), Example 4-1256: ZL3-h -N(-L 1-b -D 1-b )(-L 2-a -D 2-ap ), Example 4-1257: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-b -D 2-aq ), Example 4-1258: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-b -D 2-ar ), Example 4-1259: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-b -D 2-as ), Example 4-1260: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-b -D 2-at ), Example 4-1261: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-c -D 2-aa ), Example 4-1262: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-c -D 2-ab ), Example 4-1263: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-c -D 2-ac ), Example 4-1264: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-c -D 2-ad ), Example 4-1265: ZL 3-h -N(-L 1-b -D 1-b )(-L2-c -D 2-ae ), Example 4-1266: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-c -D 2-af ), Example 4-1267: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-c -D 2-ag ), Example 4-1268: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-c -D 2-ah ), Example 4-1269: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-c -D 2-ai ), Example 4-1270: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-c -D 2-aj ), Example 4-1271: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-c -D 2-ak ), Example 4-1272: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-c -D 2-al ), Example 4-1273: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-c -D 2-am ), Example 4-1274: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-c -D 2-an ), Example 4-1275: ZL3-h -N(-L 1-b -D 1-b )(-L 2-c -D 2-ao ), Example 4-1276: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-c -D 2-ap ), Example 4-1277: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-d -D 2-aq ), Example 4-1278: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-d -D 2-ar ), Example 4-1279: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-d -D 2-as ), Example 4-1280: ZL 3-h -N(-L 1-b -D 1-b )(-L 2-d -D 2-at ), Example 4-1281: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-a -D 2-aa ), Example 4-1282: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-a -D 2-ab ), Example 4-1283: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-a -D 2-ac ), Example 4-1284: ZL 3-i -N(-L 1-a -D 1-a )(-L2-a -D 2-ad ), Example 4-1285: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-a -D 2-ae ), Example 4-1286: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-a -D 2-af ), Example 4-1287: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-a -D 2-ag ), Example 4-1288: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-a -D 2-ah ), Example 4-1289: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-a -D 2-ai ), Example 4-1290: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-a -D 2-aj ), Example 4-1291: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-a -D 2-ak ), Example 4-1292: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-a -D 2-al ), Example 4-1293: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-a -D 2-am ), Example 4-1294: ZL3-i -N(-L 1-a -D 1-a )(-L 2-a -D 2-an ), Example 4-1295: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-a -D 2-ao ), Example 4-1296: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-a -D 2-ap ), Example 4-1297: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-b -D 2-aq ), Example 4-1298: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-b -D 2-ar ), Example 4-1299: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-b -D 2-as ), Example 4-1300: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-b -D 2-at ), Example 4-1301: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-c -D 2-aa ), Example 4-1302: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-c -D 2-ab ), Example 4-1303: ZL 3-i -N(-L 1-a -D 1-a )(-L2-c -D 2-ac ), Example 4-1304: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-c -D 2-ad ), Example 4-1305: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-c -D 2-ae ), Example 4-1306: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-c -D 2-af ), Example 4-1307: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-c -D 2-ag ), Example 4-1308: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-c -D 2-ah ), Example 4-1309: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-c -D 2-ai ), Example 4-1310: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-c -D 2-aj ), Example 4-1311: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-c -D 2-ak ), Example 4-1312: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-c -D 2-al ), Example 4-1313: ZL3-i -N(-L 1-a -D 1-a )(-L 2-c -D 2-am ), Example 4-1314: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-c -D 2-an ), Example 4-1315: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-c -D 2-ao ), Example 4-1316: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-c -D 2-ap ), Example 4-1317: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-d -D 2-aq ), Example 4-1318: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-d -D 2-ar ), Example 4-1319: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-d -D 2-as ), Example 4-1320: ZL 3-i -N(-L 1-a -D 1-a )(-L 2-d -D 2-at ), Example 4-1321: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-a -D 2-aa ), Example 4-1322: ZL 3-i -N(-L 1-b -D 1-a )(-L2-a -D 2-ab ), Example 4-1323: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-a -D 2-ac ), Example 4-1324: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-a -D 2-ad ), Example 4-1325: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-a -D 2-ae ), Example 4-1326: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-a -D 2-af ), Example 4-1327: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-a -D 2-ag ), Example 4-1328: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-a -D 2-ah ), Example 4-1329: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-a -D 2-ai ), Example 4-1330: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-a -D 2-aj ), Example 4-1331: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-a -D 2-ak ), Example 4-1332: ZL3-i -N(-L 1-b -D 1-a )(-L 2-a -D 2-al ), Example 4-1333: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-a -D 2-am ), Example 4-1334: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-a -D 2-an ), Example 4-1335: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-a -D 2-ao ), Example 4-1336: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-a -D 2-ap ), Example 4-1337: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-b -D 2-aq ), Example 4-1338: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-b -D 2-ar ), Example 4-1339: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-b -D 2-as ), Example 4-1340: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-b -D 2-at ), Example 4-1341: ZL 3-i -N(-L 1-b -D 1-a )(-L2-c -D 2-aa ), Example 4-1342: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-c -D 2-ab ), Example 4-1343: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-c -D 2-ac ), Example 4-1344: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-c -D 2-ad ), Example 4-1345: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-c -D 2-ae ), Example 4-1346: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-c -D 2-af ), Example 4-1347: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-c -D 2-ag ), Example 4-1348: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-c -D 2-ah ), Example 4-1349: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-c -D 2-ai ), Example 4-1350: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-c -D 2-aj ), Example 4-1351: ZL3-i -N(-L 1-b -D 1-a )(-L 2-c -D 2-ak ), Example 4-1352: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-c -D 2-al ), Example 4-1353: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-c -D 2-am ), Example 4-1354: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-c -D 2-an ), Example 4-1355: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-c -D 2-ao ), Example 4-1356: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-c -D 2-ap ), Example 4-1357: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-d -D 2-aq ), Example 4-1358: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-d -D 2-ar ), Example 4-1359: ZL 3-i -N(-L 1-b -D 1-a )(-L 2-d -D 2-as ), Example 4-1360: ZL 3-i -N(-L 1-b -D 1-a )(-L2-d -D 2-at ), Example 4-1361: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-a -D 2-aa ), Example 4-1362: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-a -D 2-ab ), Example 4-1363: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-a -D 2-ac ), Example 4-1364: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-a -D 2-ad ), Example 4-1365: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-a -D 2-ae ), Example 4-1366: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-a -D 2-af ), Example 4-1367: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-a -D 2-ag ), Example 4-1368: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-a -D 2-ah ), Example 4-1369: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-a -D 2-ai ), Example 4-1370: ZL3-i -N(-L 1-a -D 1-b )(-L 2-a -D 2-aj ), Example 4-1371: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-a -D 2-ak ), Example 4-1372: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-a -D 2-al ), Example 4-1373: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-a -D 2-am ), Example 4-1374: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-a -D 2-an ), Example 4-1375: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-a -D 2-ao ), Example 4-1376: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-a -D 2-ap ), Example 4-1377: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-b -D 2-aq ), Example 4-1378: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-b -D 2-ar ), Example 4-1379: ZL 3-i -N(-L 1-a -D 1-b )(-L2-b -D 2-as ), Example 4-1380: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-b -D 2-at ), Example 4-1381: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-c -D 2-aa ), Example 4-1382: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-c -D 2-ab ), Example 4-1383: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-c -D 2-ac ), Example 4-1384: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-c -D 2-ad ), Example 4-1385: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-c -D 2-ae ), Example 4-1386: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-c -D 2-af ), Example 4-1387: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-c -D 2-ag ), Example 4-1388: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-c -D 2-ah ), Example 4-1389: ZL3-i -N(-L 1-a -D 1-b )(-L 2-c -D 2-ai ), Example 4-1390: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-c -D 2-aj ), Example 4-1391: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-c -D 2-ak ), Example 4-1392: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-c -D 2-al ), Example 4-1393: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-c -D 2-am ), Example 4-1394: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-c -D 2-an ), Example 4-1395: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-c -D 2-ao ), Example 4-1396: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-c -D 2-ap ), Example 4-1397: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-d -D 2-aq ), Example 4-1398: ZL 3-i -N(-L 1-a -D 1-b )(-L2-d -D 2-ar ), Example 4-1399: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-d -D 2-as ), Example 4-1400: ZL 3-i -N(-L 1-a -D 1-b )(-L 2-d -D 2-at ), Example 4-1401: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-a -D 2-aa ), Example 4-1402: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-a -D 2-ab ), Example 4-1403: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-a -D 2-ac ), Example 4-1404: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-a -D 2-ad ), Example 4-1405: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-a -D 2-ae ), Example 4-1406: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-a -D 2-af ), Example 4-1407: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-a -D 2-ag ), Example 4-1408: ZL3-i -N(-L 1-b -D 1-b )(-L 2-a -D 2-ah ), Example 4-1409: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-a -D 2-ai ), Example 4-1410: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-a -D 2-aj ), Example 4-1411: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-a -D 2-ak ), Example 4-1412: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-a -D 2-al ), Example 4-1413: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-a -D 2-am ), Example 4-1414: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-a -D 2-an ), Example 4-1415: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-a -D 2-ao ), Example 4-1416: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-a -D 2-ap ), Example 4-1417: ZL 3-i -N(-L 1-b -D 1-b )(-L2-b -D 2-aq ), Example 4-1418: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-b -D 2-ar ), Example 4-1419: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-b -D 2-as ), Example 4-1420: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-b -D 2-at ), Example 4-1421: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-c -D 2-aa ), Example 4-1422: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-c -D 2-ab ), Example 4-1423: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-c -D 2-ac ), Example 4-1424: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-c -D 2-ad ), Example 4-1425: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-c -D 2-ae ), Example 4-1426: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-c -D 2-af ), Example 4-1427: ZL3-i -N(-L 1-b -D 1-b )(-L 2-c -D 2-ag ), Example 4-1428: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-c -D 2-ah ), Example 4-1429: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-c -D 2-ai ), Example 4-1430: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-c -D 2-aj ), Example 4-1431: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-c -D 2-ak ), Example 4-1432: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-c -D 2-al ), Example 4-1433: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-c -D 2-am ), Example 4-1434: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-c -D 2-an ), Example 4-1435: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-c -D 2-ao ), Example 4-1436: ZL 3-i -N(-L 1-b -D 1-b )(-L2-c -D 2-ap ), Example 4-1437: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-d -D 2-aq ), Example 4-1438: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-d -D 2-ar ), Example 4-1439: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-d -D 2-as ), Example 4-1440: ZL 3-i -N(-L 1-b -D 1-b )(-L 2-d -D 2-at ).

[0119] The present invention also provides exemplary precursor compounds (Example 5-1 to Example 5-504) {In the following formula, Z, L 1-a To L 1-b , L 2-b , L 2-d To L 2-h , L 3-a To L 3-i , D 1-a To D 1-b and D 2-ba To D 2-bg As defined above}. Example 5-1: ZL 3-a -N(-L 1-a -D 1-a )(L 2-e -D 2-ba ), Example 5-2: ZL 3-a -N(-L 1-a -D 1-a )(L 2-g -D 2-bb ), Example 5-3: ZL 3-a -N(-L 1-a -D 1-a )(L 2-e -D 2-bc ), Example 5-4: ZL 3-a -N(-L 1-a -D 1-a )(L 2-e -D 2-bd ), Example 5-5: ZL 3-a -N(-L 1-a -D 1-a )(L 2-g -D 2-be ), Example 5-6: ZL 3-a -N(-L 1-a -D 1-a )(L 2-b -D 2-bf ), Example 5-7: ZL 3-a -N(-L 1-a -D 1-a )(L 2-b -D 2-bg ), Example 5-8: ZL 3-a -N(-L 1-a -D 1-a )(L 2-f -D 2-ba ), Example 5-9: ZL 3-a -N(-L 1-a -D 1-a )(L 2-h -D 2-bb ), Example 5-10: ZL 3-a -N(-L 1-a -D 1-a )(L 2-f -D 2-bc ), Example 5-11: ZL 3-a -N(-L 1-a -D 1-a )(L 2-f -D 2-bd ), Example 5-12: ZL 3-a -N(-L 1-a -D 1-a )(L 2-h -D 2-be ), Example 5-13: ZL 3-a -N(-L 1-a -D 1-a )(L 2-d -D 2-bf ), Example 5-14: ZL 3-a -N(-L 1-a -D 1-a )(L 2-d -D 2-bg ), Example 5-15: ZL 3-a -N(-L 1-a -D 1-b )(L 2-e -D 2-ba ), Example 5-16: ZL 3-a -N(-L 1-a -D 1-b )(L 2-g -D 2-bb ), Example 5-17: ZL 3-a -N(-L 1-a -D 1-b )(L 2-e -D 2-bc ), Example 5-18: ZL 3-a -N(-L 1-a -D 1-b )(L 2-e -D 2-bd ), Example 5-19: ZL 3-a -N(-L 1-a -D 1-b )(L 2-g -D 2-be ), Example 5-20: ZL 3-a -N(-L 1-a -D 1-b )(L 2-b -D 2-bf ), Example 5-21: ZL 3-a -N(-L 1-a -D 1-b )(L 2-b -D 2-bg ), Example 5-22: ZL 3-a -N(-L 1-a -D 1-b )(L 2-f -D 2-ba ), Example 5-23: ZL 3-a -N(-L 1-a -D 1-b )(L 2-h-D 2-bb ), Example 5-24: ZL 3-a -N(-L 1-a -D 1-b )(L 2-f -D 2-bc ), Example 5-25: ZL 3-a -N(-L 1-a -D 1-b )(L 2-f -D 2-bd ), Example 5-26: ZL 3-a -N(-L 1-a -D 1-b )(L 2-h -D 2-be ), Example 5-27: ZL 3-a -N(-L 1-a -D 1-b )(L 2-d -D 2-bf ), Example 5-28: ZL 3-a -N(-L 1-a -D 1-b )(L 2-d -D 2-bg ), Example 5-29: ZL 3-a -N(-L 1-b -D 1-a )(L 2-e -D 2-ba ), Example 5-30: ZL 3-a -N(-L 1-b -D 1-a )(L 2-g -D 2-bb ), Example 5-31: ZL 3-a -N(-L 1-b -D 1-a )(L 2-e -D 2-bc ), Example 5-32: ZL 3-a -N(-L 1-b -D 1-a )(L 2-e -D 2-bd ), Example 5-33: ZL 3-a -N(-L 1-b -D1-a )(L 2-g -D 2-be ), Example 5-34: ZL 3-a -N(-L 1-b -D 1-a )(L 2-b -D 2-bf ), Example 5-35: ZL 3-a -N(-L 1-b -D 1-a )(L 2-b -D 2-bg ), Example 5-36: ZL 3-a -N(-L 1-b -D 1-a )(L 2-f -D 2-ba ), Example 5-37: ZL 3-a -N(-L 1-b -D 1-a )(L 2-h -D 2-bb ), Example 5-38: ZL 3-a -N(-L 1-b -D 1-a )(L 2-f -D 2-bc ), Example 5-39: ZL 3-a -N(-L 1-b -D 1-a )(L 2-f -D 2-bd ), Example 5-40: ZL 3-a -N(-L 1-b -D 1-a )(L 2-h -D 2-be ), Example 5-41: ZL 3-a -N(-L 1-b -D 1-a )(L 2-d -D 2-bf ), Example 5-42: ZL 3-a -N(-L 1-b -D 1-a )(L 2-d -D 2-bg ), Example 5-43: ZL 3-a-N(-L 1-b -D 1-b )(L 2-e -D 2-ba ), Example 5-44: ZL 3-a -N(-L 1-b -D 1-b )(L 2-g -D 2-bb ), Example 5-45: ZL 3-a -N(-L 1-b -D 1-b )(L 2-e -D 2-bc ), Example 5-46: ZL 3-a -N(-L 1-b -D 1-b )(L 2-e -D 2-bd ), Example 5-47: ZL 3-a -N(-L 1-b -D 1-b )(L 2-g -D 2-be ), Example 5-48: ZL 3-a -N(-L 1-b -D 1-b )(L 2-b -D 2-bf ), Example 5-49: ZL 3-a -N(-L 1-b -D 1-b )(L 2-b -D 2-bg ), Example 5-50: ZL 3-a -N(-L 1-b -D 1-b )(L 2-f -D 2-ba ), Example 5-51: ZL 3-a -N(-L 1-b -D 1-b )(L 2-h -D 2-bb ), Example 5-52: ZL 3-a -N(-L 1-b -D 1-b )(L 2-f -D 2-bc ), Example 5-53: ZL 3-a -N(-L 1-b -D 1-b )(L 2-f -D 2-bd ), Example 5-54: ZL 3-a -N(-L 1-b -D 1-b )(L 2-h -D 2-be ), Example 5-55: ZL 3-a -N(-L 1-b -D 1-b )(L 2-d -D 2-bf ), Example 5-56: ZL 3-a -N(-L 1-b -D 1-b )(L 2-d -D 2-bg ), Example 5-57: ZL 3-b -N(-L 1-a -D 1-a )(L 2-e -D 2-ba ), Example 5-58: ZL 3-b -N(-L 1-a -D 1-a )(L 2-g -D 2-bb ), Example 5-59: ZL 3-b -N(-L 1-a -D 1-a )(L 2-e -D 2-bc ), Example 5-60: ZL 3-b -N(-L 1-a -D 1-a )(L 2-e -D 2-bd ), Example 5-61: ZL 3-b -N(-L 1-a -D 1-a )(L 2-g -D 2-be ), Example 5-62: ZL 3-b -N(-L 1-a -D 1-a )(L 2-b -D2-bf ), Example 5-63: ZL 3-b -N(-L 1-a -D 1-a )(L 2-b -D 2-bg ), Example 5-64: ZL 3-b -N(-L 1-a -D 1-a )(L 2-f -D 2-ba ), Example 5-65: ZL 3-b -N(-L 1-a -D 1-a )(L 2-h -D 2-bb ), Example 5-66: ZL 3-b -N(-L 1-a -D 1-a )(L 2-f -D 2-bc ), Example 5-67: ZL 3-b -N(-L 1-a -D 1-a )(L 2-f -D 2-bd ), Example 5-68: ZL 3-b -N(-L 1-a -D 1-a )(L 2-h -D 2-be ), Example 5-69: ZL 3-b -N(-L 1-a -D 1-a )(L 2-d -D 2-bf ), Example 5-70: ZL 3-b -N(-L 1-a -D 1-a )(L 2-d -D 2-bg ), Example 5-71: ZL 3-b -N(-L 1-a -D 1-b )(L 2-e -D 2-ba ), Example 5-72: ZL 3-b -N(-L 1-a -D 1-b)(L 2-g -D 2-bb ), Example 5-73: ZL 3-b -N(-L 1-a -D 1-b )(L 2-e -D 2-bc ), Example 5-74: ZL 3-b -N(-L 1-a -D 1-b )(L 2-e -D 2-bd ), Example 5-75: ZL 3-b -N(-L 1-a -D 1-b )(L 2-g -D 2-be ), Example 5-76: ZL 3-b -N(-L 1-a -D 1-b )(L 2-b -D 2-bf ), Example 5-77: ZL 3-b -N(-L 1-a -D 1-b )(L 2-b -D 2-bg ), Example 5-78: ZL 3-b -N(-L 1-a -D 1-b )(L 2-f -D 2-ba ), Example 5-79: ZL 3-b -N(-L 1-a -D 1-b )(L 2-h -D 2-bb ), Example 5-80: ZL 3-b -N(-L 1-a -D 1-b )(L 2-f -D 2-bc ), Example 5-81: ZL 3-b -N(-L 1-a -D 1-b )(L 2-f -D 2-bd ), Example 5-82: ZL 3-b -N(-L1-a -D 1-b )(L 2-h -D 2-be ), Example 5-83: ZL 3-b -N(-L 1-a -D 1-b )(L 2-d -D 2-bf ), Example 5-84: ZL 3-b -N(-L 1-a -D 1-b )(L 2-d -D 2-bg ), Example 5-85: ZL 3-b -N(-L 1-b -D 1-a )(L 2-e -D 2-ba ), Example 5-86: ZL 3-b -N(-L 1-b -D 1-a )(L 2-g -D 2-bb ), Example 5-87: ZL 3-b -N(-L 1-b -D 1-a )(L 2-e -D 2-bc ), Example 5-88: ZL 3-b -N(-L 1-b -D 1-a )(L 2-e -D 2-bd ), Example 5-89: ZL 3-b -N(-L 1-b -D 1-a )(L 2-g -D 2-be ), Example 5-90: ZL 3-b -N(-L 1-b -D 1-a )(L 2-b -D 2-bf ), Example 5-91: ZL 3-b -N(-L 1-b -D 1-a )(L 2-b -D 2-bg ), Example 5-92: ZL3-b -N(-L 1-b -D 1-a )(L 2-f -D 2-ba ), Example 5-93: ZL 3-b -N(-L 1-b -D 1-a )(L 2-h -D 2-bb ), Example 5-94: ZL 3-b -N(-L 1-b -D 1-a )(L 2-f -D 2-bc ), Example 5-95: ZL 3-b -N(-L 1-b -D 1-a )(L 2-f -D 2-bd ), Example 5-96: ZL 3-b -N(-L 1-b -D 1-a )(L 2-h -D 2-be ), Example 5-97: ZL 3-b -N(-L 1-b -D 1-a )(L 2-d -D 2-bf ), Example 5-98: ZL 3-b -N(-L 1-b -D 1-a )(L 2-d -D 2-bg ), Example 5-99: ZL 3-b -N(-L 1-b -D 1-b )(L 2-e -D 2-ba ), Example 5-100: ZL 3-b -N(-L 1-b -D 1-b )(L 2-g -D 2-bb ), Example 5-101: ZL 3-b -N(-L 1-b -D 1-b )(L 2-e -D 2-bc ), Example 5-102: ZL 3-b -N(-L 1-b -D 1-b )(L 2-e -D 2-bd ), Example 5-103: ZL 3-b -N(-L 1-b -D 1-b )(L 2-g -D 2-be ), Example 5-104: ZL 3-b -N(-L 1-b -D 1-b )(L 2-b -D 2-bf ), Example 5-105: ZL 3-b -N(-L 1-b -D 1-b )(L 2-b -D 2-bg ), Example 5-106: ZL 3-b -N(-L 1-b -D 1-b )(L 2-f -D 2-ba ), Example 5-107: ZL 3-b -N(-L 1-b -D 1-b )(L 2-h -D 2-bb ), Example 5-108: ZL 3-b -N(-L 1-b -D 1-b )(L 2-f -D 2-bc ), Example 5-109: ZL 3-b -N(-L 1-b -D 1-b )(L 2-f -D 2-bd ), Example 5-110: ZL 3-b -N(-L 1-b -D 1-b )(L 2-h -D 2-be ), Example 5-111: ZL 3-b -N(-L 1-b -D 1-b )(L2-d -D 2-bf ), Example 5-112: ZL 3-b -N(-L 1-b -D 1-b )(L 2-d -D 2-bg ), Example 5-113: ZL 3-c -N(-L 1-a -D 1-a )(L 2-e -D 2-ba ), Example 5-114: ZL 3-c -N(-L 1-a -D 1-a )(L 2-g -D 2-bb ), Example 5-115: ZL 3-c -N(-L 1-a -D 1-a )(L 2-e -D 2-bc ), Example 5-116: ZL 3-c -N(-L 1-a -D 1-a )(L 2-e -D 2-bd ), Example 5-117: ZL 3-c -N(-L 1-a -D 1-a )(L 2-g -D 2-be ), Example 5-118: ZL 3-c -N(-L 1-a -D 1-a )(L 2-b -D 2-bf ), Example 5-119: ZL 3-c -N(-L 1-a -D 1-a )(L 2-b -D 2-bg ), Example 5-120: ZL 3-c -N(-L 1-a -D 1-a )(L 2-f -D 2-ba ), Example 5-121: ZL 3-c -N(-L1-a -D 1-a )(L 2-h -D 2-bb ), Example 5-122: ZL 3-c -N(-L 1-a -D 1-a )(L 2-f -D 2-bc ), Example 5-123: ZL 3-c -N(-L 1-a -D 1-a )(L 2-f -D 2-bd ), Example 5-124: ZL 3-c -N(-L 1-a -D 1-a )(L 2-h -D 2-be ), Example 5-125: ZL 3-c -N(-L 1-a -D 1-a )(L 2-d -D 2-bf ), Example 5-126: ZL 3-c -N(-L 1-a -D 1-a )(L 2-d -D 2-bg ), Example 5-127: ZL 3-c -N(-L 1-a -D 1-b )(L 2-e -D 2-ba ), Example 5-128: ZL 3-c -N(-L 1-a -D 1-b )(L 2-g -D 2-bb ), Example 5-129: ZL 3-c -N(-L 1-a -D 1-b )(L 2-e -D 2-bc ), Example 5-130: ZL 3-c -N(-L 1-a -D 1-b )(L 2-e -D 2-bd ), Example 5-131: ZL 3-c -N(-L 1-a -D 1-b )(L 2-g -D 2-be ), Example 5-132: ZL 3-c -N(-L 1-a -D 1-b )(L 2-b -D 2-bf ), Example 5-133: ZL 3-c -N(-L 1-a -D 1-b )(L 2-b -D 2-bg ), Example 5-134: ZL 3-c -N(-L 1-a -D 1-b )(L 2-f -D 2-ba ), Example 5-135: ZL 3-c -N(-L 1-a -D 1-b )(L 2-h -D 2-bb ), Example 5-136: ZL 3-c -N(-L 1-a -D 1-b )(L 2-f -D 2-bc ), Example 5-137: ZL 3-c -N(-L 1-a -D 1-b )(L 2-f -D 2-bd ), Example 5-138: ZL 3-c -N(-L 1-a -D 1-b )(L 2-h -D 2-be ), Example 5-139: ZL 3-c -N(-L 1-a -D 1-b )(L 2-d -D 2-bf ), Example 5-140: ZL 3-c -N(-L 1-a -D 1-b )(L 2-d-D 2-bg ), Example 5-141: ZL 3-c -N(-L 1-b -D 1-a )(L 2-e -D 2-ba ), Example 5-142: ZL 3-c -N(-L 1-b -D 1-a )(L 2-g -D 2-bb ), Example 5-143: ZL 3-c -N(-L 1-b -D 1-a )(L 2-e -D 2-bc ), Example 5-144: ZL 3-c -N(-L 1-b -D 1-a )(L 2-e -D 2-bd ), Example 5-145: ZL 3-c -N(-L 1-b -D 1-a )(L 2-g -D 2-be ), Example 5-146: ZL 3-c -N(-L 1-b -D 1-a )(L 2-b -D 2-bf ), Example 5-147: ZL 3-c -N(-L 1-b -D 1-a )(L 2-b -D 2-bg ), Example 5-148: ZL 3-c -N(-L 1-b -D 1-a )(L 2-f -D 2-ba ), Example 5-149: ZL 3-c -N(-L 1-b -D 1-a )(L 2-h -D 2-bb ), Example 5-150: ZL 3-c -N(-L 1-b -D1-a )(L 2-f -D 2-bc ), Example 5-151: ZL 3-c -N(-L 1-b -D 1-a )(L 2-f -D 2-bd ), Example 5-152: ZL 3-c -N(-L 1-b -D 1-a )(L 2-h -D 2-be ), Example 5-153: ZL 3-c -N(-L 1-b -D 1-a )(L 2-d -D 2-bf ), Example 5-154: ZL 3-c -N(-L 1-b -D 1-a )(L 2-d -D 2-bg ), Example 5-155: ZL 3-c -N(-L 1-b -D 1-b )(L 2-e -D 2-ba ), Example 5-156: ZL 3-c -N(-L 1-b -D 1-b )(L 2-g -D 2-bb ), Example 5-157: ZL 3-c -N(-L 1-b -D 1-b )(L 2-e -D 2-bc ), Example 5-158: ZL 3-c -N(-L 1-b -D 1-b )(L 2-e -D 2-bd ), Example 5-159: ZL 3-c -N(-L 1-b -D 1-b )(L 2-g -D 2-be ), Example 5-160: ZL3-c -N(-L 1-b -D 1-b )(L 2-b -D 2-bf ), Example 5-161: ZL 3-c -N(-L 1-b -D 1-b )(L 2-b -D 2-bg ), Example 5-162: ZL 3-c -N(-L 1-b -D 1-b )(L 2-f -D 2-ba ), Example 5-163: ZL 3-c -N(-L 1-b -D 1-b )(L 2-h -D 2-bb ), Example 5-164: ZL 3-c -N(-L 1-b -D 1-b )(L 2-f -D 2-bc ), Example 5-165: ZL 3-c -N(-L 1-b -D 1-b )(L 2-f -D 2-bd ), Example 5-166: ZL 3-c -N(-L 1-b -D 1-b )(L 2-h -D 2-be ), Example 5-167: ZL 3-c -N(-L 1-b -D 1-b )(L 2-d -D 2-bf ), Example 5-168: ZL 3-c -N(-L 1-b -D 1-b )(L 2-d -D 2-bg ), Example 5-169: ZL 3-d -N(-L 1-a -D 1-a )(L 2-e -D 2-ba), Example 5-170: ZL 3-d -N(-L 1-a -D 1-a )(L 2-g -D 2-bb ), Example 5-171: ZL 3-d -N(-L 1-a -D 1-a )(L 2-e -D 2-bc ), Example 5-172: ZL 3-d -N(-L 1-a -D 1-a )(L 2-e -D 2-bd ), Example 5-173: ZL 3-d -N(-L 1-a -D 1-a )(L 2-g -D 2-be ), Example 5-174: ZL 3-d -N(-L 1-a -D 1-a )(L 2-b -D 2-bf ), Example 5-175: ZL 3-d -N(-L 1-a -D 1-a )(L 2-b -D 2-bg ), Example 5-176: ZL 3-d -N(-L 1-a -D 1-a )(L 2-f -D 2-ba ), Example 5-177: ZL 3-d -N(-L 1-a -D 1-a )(L 2-h -D 2-bb ), Example 5-178: ZL 3-d -N(-L 1-a -D 1-a )(L 2-f -D 2-bc ), Example 5-179: ZL 3-d -N(-L 1-a -D 1-a)(L 2-f -D 2-bd ), Example 5-180: ZL 3-d -N(-L 1-a -D 1-a )(L 2-h -D 2-be ), Example 5-181: ZL 3-d -N(-L 1-a -D 1-a )(L 2-d -D 2-bf ), Example 5-182: ZL 3-d -N(-L 1-a -D 1-a )(L 2-d -D 2-bg ), Example 5-183: ZL 3-d -N(-L 1-a -D 1-b )(L 2-e -D 2-ba ), Example 5-184: ZL 3-d -N(-L 1-a -D 1-b )(L 2-g -D 2-bb ), Example 5-185: ZL 3-d -N(-L 1-a -D 1-b )(L 2-e -D 2-bc ), Example 5-186: ZL 3-d -N(-L 1-a -D 1-b )(L 2-e -D 2-bd ), Example 5-187: ZL 3-d -N(-L 1-a -D 1-b )(L 2-g -D 2-be ), Example 5-188: ZL 3-d -N(-L 1-a -D 1-b )(L 2-b -D 2-bf ), Example 5-189: ZL 3-d-N(-L 1-a -D 1-b )(L 2-b -D 2-bg ), Example 5-190: ZL 3-d -N(-L 1-a -D 1-b )(L 2-f -D 2-ba ), Example 5-191: ZL 3-d -N(-L 1-a -D 1-b )(L 2-h -D 2-bb ), Example 5-192: ZL 3-d -N(-L 1-a -D 1-b )(L 2-f -D 2-bc ), Example 5-193: ZL 3-d -N(-L 1-a -D 1-b )(L 2-f -D 2-bd ), Example 5-194: ZL 3-d -N(-L 1-a -D 1-b )(L 2-h -D 2-be ), Example 5-195: ZL 3-d -N(-L 1-a -D 1-b )(L 2-d -D 2-bf ), Example 5-196: ZL 3-d -N(-L 1-a -D 1-b )(L 2-d -D 2-bg ), Example 5-197: ZL 3-d -N(-L 1-b -D 1-a )(L 2-e -D 2-ba ), Example 5-198: ZL 3-d -N(-L 1-b -D 1-a )(L 2-g -D 2-bb ), Example 5-199: ZL 3-d -N(-L 1-b -D 1-a )(L 2-e -D 2-bc ), Example 5-200: ZL 3-d -N(-L 1-b -D 1-a )(L 2-e -D 2-bd ), Example 5-201: ZL 3-d -N(-L 1-b -D 1-a )(L 2-g -D 2-be ), Example 5-202: ZL 3-d -N(-L 1-b -D 1-a )(L 2-b -D 2-bf ), Example 5-203: ZL 3-d -N(-L 1-b -D 1-a )(L 2-b -D 2-bg ), Example 5-204: ZL 3-d -N(-L 1-b -D 1-a )(L 2-f -D 2-ba ), Example 5-205: ZL 3-d -N(-L 1-b -D 1-a )(L 2-h -D 2-bb ), Example 5-206: ZL 3-d -N(-L 1-b -D 1-a )(L 2-f -D 2-bc ), Example 5-207: ZL 3-d -N(-L 1-b -D 1-a )(L 2-f -D 2-bd ), Example 5-208: ZL 3-d -N(-L 1-b -D 1-a )(L2-h -D 2-be ), Example 5-209: ZL 3-d -N(-L 1-b -D 1-a )(L 2-d -D 2-bf ), Example 5-210: ZL 3-d -N(-L 1-b -D 1-a )(L 2-d -D 2-bg ), Example 5-211: ZL 3-d -N(-L 1-b -D 1-b )(L 2-e -D 2-ba ), Example 5-212: ZL 3-d -N(-L 1-b -D 1-b )(L 2-g -D 2-bb ), Example 5-213: ZL 3-d -N(-L 1-b -D 1-b )(L 2-e -D 2-bc ), Example 5-214: ZL 3-d -N(-L 1-b -D 1-b )(L 2-e -D 2-bd ), Example 5-215: ZL 3-d -N(-L 1-b -D 1-b )(L 2-g -D 2-be ), Example 5-216: ZL 3-d -N(-L 1-b -D 1-b )(L 2-b -D 2-bf ), Example 5-217: ZL 3-d -N(-L 1-b -D 1-b )(L 2-b -D 2-bg ), Example 5-218: ZL 3-d -N(-L1-b -D 1-b )(L 2-f -D 2-ba ), Example 5-219: ZL 3-d -N(-L 1-b -D 1-b )(L 2-h -D 2-bb ), Example 5-220: ZL 3-d -N(-L 1-b -D 1-b )(L 2-f -D 2-bc ), Example 5-221: ZL 3-d -N(-L 1-b -D 1-b )(L 2-f -D 2-bd ), Example 5-222: ZL 3-d -N(-L 1-b -D 1-b )(L 2-h -D 2-be ), Example 5-223: ZL 3-d -N(-L 1-b -D 1-b )(L 2-d -D 2-bf ), Example 5-224: ZL 3-d -N(-L 1-b -D 1-b )(L 2-d -D 2-bg ), Example 5-225: ZL 3-e -N(-L 1-a -D 1-a )(L 2-e -D 2-ba ), Example 5-226: ZL 3-e -N(-L 1-a -D 1-a )(L 2-g -D 2-bb ), Example 5-227: ZL 3-e -N(-L 1-a -D 1-a )(L 2-e -D 2-bc ), Example 5-228: ZL 3-e -N(-L 1-a -D 1-a )(L 2-e -D 2-bd ), Example 5-229: ZL 3-e -N(-L 1-a -D 1-a )(L 2-g -D 2-be ), Example 5-230: ZL 3-e -N(-L 1-a -D 1-a )(L 2-b -D 2-bf ), Example 5-231: ZL 3-e -N(-L 1-a -D 1-a )(L 2-b -D 2-bg ), Example 5-232: ZL 3-e -N(-L 1-a -D 1-a )(L 2-f -D 2-ba ), Example 5-233: ZL 3-e -N(-L 1-a -D 1-a )(L 2-h -D 2-bb ), Example 5-234: ZL 3-e -N(-L 1-a -D 1-a )(L 2-f -D 2-bc ), Example 5-235: ZL 3-e -N(-L 1-a -D 1-a )(L 2-f -D 2-bd ), Example 5-236: ZL 3-e -N(-L 1-a -D 1-a )(L 2-h -D 2-be ), Example 5-237: ZL 3-e -N(-L 1-a -D 1-a )(L 2-d-D 2-bf ), Example 5-238: ZL 3-e -N(-L 1-a -D 1-a )(L 2-d -D 2-bg ), Example 5-239: ZL 3-e -N(-L 1-a -D 1-b )(L 2-e -D 2-ba ), Example 5-240: ZL 3-e -N(-L 1-a -D 1-b )(L 2-g -D 2-bb ), Example 5-241: ZL 3-e -N(-L 1-a -D 1-b )(L 2-e -D 2-bc ), Example 5-242: ZL 3-e -N(-L 1-a -D 1-b )(L 2-e -D 2-bd ), Example 5-243: ZL 3-e -N(-L 1-a -D 1-b )(L 2-g -D 2-be ), Example 5-244: ZL 3-e -N(-L 1-a -D 1-b )(L 2-b -D 2-bf ), Example 5-245: ZL 3-e -N(-L 1-a -D 1-b )(L 2-b -D 2-bg ), Example 5-246: ZL 3-e -N(-L 1-a -D 1-b )(L 2-f -D 2-ba ), Example 5-247: ZL 3-e -N(-L 1-a -D1-b )(L 2-h -D 2-bb ), Example 5-248: ZL 3-e -N(-L 1-a -D 1-b )(L 2-f -D 2-bc ), Example 5-249: ZL 3-e -N(-L 1-a -D 1-b )(L 2-f -D 2-bd ), Example 5-250: ZL 3-e -N(-L 1-a -D 1-b )(L 2-h -D 2-be ), Example 5-251: ZL 3-e -N(-L 1-a -D 1-b )(L 2-d -D 2-bf ), Example 5-252: ZL 3-e -N(-L 1-a -D 1-b )(L 2-d -D 2-bg ), Example 5-253: ZL 3-e -N(-L 1-b -D 1-a )(L 2-e -D 2-ba ), Example 5-254: ZL 3-e -N(-L 1-b -D 1-a )(L 2-g -D 2-bb ), Example 5-255: ZL 3-e -N(-L 1-b -D 1-a )(L 2-e -D 2-bc ), Example 5-256: ZL 3-e -N(-L 1-b -D 1-a )(L 2-e -D 2-bd ), Example 5-257: ZL3-e -N(-L 1-b -D 1-a )(L 2-g -D 2-be ), Example 5-258: ZL 3-e -N(-L 1-b -D 1-a )(L 2-b -D 2-bf ), Example 5-259: ZL 3-e -N(-L 1-b -D 1-a )(L 2-b -D 2-bg ), Example 5-260: ZL 3-e -N(-L 1-b -D 1-a )(L 2-f -D 2-ba ), Example 5-261: ZL 3-e -N(-L 1-b -D 1-a )(L 2-h -D 2-bb ), Example 5-262: ZL 3-e -N(-L 1-b -D 1-a )(L 2-f -D 2-bc ), Example 5-263: ZL 3-e -N(-L 1-b -D 1-a )(L 2-f -D 2-bd ), Example 5-264: ZL 3-e -N(-L 1-b -D 1-a )(L 2-h -D 2-be ), Example 5-265: ZL 3-e -N(-L 1-b -D 1-a )(L 2-d -D 2-bf ), Example 5-266: ZL 3-e -N(-L 1-b -D 1-a )(L 2-d -D 2-bg), Example 5-267: ZL 3-e -N(-L 1-b -D 1-b )(L 2-e -D 2-ba ), Example 5-268: ZL 3-e -N(-L 1-b -D 1-b )(L 2-g -D 2-bb ), Example 5-269: ZL 3-e -N(-L 1-b -D 1-b )(L 2-e -D 2-bc ), Example 5-270: ZL 3-e -N(-L 1-b -D 1-b )(L 2-e -D 2-bd ), Example 5-271: ZL 3-e -N(-L 1-b -D 1-b )(L 2-g -D 2-be ), Example 5-272: ZL 3-e -N(-L 1-b -D 1-b )(L 2-b -D 2-bf ), Example 5-273: ZL 3-e -N(-L 1-b -D 1-b )(L 2-b -D 2-bg ), Example 5-274: ZL 3-e -N(-L 1-b -D 1-b )(L 2-f -D 2-ba ), Example 5-275: ZL 3-e -N(-L 1-b -D 1-b )(L 2-h -D 2-bb ), Example 5-276: ZL 3-e -N(-L 1-b -D 1-b)(L 2-f -D 2-bc ), Example 5-277: ZL 3-e -N(-L 1-b -D 1-b )(L 2-f -D 2-bd ), Example 5-278: ZL 3-e -N(-L 1-b -D 1-b )(L 2-h -D 2-be ), Example 5-279: ZL 3-e -N(-L 1-b -D 1-b )(L 2-d -D 2-bf ), Example 5-280: ZL 3-e -N(-L 1-b -D 1-b )(L 2-d -D 2-bg ), Example 5-281: ZL 3-f -N(-L 1-a -D 1-a )(L 2-e -D 2-ba ), Example 5-282: ZL 3-f -N(-L 1-a -D 1-a )(L 2-g -D 2-bb ), Example 5-283: ZL 3-f -N(-L 1-a -D 1-a )(L 2-e -D 2-bc ), Example 5-284: ZL 3-f -N(-L 1-a -D 1-a )(L 2-e -D 2-bd ), Example 5-285: ZL 3-f -N(-L 1-a -D 1-a )(L 2-g -D 2-be ), Example 5-286: ZL 3-f-N(-L 1-a -D 1-a )(L 2-b -D 2-bf ), Example 5-287: ZL 3-f -N(-L 1-a -D 1-a )(L 2-b -D 2-bg ), Example 5-288: ZL 3-f -N(-L 1-a -D 1-a )(L 2-f -D 2-ba ), Example 5-289: ZL 3-f -N(-L 1-a -D 1-a )(L 2-h -D 2-bb ), Example 5-290: ZL 3-f -N(-L 1-a -D 1-a )(L 2-f -D 2-bc ), Example 5-291: ZL 3-f -N(-L 1-a -D 1-a )(L 2-f -D 2-bd ), Example 5-292: ZL 3-f -N(-L 1-a -D 1-a )(L 2-h -D 2-be ), Example 5-293: ZL 3-f -N(-L 1-a -D 1-a )(L 2-d -D 2-bf ), Example 5-294: ZL 3-f -N(-L 1-a -D 1-a )(L 2-d -D 2-bg ), Example 5-295: ZL 3-f -N(-L 1-a -D 1-b )(L 2-e -D 2-ba ), Example 5-296: ZL 3-f -N(-L 1-a -D 1-b )(L 2-g -D 2-bb ), Example 5-297: ZL 3-f -N(-L 1-a -D 1-b )(L 2-e -D 2-bc ), Example 5-298: ZL 3-f -N(-L 1-a -D 1-b )(L 2-e -D 2-bd ), Example 5-299: ZL 3-f -N(-L 1-a -D 1-b )(L 2-g -D 2-be ), Example 5-300: ZL 3-f -N(-L 1-a -D 1-b )(L 2-b -D 2-bf ), Example 5-301: ZL 3-f -N(-L 1-a -D 1-b )(L 2-b -D 2-bg ), Example 5-302: ZL 3-f -N(-L 1-a -D 1-b )(L 2-f -D 2-ba ), Example 5-303: ZL 3-f -N(-L 1-a -D 1-b )(L 2-h -D 2-bb ), Example 5-304: ZL 3-f -N(-L 1-a -D 1-b )(L 2-f -D 2-bc ), Example 5-305: ZL 3-f -N(-L 1-a -D 1-b )(L2-f -D 2-bd ), Example 5-306: ZL 3-f -N(-L 1-a -D 1-b )(L 2-h -D 2-be ), Example 5-307: ZL 3-f -N(-L 1-a -D 1-b )(L 2-d -D 2-bf ), Example 5-308: ZL 3-f -N(-L 1-a -D 1-b )(L 2-d -D 2-bg ), Example 5-309: ZL 3-f -N(-L 1-b -D 1-a )(L 2-e -D 2-ba ), Example 5-310: ZL 3-f -N(-L 1-b -D 1-a )(L 2-g -D 2-bb ), Example 5-311: ZL 3-f -N(-L 1-b -D 1-a )(L 2-e -D 2-bc ), Example 5-312: ZL 3-f -N(-L 1-b -D 1-a )(L 2-e -D 2-bd ), Example 5-313: ZL 3-f -N(-L 1-b -D 1-a )(L 2-g -D 2-be ), Example 5-314: ZL 3-f -N(-L 1-b -D 1-a )(L 2-b -D 2-bf ), Example 5-315: ZL 3-f -N(-L1-b -D 1-a )(L 2-b -D 2-bg ), Example 5-316: ZL 3-f -N(-L 1-b -D 1-a )(L 2-f -D 2-ba ), Example 5-317: ZL 3-f -N(-L 1-b -D 1-a )(L 2-h -D 2-bb ), Example 5-318: ZL 3-f -N(-L 1-b -D 1-a )(L 2-f -D 2-bc ), Example 5-319: ZL 3-f -N(-L 1-b -D 1-a )(L 2-f -D 2-bd ), Example 5-320: ZL 3-f -N(-L 1-b -D 1-a )(L 2-h -D 2-be ), Example 5-321: ZL 3-f -N(-L 1-b -D 1-a )(L 2-d -D 2-bf ), Example 5-322: ZL 3-f -N(-L 1-b -D 1-a )(L 2-d -D 2-bg ), Example 5-323: ZL 3-f -N(-L 1-b -D 1-b )(L 2-e -D 2-ba ), Example 5-324: ZL 3-f -N(-L 1-b -D 1-b )(L 2-g -D 2-bb ), Example 5-325: ZL 3-f -N(-L 1-b -D 1-b )(L 2-e -D 2-bc ), Example 5-326: ZL 3-f -N(-L 1-b -D 1-b )(L 2-e -D 2-bd ), Example 5-327: ZL 3-f -N(-L 1-b -D 1-b )(L 2-g -D 2-be ), Example 5-328: ZL 3-f -N(-L 1-b -D 1-b )(L 2-b -D 2-bf ), Example 5-329: ZL 3-f -N(-L 1-b -D 1-b )(L 2-b -D 2-bg ), Example 5-330: ZL 3-f -N(-L 1-b -D 1-b )(L 2-f -D 2-ba ), Example 5-331: ZL 3-f -N(-L 1-b -D 1-b )(L 2-h -D 2-bb ), Example 5-332: ZL 3-f -N(-L 1-b -D 1-b )(L 2-f -D 2-bc ), Example 5-333: ZL 3-f -N(-L 1-b -D 1-b )(L 2-f -D 2-bd ), Example 5-334: ZL 3-f -N(-L 1-b -D 1-b )(L 2-h-D 2-be ), Example 5-335: ZL 3-f -N(-L 1-b -D 1-b )(L 2-d -D 2-bf ), Example 5-336: ZL 3-f -N(-L 1-b -D 1-b )(L 2-d -D 2-bg ), Example 5-337: ZL 3-g -N(-L 1-a -D 1-a )(L 2-e -D 2-ba ), Example 5-338: ZL 3-g -N(-L 1-a -D 1-a )(L 2-g -D 2-bb ), Example 5-339: ZL 3-g -N(-L 1-a -D 1-a )(L 2-e -D 2-bc ), Example 5-340: ZL 3-g -N(-L 1-a -D 1-a )(L 2-e -D 2-bd ), Example 5-341: ZL 3-g -N(-L 1-a -D 1-a )(L 2-g -D 2-be ), Example 5-342: ZL 3-g -N(-L 1-a -D 1-a )(L 2-b -D 2-bf ), Example 5-343: ZL 3-g -N(-L 1-a -D 1-a )(L 2-b -D 2-bg ), Example 5-344: ZL 3-g -N(-L 1-a -D1-a )(L 2-f -D 2-ba ), Example 5-345: ZL 3-g -N(-L 1-a -D 1-a )(L 2-h -D 2-bb ), Example 5-346: ZL 3-g -N(-L 1-a -D 1-a )(L 2-f -D 2-bc ), Example 5-347: ZL 3-g -N(-L 1-a -D 1-a )(L 2-f -D 2-bd ), Example 5-348: ZL 3-g -N(-L 1-a -D 1-a )(L 2-h -D 2-be ), Example 5-349: ZL 3-g -N(-L 1-a -D 1-a )(L 2-d -D 2-bf ), Example 5-350: ZL 3-g -N(-L 1-a -D 1-a )(L 2-d -D 2-bg ), Example 5-351: ZL 3-g -N(-L 1-a -D 1-b )(L 2-e -D 2-ba ), Example 5-352: ZL 3-g -N(-L 1-a -D 1-b )(L 2-g -D 2-bb ), Example 5-353: ZL 3-g -N(-L 1-a -D 1-b )(L 2-e -D 2-bc ), Example 5-354: ZL3-g -N(-L 1-a -D 1-b )(L 2-e -D 2-bd ), Example 5-355: ZL 3-g -N(-L 1-a -D 1-b )(L 2-g -D 2-be ), Example 5-356: ZL 3-g -N(-L 1-a -D 1-b )(L 2-b -D 2-bf ), Example 5-357: ZL 3-g -N(-L 1-a -D 1-b )(L 2-b -D 2-bg ), Example 5-358: ZL 3-g -N(-L 1-a -D 1-b )(L 2-f -D 2-ba ), Example 5-359: ZL 3-g -N(-L 1-a -D 1-b )(L 2-h -D 2-bb ), Example 5-360: ZL 3-g -N(-L 1-a -D 1-b )(L 2-f -D 2-bc ), Example 5-361: ZL 3-g -N(-L 1-a -D 1-b )(L 2-f -D 2-bd ), Example 5-362: ZL 3-g -N(-L 1-a -D 1-b )(L 2-h -D 2-be ), Example 5-363: ZL 3-g -N(-L 1-a -D 1-b )(L 2-d -D 2-bf), Example 5-364: ZL 3-g -N(-L 1-a -D 1-b )(L 2-d -D 2-bg ), Example 5-365: ZL 3-g -N(-L 1-b -D 1-a )(L 2-e -D 2-ba ), Example 5-366: ZL 3-g -N(-L 1-b -D 1-a )(L 2-g -D 2-bb ), Example 5-367: ZL 3-g -N(-L 1-b -D 1-a )(L 2-e -D 2-bc ), Example 5-368: ZL 3-g -N(-L 1-b -D 1-a )(L 2-e -D 2-bd ), Example 5-369: ZL 3-g -N(-L 1-b -D 1-a )(L 2-g -D 2-be ), Example 5-370: ZL 3-g -N(-L 1-b -D 1-a )(L 2-b -D 2-bf ), Example 5-371: ZL 3-g -N(-L 1-b -D 1-a )(L 2-b -D 2-bg ), Example 5-372: ZL 3-g -N(-L 1-b -D 1-a )(L 2-f -D 2-ba ), Example 5-373: ZL 3-g -N(-L 1-b -D 1-a)(L 2-h -D 2-bb ), Example 5-374: ZL 3-g -N(-L 1-b -D 1-a )(L 2-f -D 2-bc ), Example 5-375: ZL 3-g -N(-L 1-b -D 1-a )(L 2-f -D 2-bd ), Example 5-376: ZL 3-g -N(-L 1-b -D 1-a )(L 2-h -D 2-be ), Example 5-377: ZL 3-g -N(-L 1-b -D 1-a )(L 2-d -D 2-bf ), Example 5-378: ZL 3-g -N(-L 1-b -D 1-a )(L 2-d -D 2-bg ), Example 5-379: ZL 3-g -N(-L 1-b -D 1-b )(L 2-e -D 2-ba ), Example 5-380: ZL 3-g -N(-L 1-b -D 1-b )(L 2-g -D 2-bb ), Example 5-381: ZL 3-g -N(-L 1-b -D 1-b )(L 2-e -D 2-bc ), Example 5-382: ZL 3-g -N(-L 1-b -D 1-b )(L 2-e -D 2-bd ), Example 5-383: ZL 3-g-N(-L 1-b -D 1-b )(L 2-g -D 2-be ), Example 5-384: ZL 3-g -N(-L 1-b -D 1-b )(L 2-b -D 2-bf ), Example 5-385: ZL 3-g -N(-L 1-b -D 1-b )(L 2-b -D 2-bg ), Example 5-386: ZL 3-g -N(-L 1-b -D 1-b )(L 2-f -D 2-ba ), Example 5-387: ZL 3-g -N(-L 1-b -D 1-b )(L 2-h -D 2-bb ), Example 5-388: ZL 3-g -N(-L 1-b -D 1-b )(L 2-f -D 2-bc ), Example 5-389: ZL 3-g -N(-L 1-b -D 1-b )(L 2-f -D 2-bd ), Example 5-390: ZL 3-g -N(-L 1-b -D 1-b )(L 2-h -D 2-be ), Example 5-391: ZL 3-g -N(-L 1-b -D 1-b )(L 2-d -D 2-bf ), Example 5-392: ZL 3-g -N(-L 1-b -D 1-b )(L 2-d -D 2-bg ), Example 5-393: ZL 3-h -N(-L 1-a -D 1-a )(L 2-e -D 2-ba ), Example 5-394: ZL 3-h -N(-L 1-a -D 1-a )(L 2-g -D 2-bb ), Example 5-395: ZL 3-h -N(-L 1-a -D 1-a )(L 2-e -D 2-bc ), Example 5-396: ZL 3-h -N(-L 1-a -D 1-a )(L 2-e -D 2-bd ), Example 5-397: ZL 3-h -N(-L 1-a -D 1-a )(L 2-g -D 2-be ), Example 5-398: ZL 3-h -N(-L 1-a -D 1-a )(L 2-b -D 2-bf ), Example 5-399: ZL 3-h -N(-L 1-a -D 1-a )(L 2-b -D 2-bg ), Example 5-400: ZL 3-h -N(-L 1-a -D 1-a )(L 2-f -D 2-ba ), Example 5-401: ZL 3-h -N(-L 1-a -D 1-a )(L 2-h -D 2-bb ), Example 5-402: ZL 3-h -N(-L 1-a -D 1-a )(L2-f -D 2-bc ), Example 5-403: ZL 3-h -N(-L 1-a -D 1-a )(L 2-f -D 2-bd ), Example 5-404: ZL 3-h -N(-L 1-a -D 1-a )(L 2-h -D 2-be ), Example 5-405: ZL 3-h -N(-L 1-a -D 1-a )(L 2-d -D 2-bf ), Example 5-406: ZL 3-h -N(-L 1-a -D 1-a )(L 2-d -D 2-bg ), Example 5-407: ZL 3-h -N(-L 1-a -D 1-b )(L 2-e -D 2-ba ), Example 5-408: ZL 3-h -N(-L 1-a -D 1-b )(L 2-g -D 2-bb ), Example 5-409: ZL 3-h -N(-L 1-a -D 1-b )(L 2-e -D 2-bc ), Example 5-410: ZL 3-h -N(-L 1-a -D 1-b )(L 2-e -D 2-bd ), Example 5-411: ZL 3-h -N(-L 1-a -D 1-b )(L 2-g -D 2-be ), Example 5-412: ZL 3-h -N(-L1-a -D 1-b )(L 2-b -D 2-bf ), Example 5-413: ZL 3-h -N(-L 1-a -D 1-b )(L 2-b -D 2-bg ), Example 5-414: ZL 3-h -N(-L 1-a -D 1-b )(L 2-f -D 2-ba ), Example 5-415: ZL 3-h -N(-L 1-a -D 1-b )(L 2-h -D 2-bb ), Example 5-416: ZL 3-h -N(-L 1-a -D 1-b )(L 2-f -D 2-bc ), Example 5-417: ZL 3-h -N(-L 1-a -D 1-b )(L 2-f -D 2-bd ), Example 5-418: ZL 3-h -N(-L 1-a -D 1-b )(L 2-h -D 2-be ), Example 5-419: ZL 3-h -N(-L 1-a -D 1-b )(L 2-d -D 2-bf ), Example 5-420: ZL 3-h -N(-L 1-a -D 1-b )(L 2-d -D 2-bg ), Example 5-421: ZL 3-h -N(-L 1-b -D 1-a )(L 2-e -D 2-ba ), Example 5-422: ZL 3-h -N(-L 1-b -D 1-a )(L 2-g -D 2-bb ), Example 5-423: ZL 3-h -N(-L 1-b -D 1-a )(L 2-e -D 2-bc ), Example 5-424: ZL 3-h -N(-L 1-b -D 1-a )(L 2-e -D 2-bd ), Example 5-425: ZL 3-h -N(-L 1-b -D 1-a )(L 2-g -D 2-be ), Example 5-426: ZL 3-h -N(-L 1-b -D 1-a )(L 2-b -D 2-bf ), Example 5-427: ZL 3-h -N(-L 1-b -D 1-a )(L 2-b -D 2-bg ), Example 5-428: ZL 3-h -N(-L 1-b -D 1-a )(L 2-f -D 2-ba ), Example 5-429: ZL 3-h -N(-L 1-b -D 1-a )(L 2-h -D 2-bb ), Example 5-430: ZL 3-h -N(-L 1-b -D 1-a )(L 2-f -D 2-bc ), Example 5-431: ZL 3-h -N(-L 1-b -D 1-a )(L 2-f-D 2-bd ), Example 5-432: ZL 3-h -N(-L 1-b -D 1-a )(L 2-h -D 2-be ), Example 5-433: ZL 3-h -N(-L 1-b -D 1-a )(L 2-d -D 2-bf ), Example 5-434: ZL 3-h -N(-L 1-b -D 1-a )(L 2-d -D 2-bg ), Example 5-435: ZL 3-h -N(-L 1-b -D 1-b )(L 2-e -D 2-ba ), Example 5-436: ZL 3-h -N(-L 1-b -D 1-b )(L 2-g -D 2-bb ), Example 5-437: ZL 3-h -N(-L 1-b -D 1-b )(L 2-e -D 2-bc ), Example 5-438: ZL 3-h -N(-L 1-b -D 1-b )(L 2-e -D 2-bd ), Example 5-439: ZL 3-h -N(-L 1-b -D 1-b )(L 2-g -D 2-be ), Example 5-440: ZL 3-h -N(-L 1-b -D 1-b )(L 2-b -D 2-bf ), Example 5-441: ZL 3-h -N(-L 1-b -D1-b )(L 2-b -D 2-bg ), Example 5-442: ZL 3-h -N(-L 1-b -D 1-b )(L 2-f -D 2-ba ), Example 5-443: ZL 3-h -N(-L 1-b -D 1-b )(L 2-h -D 2-bb ), Example 5-444: ZL 3-h -N(-L 1-b -D 1-b )(L 2-f -D 2-bc ), Example 5-445: ZL 3-h -N(-L 1-b -D 1-b )(L 2-f -D 2-bd ), Example 5-446: ZL 3-h -N(-L 1-b -D 1-b )(L 2-h -D 2-be ), Example 5-447: ZL 3-h -N(-L 1-b -D 1-b )(L 2-d -D 2-bf ), Example 5-448: ZL 3-h -N(-L 1-b -D 1-b )(L 2-d -D 2-bg ), Example 5-449: ZL 3-i -N(-L 1-a -D 1-a )(L 2-e -D 2-ba ), Example 5-450: ZL 3-i -N(-L 1-a -D 1-a )(L 2-g -D 2-bb ), Example 5-451: ZL3-i -N(-L 1-a -D 1-a )(L 2-e -D 2-bc ), Example 5-452: ZL 3-i -N(-L 1-a -D 1-a )(L 2-e -D 2-bd ), Example 5-453: ZL 3-i -N(-L 1-a -D 1-a )(L 2-g -D 2-be ), Example 5-454: ZL 3-i -N(-L 1-a -D 1-a )(L 2-b -D 2-bf ), Example 5-455: ZL 3-i -N(-L 1-a -D 1-a )(L 2-b -D 2-bg ), Example 5-456: ZL 3-i -N(-L 1-a -D 1-a )(L 2-f -D 2-ba ), Example 5-457: ZL 3-i -N(-L 1-a -D 1-a )(L 2-h -D 2-bb ), Example 5-458: ZL 3-i -N(-L 1-a -D 1-a )(L 2-f -D 2-bc ), Example 5-459: ZL 3-i -N(-L 1-a -D 1-a )(L 2-f -D 2-bd ), Example 5-460: ZL 3-i -N(-L 1-a -D 1-a )(L 2-h -D 2-be), Example 5-461: ZL 3-i -N(-L 1-a -D 1-a )(L 2-d -D 2-bf ), Example 5-462: ZL 3-i -N(-L 1-a -D 1-a )(L 2-d -D 2-bg ), Example 5-463: ZL 3-i -N(-L 1-a -D 1-b )(L 2-e -D 2-ba ), Example 5-464: ZL 3-i -N(-L 1-a -D 1-b )(L 2-g -D 2-bb ), Example 5-465: ZL 3-i -N(-L 1-a -D 1-b )(L 2-e -D 2-bc ), Example 5-466: ZL 3-i -N(-L 1-a -D 1-b )(L 2-e -D 2-bd ), Example 5-467: ZL 3-i -N(-L 1-a -D 1-b )(L 2-g -D 2-be ), Example 5-468: ZL 3-i -N(-L 1-a -D 1-b )(L 2-b -D 2-bf ), Example 5-469: ZL 3-i -N(-L 1-a -D 1-b )(L 2-b -D 2-bg ), Example 5-470: ZL 3-i -N(-L 1-a -D 1-b)(L 2-f -D 2-ba ), Example 5-471: ZL 3-i -N(-L 1-a -D 1-b )(L 2-h -D 2-bb ), Example 5-472: ZL 3-i -N(-L 1-a -D 1-b )(L 2-f -D 2-bc ), Example 5-473: ZL 3-i -N(-L 1-a -D 1-b )(L 2-f -D 2-bd ), Example 5-474: ZL 3-i -N(-L 1-a -D 1-b )(L 2-h -D 2-be ), Example 5-475: ZL 3-i -N(-L 1-a -D 1-b )(L 2-d -D 2-bf ), Example 5-476: ZL 3-i -N(-L 1-a -D 1-b )(L 2-d -D 2-bg ), Example 5-477: ZL 3-i -N(-L 1-b -D 1-a )(L 2-e -D 2-ba ), Example 5-478: ZL 3-i -N(-L 1-b -D 1-a )(L 2-g -D 2-bb ), Example 5-479: ZL 3-i -N(-L 1-b -D 1-a )(L 2-e -D 2-bc ), Example 5-480: ZL 3-i-N(-L 1-b -D 1-a )(L 2-e -D 2-bd ), Example 5-481: ZL 3-i -N(-L 1-b -D 1-a )(L 2-g -D 2-be ), Example 5-482: ZL 3-i -N(-L 1-b -D 1-a )(L 2-b -D 2-bf ), Example 5-483: ZL 3-i -N(-L 1-b -D 1-a )(L 2-b -D 2-bg ), Example 5-484: ZL 3-i -N(-L 1-b -D 1-a )(L 2-f -D 2-ba ), Example 5-485: ZL 3-i -N(-L 1-b -D 1-a )(L 2-h -D 2-bb ), Example 5-486: ZL 3-i -N(-L 1-b -D 1-a )(L 2-f -D 2-bc ), Example 5-487: ZL 3-i -N(-L 1-b -D 1-a )(L 2-f -D 2-bd ), Example 5-488: ZL 3-i -N(-L 1-b -D 1-a )(L 2-h -D 2-be ), Example 5-489: ZL 3-i -N(-L 1-b -D 1-a )(L 2-d -D 2-bf ), Example 5-490: ZL 3-i -N(-L 1-b -D 1-a )(L 2-d -D 2-bg ), Example 5-491: ZL 3-i -N(-L 1-b -D 1-b )(L 2-e -D 2-ba ), Example 5-492: ZL 3-i -N(-L 1-b -D 1-b )(L 2-g -D 2-bb ), Example 5-493: ZL 3-i -N(-L 1-b -D 1-b )(L 2-e -D 2-bc ), Example 5-494: ZL 3-i -N(-L 1-b -D 1-b )(L 2-e -D 2-bd ), Example 5-495: ZL 3-i -N(-L 1-b -D 1-b )(L 2-g -D 2-be ), Example 5-496: ZL 3-i -N(-L 1-b -D 1-b )(L 2-b -D 2-bf ), Example 5-497: ZL 3-i -N(-L 1-b -D 1-b )(L 2-b -D 2-bg ), Example 5-498: ZL 3-i -N(-L 1-b -D 1-b )(L 2-f -D 2-ba ), Example 5-499: ZL 3-i -N(-L 1-b -D 1-b )(L2-h -D 2-bb ), Example 5-500: ZL 3-i -N(-L 1-b -D 1-b )(L 2-f -D 2-bc ), Example 5-501: ZL 3-i -N(-L 1-b -D 1-b )(L 2-f -D 2-bd ), Example 5-502: ZL 3-i -N(-L 1-b -D 1-b )(L 2-h -D 2-be ), Example 5-503: ZL 3-i -N(-L 1-b -D 1-b )(L 2-d -D 2-bf ), Example 5-504: ZL 3-i -N(-L 1-b -D 1-b )(L 2-d -D 2-bg ).

[0120] The present invention also provides exemplary precursor compounds (Example 6-1 to Example 6-936) {In the following formula, Z, L 1-a To L 1-b , L 2-b , L 2-d , L 2-i To L 2-n , L 3-a To L 3-i , D 1-a To D 1-b and D 2-ca To D 2-ch As defined above}. Example 6-1: ZL 3-a -N(-L 1-a -D 1-a )(L 2-i -D 2-ca ), Example 6-2: ZL 3-a -N(-L 1-a -D 1-a )(L 2-i -D 2-cc ), Example 6-3: ZL 3-a -N(-L 1-a -D 1-a )(L 2-i -D 2-cd ), Example 6-4: ZL 3-a -N(-L 1-a -D 1-a )(L 2-i -D 2-ce ), Example 6-5: ZL 3-a -N(-L 1-a -D 1-a )(L 2-i -D 2-cf ), Example 6-6: ZL 3-a -N(-L 1-a -D 1-a )(L 2-j -D 2-ca ), Example 6-7: ZL 3-a -N(-L 1-a -D 1-a )(L 2-j -D 2-cc ), Example 6-8: ZL 3-a -N(-L 1-a -D 1-a )(L 2-j -D 2-cd ), Example 6-9: ZL 3-a -N(-L 1-a -D 1-a )(L 2-j -D 2-ce ), Example 6-10: ZL 3-a -N(-L 1-a -D 1-a )(L 2-j -D 2-cf ), Example 6-11: ZL 3-a -N(-L 1-a -D 1-a )(L 2-k -D 2-cb ), Example 6-12: ZL 3-a -N(-L 1-a -D 1-a )(L 2-l -D2-ca ), Example 6-13: ZL 3-a -N(-L 1-a -D 1-a )(L 2-l -D 2-cc ), Example 6-14: ZL 3-a -N(-L 1-a -D 1-a )(L 2-l -D 2-cd ), Example 6-15: ZL 3-a -N(-L 1-a -D 1-a )(L 2-l -D 2-ce ), Example 6-16: ZL 3-a -N(-L 1-a -D 1-a )(L 2-l -D 2-cf ), Example 6-17: ZL 3-a -N(-L 1-a -D 1-a )(L 2-m -D 2-ca ), Example 6-18: ZL 3-a -N(-L 1-a -D 1-a )(L 2-m -D 2-cc ), Example 6-19: ZL 3-a -N(-L 1-a -D 1-a )(L 2-m -D 2-cd ), Example 6-20: ZL 3-a -N(-L 1-a -D 1-a )(L 2-m -D 2-ce ), Example 6-21: ZL 3-a -N(-L 1-a -D 1-a )(L 2-m -D 2-cf ), Example 6-22: ZL 3-a -N(-L 1-a -D 1-a)(L 2-n -D 2-cb ), Example 6-23: ZL 3-a -N(-L 1-a -D 1-a )(L 2-b -D 2-cg ), Example 6-24: ZL 3-a -N(-L 1-a -D 1-a )(L 2-b -D 2-ch ), Example 6-25: ZL 3-a -N(-L 1-a -D 1-a )(L 2-d -D 2-cg ), Example 6-26: ZL 3-a -N(-L 1-a -D 1-a )(L 2-d -D 2-ch ), Example 6-27: ZL 3-a -N(-L 1-a -D 1-b )(L 2-i -D 2-ca ), Example 6-28: ZL 3-a -N(-L 1-a -D 1-b )(L 2-i -D 2-cc ), Example 6-29: ZL 3-a -N(-L 1-a -D 1-b )(L 2-i -D 2-cd ), Example 6-30: ZL 3-a -N(-L 1-a -D 1-b )(L 2-i -D 2-ce ), Example 6-31: ZL 3-a -N(-L 1-a -D 1-b )(L 2-i -D 2-cf ), Example 6-32: ZL 3-a -N(-L1-a -D 1-b )(L 2-j -D 2-ca ), Example 6-33: ZL 3-a -N(-L 1-a -D 1-b )(L 2-j -D 2-cc ), Example 6-34: ZL 3-a -N(-L 1-a -D 1-b )(L 2-j -D 2-cd ), Example 6-35: ZL 3-a -N(-L 1-a -D 1-b )(L 2-j -D 2-ce ), Example 6-36: ZL 3-a -N(-L 1-a -D 1-b )(L 2-j -D 2-cf ), Example 6-37: ZL 3-a -N(-L 1-a -D 1-b )(L 2-k -D 2-cb ), Example 6-38: ZL 3-a -N(-L 1-a -D 1-b )(L 2-l -D 2-ca ), Example 6-39: ZL 3-a -N(-L 1-a -D 1-b )(L 2-l -D 2-cc ), Example 6-40: ZL 3-a -N(-L 1-a -D 1-b )(L 2-l -D 2-cd ), Example 6-41: ZL 3-a -N(-L 1-a -D 1-b )(L 2-l -D 2-ce ), Example 6-42: ZL3-a -N(-L 1-a -D 1-b )(L 2-l -D 2-cf ), Example 6-43: ZL 3-a -N(-L 1-a -D 1-b )(L 2-m -D 2-ca ), Example 6-44: ZL 3-a -N(-L 1-a -D 1-b )(L 2-m -D 2-cc ), Example 6-45: ZL 3-a -N(-L 1-a -D 1-b )(L 2-m -D 2-cd ), Example 6-46: ZL 3-a -N(-L 1-a -D 1-b )(L 2-m -D 2-ce ), Example 6-47: ZL 3-a -N(-L 1-a -D 1-b )(L 2-m -D 2-cf ), Example 6-48: ZL 3-a -N(-L 1-a -D 1-b )(L 2-n -D 2-cb ), Example 6-49: ZL 3-a -N(-L 1-a -D 1-b )(L 2-b -D 2-cg ), Example 6-50: ZL 3-a -N(-L 1-a -D 1-b )(L 2-b -D 2-ch ), Example 6-51: ZL 3-a -N(-L 1-a -D 1-b )(L 2-d -D 2-cg ), Example 6-52: ZL 3-a -N(-L 1-a -D 1-b )(L 2-d -D 2-ch ), Example 6-53: ZL 3-a -N(-L 1-b -D 1-a )(L 2-i -D 2-ca ), Example 6-54: ZL 3-a -N(-L 1-b -D 1-a )(L 2-i -D 2-cc ), Example 6-55: ZL 3-a -N(-L 1-b -D 1-a )(L 2-i -D 2-cd ), Example 6-56: ZL 3-a -N(-L 1-b -D 1-a )(L 2-i -D 2-ce ), Example 6-57: ZL 3-a -N(-L 1-b -D 1-a )(L 2-i -D 2-cf ), Example 6-58: ZL 3-a -N(-L 1-b -D 1-a )(L 2-j -D 2-ca ), Example 6-59: ZL 3-a -N(-L 1-b -D 1-a )(L 2-j -D 2-cc ), Example 6-60: ZL 3-a -N(-L 1-b -D 1-a )(L 2-j -D 2-cd ), Example 6-61: ZL 3-a -N(-L 1-b -D 1-a )(L 2-j-D 2-ce ), Example 6-62: ZL 3-a -N(-L 1-b -D 1-a )(L 2-j -D 2-cf ), Example 6-63: ZL 3-a -N(-L 1-b -D 1-a )(L 2-k -D 2-cb ), Example 6-64: ZL 3-a -N(-L 1-b -D 1-a )(L 2-l -D 2-ca ), Example 6-65: ZL 3-a -N(-L 1-b -D 1-a )(L 2-l -D 2-cc ), Example 6-66: ZL 3-a -N(-L 1-b -D 1-a )(L 2-l -D 2-cd ), Example 6-67: ZL 3-a -N(-L 1-b -D 1-a )(L 2-l -D 2-ce ), Example 6-68: ZL 3-a -N(-L 1-b -D 1-a )(L 2-l -D 2-cf ), Example 6-69: ZL 3-a -N(-L 1-b -D 1-a )(L 2-m -D 2-ca ), Example 6-70: ZL 3-a -N(-L 1-b -D 1-a )(L 2-m -D 2-cc ), Example 6-71: ZL 3-a -N(-L 1-b -D1-a )(L 2-m -D 2-cd ), Example 6-72: ZL 3-a -N(-L 1-b -D 1-a )(L 2-m -D 2-ce ), Example 6-73: ZL 3-a -N(-L 1-b -D 1-a )(L 2-m -D 2-cf ), Example 6-74: ZL 3-a -N(-L 1-b -D 1-a )(L 2-n -D 2-cb ), Example 6-75: ZL 3-a -N(-L 1-b -D 1-a )(L 2-b -D 2-cg ), Example 6-76: ZL 3-a -N(-L 1-b -D 1-a )(L 2-b -D 2-ch ), Example 6-77: ZL 3-a -N(-L 1-b -D 1-a )(L 2-d -D 2-cg ), Example 6-78: ZL 3-a -N(-L 1-b -D 1-a )(L 2-d -D 2-ch ), Example 6-79: ZL 3-a -N(-L 1-b -D 1-b )(L 2-i -D 2-ca ), Example 6-80: ZL 3-a -N(-L 1-b -D 1-b )(L 2-i -D 2-cc ), Example 6-81: ZL 3-a-N(-L 1-b -D 1-b )(L 2-i -D 2-cd ), Example 6-82: ZL 3-a -N(-L 1-b -D 1-b )(L 2-i -D 2-ce ), Example 6-83: ZL 3-a -N(-L 1-b -D 1-b )(L 2-i -D 2-cf ), Example 6-84: ZL 3-a -N(-L 1-b -D 1-b )(L 2-j -D 2-ca ), Example 6-85: ZL 3-a -N(-L 1-b -D 1-b )(L 2-j -D 2-cc ), Example 6-86: ZL 3-a -N(-L 1-b -D 1-b )(L 2-j -D 2-cd ), Example 6-87: ZL 3-a -N(-L 1-b -D 1-b )(L 2-j -D 2-ce ), Example 6-88: ZL 3-a -N(-L 1-b -D 1-b )(L 2-j -D 2-cf ), Example 6-89: ZL 3-a -N(-L 1-b -D 1-b )(L 2-k -D 2-cb ), Example 6-90: ZL 3-a -N(-L 1-b -D 1-b )(L 2-l -D 2-ca ), Example 6-91: ZL 3-a -N(-L 1-b -D 1-b )(L 2-l -D 2-cc ), Example 6-92: ZL 3-a -N(-L 1-b -D 1-b )(L 2-l -D 2-cd ), Example 6-93: ZL 3-a -N(-L 1-b -D 1-b )(L 2-l -D 2-ce ), Example 6-94: ZL 3-a -N(-L 1-b -D 1-b )(L 2-l -D 2-cf ), Example 6-95: ZL 3-a -N(-L 1-b -D 1-b )(L 2-m -D 2-ca ), Example 6-96: ZL 3-a -N(-L 1-b -D 1-b )(L 2-m -D 2-cc ), Example 6-97: ZL 3-a -N(-L 1-b -D 1-b )(L 2-m -D 2-cd ), Example 6-98: ZL 3-a -N(-L 1-b -D 1-b )(L 2-m -D 2-ce ), Example 6-99: ZL 3-a -N(-L 1-b -D 1-b )(L 2-m -D 2-cf ), Example 6-100: ZL 3-a -N(-L 1-b -D 1-b )(L 2-n -D2-cb ), Example 6-101: ZL 3-a -N(-L 1-b -D 1-b )(L 2-b -D 2-cg ), Example 6-102: ZL 3-a -N(-L 1-b -D 1-b )(L 2-b -D 2-ch ), Example 6-103: ZL 3-a -N(-L 1-b -D 1-b )(L 2-d -D 2-cg ), Example 6-104: ZL 3-a -N(-L 1-b -D 1-b )(L 2-d -D 2-ch ), Example 6-105: ZL 3-b -N(-L 1-a -D 1-a )(L 2-i -D 2-ca ), Example 6-106: ZL 3-b -N(-L 1-a -D 1-a )(L 2-i -D 2-cc ), Example 6-107: ZL 3-b -N(-L 1-a -D 1-a )(L 2-i -D 2-cd ), Example 6-108: ZL 3-b -N(-L 1-a -D 1-a )(L 2-i -D 2-ce ), Example 6-109: ZL 3-b -N(-L 1-a -D 1-a )(L 2-i -D 2-cf ), Example 6-110: ZL 3-b -N(-L 1-a -D1-a )(L 2-j -D 2-ca ), Example 6-111: ZL 3-b -N(-L 1-a -D 1-a )(L 2-j -D 2-cc ), Example 6-112: ZL 3-b -N(-L 1-a -D 1-a )(L 2-j -D 2-cd ), Example 6-113: ZL 3-b -N(-L 1-a -D 1-a )(L 2-j -D 2-ce ), Example 6-114: ZL 3-b -N(-L 1-a -D 1-a )(L 2-j -D 2-cf ), Example 6-115: ZL 3-b -N(-L 1-a -D 1-a )(L 2-k -D 2-cb ), Example 6-116: ZL 3-b -N(-L 1-a -D 1-a )(L 2-l -D 2-ca ), Example 6-117: ZL 3-b -N(-L 1-a -D 1-a )(L 2-l -D 2-cc ), Example 6-118: ZL 3-b -N(-L 1-a -D 1-a )(L 2-l -D 2-cd ), Example 6-119: ZL 3-b -N(-L 1-a -D 1-a )(L 2-l -D 2-ce ), Example 6-120: ZL3-b -N(-L 1-a -D 1-a )(L 2-l -D 2-cf ), Example 6-121: ZL 3-b -N(-L 1-a -D 1-a )(L 2-m -D 2-ca ), Example 6-122: ZL 3-b -N(-L 1-a -D 1-a )(L 2-m -D 2-cc ), Example 6-123: ZL 3-b -N(-L 1-a -D 1-a )(L 2-m -D 2-cd ), Example 6-124: ZL 3-b -N(-L 1-a -D 1-a )(L 2-m -D 2-ce ), Example 6-125: ZL 3-b -N(-L 1-a -D 1-a )(L 2-m -D 2-cf ), Example 6-126: ZL 3-b -N(-L 1-a -D 1-a )(L 2-n -D 2-cb ), Example 6-127: ZL 3-b -N(-L 1-a -D 1-a )(L 2-b -D 2-cg ), Example 6-128: ZL 3-b -N(-L 1-a -D 1-a )(L 2-b -D 2-ch ), Example 6-129: ZL 3-b -N(-L 1-a ...

Claims

1. An antibody-multi-drug conjugate precursor represented by the following general formula (I), or a salt thereof, [C1] [In this formula, Z is a reactive group capable of reacting with a functional group present in the antibody (functional group in the antibody), G is a group represented by the following formula (i), (ii), (iii) or (iv), [C2] (i)； [C3] (ii); [C4] (iii); [C5] (iv); [in the formula, R is a hydrogen atom, a hydroxyl group, an amino group, an alkyl group or an alkyloxy group, and Cy is a cycloalkyl ring, a cycloalkenyl ring, an aryl ring, a heteroaryl ring or a heterocyclyl ring], L 1 It connects G and D 1 The connector, L 2 It connects G and D 2 The connector, L 3 It is the connector that connects G and Z. L 1 , L 2 and L 3 can be the same or different from each other, D 1 and D 2 is an antitumor drug residue in which a hydrogen atom or a hydroxyl group is removed from any position of the antitumor drug molecule or its analog, or its derivative, and these antitumor drug residues may be the same as or different from each other, One or more lactone groups and one or more phosphoryl groups are independently present as substituents or protecting groups on these anti-tumor drug residues or L 1 , L 2 or L 3 at any position of the , the total number of the lactone groups is 1 to 10, when the number of these lactone groups is two or more, these lactone groups may be the same as or different from each other, and the total number of the phosphoryl groups is 1 to 10].

2. The antibody-multi-drug conjugate precursor or a salt thereof according to claim 1, wherein Z is a maleimide group (the following formula (v)), an α-halomethylcarbonyl group (the following formula (vi)), an ethynylphosphonamide group (the following formula (vii)), a carboxyl group, an active ester of a carboxyl group, a thiol group, a hydroxyl group, an amino group, an alkynyl group, a cycloalkynyl group or an azide group (-N3 group), Formula (v) [C6] Formula (vi) [C7] Hal-CH2-C(=O)-* Formula (vii) [C8] [In this formula, * is related to L 3 The bonding point, Hal is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, and R 16 is a methyl group, an ethyl group or a -CH2CH2OCH2CH2OH group].

3. The antibody-multi-drug conjugate precursor or a salt thereof according to claim 1 or 2, wherein Z is a maleimido group (formula (v)), an α-halomethylcarbonyl group (formula (vi)), an ethynylphosphonamide group (formula (vii)), a carboxyl group or an active ester of a carboxyl group.

4. The antibody-multi-drug conjugate precursor or a salt thereof according to any one of claims 1 to 3, wherein Z is a maleimido group (formula (v)), an α-halomethylcarbonyl group (formula (vi)), a carboxyl group, or an active ester of a carboxyl group.

5. The antibody-multi-drug conjugate precursor or a salt thereof according to any one of claims 1 to 4, wherein G is a group represented by formula (i), formula (ii) or formula (iii).

6. The antibody-multi-drug conjugate precursor or a salt thereof according to any one of claims 1 to 5, wherein G is a group represented by the formula (i).

7. The antibody-multi-drug conjugate precursor or a salt thereof according to any one of claims 1 to 6, wherein L 1 , L 2 and L 3 each independently is an optionally substituted alkylene group; One or more methylene groups in the chain of the alkylene group are optionally replaced by one or more divalent groups independently selected from the group consisting of: -C(R 1 )(R 2 )-;-O-;-N(R 3 )-;-N(R 3 )-N(R 3 )-;-S-;-Se-;-Si(R 4 )(R 5 )-;-SS-;-Se-Se-;-SOm-;-SeOn-;-C(=C(R 6 )(R 7 ))-;-C(=O)-;-C(=S)-;-C(=N(R 8 ))-;-C(=N-OR 9 )-;-C(=NN(R 10 )(R 11 ))-;-P(=O)(R 12 )-;-P(=O)(OR 13 )-;-OP(=O)(R 12 )-O-;-OP(=O)(OR 13 )-O-;-C(R 14 )=;=C(R 14 )-;-C(R 14 )=C(R 14 )-;-N=;=N-;-C≡C-;-(OC(R 1 )(R 2 )-C(R 1 )(R 2 )) 1-30 -;-(C(R 1 )(R 2 )-C(R 1 )(R 2 )-0) 1-30 -; an optionally substituted alkenylene group; an optionally substituted alkynylene group; an optionally substituted cycloalkylene group; an optionally substituted cycloalkenylene group; an optionally substituted arylene group; an optionally substituted heteroarylene group; and an optionally substituted heterocyclylene group, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 and R 14 are each independently a group selected from the group consisting of a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkenyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, and an optionally substituted heterocyclyl group, and when R 3 When is an alkyl group, the alkyl group is optionally combined with an alkyl group on an adjacent methylene group to form a ring structure, and m and n are each independently an integer from 0 to 2.

8. The antibody-multi-drug conjugate precursor or a salt thereof according to claim 7, wherein L 1 , L 2 and L 3 are each independently an optionally substituted alkylene group; and One or more methylene groups in the chain of the alkylene group are replaced by one or more divalent groups independently selected from the following formulae: Formula Group -C(R 1 )(alkyl)-; -C(R 14 )=; -O-； -N(R 3 )-; -N＝； -N(R 3 )-C(R 1 )(R 2 )-(in, When R 3 With R 1 or R 2 When it is an alkyl group, R 3 With R 1 or R 2 optionally combined to form a ring structure); -N(R 3 )-C(R 1 )(R 2 )-C(=O)-(wherein, When R 3 With R 1 or R 2 When it is an alkyl group, R 3 With R 1 or R 2 optionally combined to form a ring structure); -O-C(R 1 )(R 2 )-; -S-C(R 1 )(R 2 )-; -N(R 3 )-N(R 3 )-; -N(R 3 )-O-C(R 1 )(R 2 )-; -S-； -Si(R 4 )(R 5 )-; -SS-; -SOm-; -C(=O)-; -C(R 1 )(R 2 )-C(=O)-; -C(=C(R 6 )(R 7 ))-; -C(=N(R 8 ))-; -C(=N-OR 9 )-; -C(=N-N(R 10 )(R 11 ))-; -P(=O)(R 12 )-; -P(=O)(R 12 )-O-; -OP(=O)(R) 12 )-O-; -P(=O)(OR 13 )-O-; -P(=O)(OR 13 )-N(R 3 )-; -O-P(=O)(OR 13 )-O-; -C(R 14 )=C(R 14 )-; -C(R 14 )=C(R 14 )-P(=O)(OR 13 )-N(R 3 )-;-C(R 14 )=N-; -C(R 14 )=N-N(R 3 )-; -C≡C-; -O-C(R 1 )(R 2 )-C(R 1 )(R 2 )-; -O-C(R 1 )(R 2 )-C(R 1 )(R 2 )-O-; -(O-C(R 1 )(R 2 )-C(R 1 )(R 2 )) 2-30 -; -C(=O)-O-; -C(=O)-S-; -C(=O)-N(R 3 )-; -C(=O)-N(R 3 )-O-; -C(=O)-N(R 3 )-C(R 1 )(R 2 )-(where R 3 With R 1 or R 2 When it is an alkyl group, R 3 With R 1 or R 2 optionally combined to form a ring structure); -C(=S)-O-; -C(=S)-S-; -OC(=O)-O-; -O-C(=O)-N(R 3 )-; -S-C(=O)-N(R 3 )-; -N(R 3 )-C(=O)-N(R 3 )-; an optionally substituted arylene group; optionally substituted heteroarylene groups; and Optionally substituted heterocyclylene groups.

9. The antibody-multi-drug conjugate precursor or a salt thereof according to claim 7, wherein L 1 , L 2 and L 3 are each independently an optionally substituted alkylene group; and One or more methylene groups in the chain of the alkylene group are replaced by one or more divalent groups independently selected from the following formulae: Formula Group -C(H or C1-C4 alkyl)=; -O-； -N(H or C1-C4 alkyl)=; -N＝； -S-； -C(=O)-; -O-Si(CH3)(CH3)-O-; -CH2-C(=O)-; -C(=O)-NH-; -C(=O)-O-; -C(=O)-S-; -OC(=O)-O-; -N(H or C1-C4 alkyl)-C(=O)-O-; -NH-NH-; -N(H or C1-C4 alkyl)-O-CH2-; -C(=O)-(CH2) 1-20 -C(=O)-; -C(=O)-(CH2) 1-10 -O-(CH2) 1-10 -C(=O)-; -C(=O)-CH2-(O-CH2CH2) 1-20 -O-CH2-C(=O)-; -(O-CH2CH2) 1-20 -; -C(=O)-N(H or C1-C4 alkyl)-CH2CH2-N(H or C1-C4 alkyl)-C(=O)-; [C9] [where * is the point of bonding to the adjacent group]; -C(=O)-N(H or C1-C4 alkyl)-CH2-; -P(=O)(OH)-O-; -OP(=O)(OH)-O-; -OP(=O)(OH)-OP(=O)(OH)-O-; -OP(=O)(OH)-OP(=O)(OH)-OP(=O)(OH)-O-; -CH(CH2-NH2)-; -CH(CH2-NH-C(=O))-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -CH3)-; -CH(CH2-NH-C(=O)-(CH2) 0-20 -lactone)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -CH2-lactone)-; -CH(CH2-NH-C(=O)-(CH2) 1-20 -phosphoryl)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -CH2-phosphoryl)-; -CH(CH2-NH-(CH2) 1-20 -phosphoryl)-; -(cis)-CH=CH-P(=O)(O-CH2CH3 or O-CH2CH2-OH)-NH-(phenylene)-C(=O)-; -C(=O)-(cyclohexylene)-; -(succinimidyl)-; -Gly-; -Ala-; -Val-; -Leu-; -Ile-; -Phe-; -Ser-; -Cys-; -Asp-; -Glu-; -Orn-; -Lys-; -Cit-; -Arg-; -His-; -Pro-; -GlyGly-; -PheLys-; -ValLys-; -ValCit-; -ValAla-; -AspValCit-; -GluValCit-; -LysValCit-; -SerValCit-; -AspValAla-; -GluValAla-; -LysValAla-; -SerValAla-; -GlyGlyPheGly-; -AspGlyGlyPheGly-; -GluGlyGlyPheGly-; -LysGlyGlyPheGly-; -SerGlyGlyPheGly-; -AspAspAspAspAsp-; (Among the amino acid residues in these amino acids and peptides, the carboxyl groups in the side chains of Asp and Glu optionally form lactone esters, lactone alkyl esters or phosphoryl alkyl esters; or optionally form unsubstituted amides, monoalkyl amides or dialkyl amides, and the amino group of the amide portion optionally has a lactone group, a lactone alkyl group or a phosphoryl alkyl group as a substituent; The amino groups in the side chains of Lys and Orn optionally have a lactone group, a lactone alkyl group, a lactone carbonyl group, a lactone alkylcarbonyl group, a phosphoryl group, a phosphoryl alkyl group or a phosphoryl alkylcarbonyl group as a substituent; and The hydroxyl group in the side chain of Ser and the thiol group in the side chain of Cys optionally have a lactone group, a lactone alkyl group, a lactone carbonyl group, a lactone alkylcarbonyl group, a phosphoryl group, a phosphoryl alkyl group or a phosphoryl alkylcarbonyl group as a substituent) -N(H or C1-C4 alkyl)-(optionally substituted phenylene)-CH2-OC(=O)-; -O-(optionally substituted phenylene)-CH2-OC(=O)-; -N(H or C1-C4 alkyl)-(optionally substituted pyridinylene)-CH2-OC(=O)-; [C10] [C11] [C12] [C13] as well as [C14] [In this formula, * is a point of bonding to an adjacent group].

10. The antibody-multi-drug conjugate precursor or a salt thereof according to claim 7, wherein L 1 , L 2 and L 3 are each independently an optionally substituted alkylene group; and One or more methylene groups in the chain of the alkylene group are substituted by one or more divalent groups, the one or more divalent groups being independently selected from the following formula group, Formula Group -CH2-N(CH3)-CH2-; -CH2-C(=O)-; -C(=O)-NH-CH2-; -C(=O)-(CH2) 1-10 -(O-CH2CH2) 1-20 -O-(CH2) 1-10 -C(=O)-; -C(=O)-(CH2) 1-10 -(O-CH2CH2) 1-20 -O-(CH2) 1-10 -CH2-NH-; -NH-CH2-(CH2) 1-10 -(O-CH2CH2) 1-20 -O-(CH2) 1-10 -CH2-NH-; -C(=O)-N(CH3)-CH2CH2-N(CH3)-C(=O)-; [C15] [In this formula, * is the point of bonding to the adjacent group]; -P(=O)(OH)-O-; -OP(=O)(OH)-O-; -OP(=O)(OH)-OP(=O)(OH)-O-; -OP(=O)(OH)-OP(=O)(OH)-OP(=O)(OH)-O-; -CH(CH2-NH2)-; -CH(CH2-NH(CH3))-; -CH(CH2-N(CH3)2)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 0-20 -CH3)-; -CH(CH2-NH-C(=O)-(CH2) 0-20 -lactone)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -CH2-lactone)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -CH2-NH-lactone)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -CH2-NH-C(=O)-lactone)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -C(=O)-NH-lactone)-; -CH(CH2-NH-(CH2) 1-20 -(O) 0-1 -phosphoryl)-; -CH(CH2-NH-C(=O)-(CH2) 1-20 -phosphoryl)-; -CH(CH2-NH-C(=O)-(CH2) 1-20 -C(=O)-NH-(CH2) 1-10 -phosphoryl)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -CH2-phosphoryl)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -C(=O)-NH-(CH2) 1-10 -phosphoryl)-; -CH(CH2-NH-C(=O)-(CH2CH2-O-) 1-20 -(CH2) 1-10 -C(=O)-NH-(CH2) 1-10 -C(H, OH, Cl, NH2 or C1-C4 alkyl)(P(=O)(OH)2)2)-; -(cis)-CH=CH-P(=O)(O-CH2CH3)-NH-(phenylene)-C(=O)-; -C(=O)-(cyclohexylene)-; -(succinimidyl)-; -Ser-; -Cys-; -Asp-; -Glu-; -Orn-; -Lys-; -ValLys-; -ValCit-; -ValAla-; -GlyGly-C(=O)-NH-(optionally substituted phenylene)-CH2-; -PheLys-C(=O)-NH-(optionally substituted phenylene)-CH2-; -ValLys-C(=O)-NH-(optionally substituted phenylene)-CH2-; -ValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-; -ValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-; -AspValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-; -GluValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-; -LysValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-; -SerValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-; -AspValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-; -GluValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-; -LysValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-; -SerValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-; -GlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-; -AspGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-; -GluGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-; -LysGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-; -SerGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-; -AspAspAspAspAsp-C(=O)-NH-(optionally substituted phenylene)-CH2-; -GlyGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -PheLys-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -ValLys-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -ValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -ValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -AspValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -GluValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -LysValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -SerValCit-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -AspValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -GluValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -LysValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -SerValAla-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -GlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -AspGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -GluGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -LysGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -SerGlyGlyPheGly-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -AspAspAspAspAsp-C(=O)-NH-(optionally substituted phenylene)-CH2-OC(=O)-; -GlyGlyPheGly-C(=O)-NH-CH2-; -AspGlyGlyPheGly-C(=O)-NH-CH2- (Among the amino acid residues and the amino acid residues in these peptides, One or more carboxyl groups in one or more side chains of Asp and Glu are converted into O-(lactonyl)esters, O-(lactonylalkyl)esters, O-(phosphorylalkyl)esters, N-(lactonyl)amides, N-(lactonylalkyl)amides or N-(phosphorylalkyl)amides, One or more amino groups in one or more side chains of Lys and Orn have, as one or more substituents, one or more lactone groups, one or more lactone alkyl groups, one or more lactone carbonyl groups, one or more lactone alkylcarbonyl groups, one or more phosphoryl groups, one or more phosphoryl alkyl groups, or one or more phosphoryl alkylcarbonyl groups, and The hydroxyl group in the side chain of Ser and the thiol group in the side chain of Cys optionally have, as one or more substituents, one or more lactone groups, one or more lactone alkyl groups, one or more lactone carbonyl groups, one or more lactone alkylcarbonyl groups, one or more phosphoryl groups, one or more phosphoryl alkyl groups or one or more phosphoryl alkylcarbonyl groups); [C16] [C17] [C18] [C19] as well as [C20] [In this formula, * is a point of bonding to an adjacent group].

11. The antibody-multi-drug conjugate precursor or a salt thereof according to any one of claims 1 to 10, wherein D 1 and D 2 is a residue of an antitumor drug molecule independently selected from the group consisting of: camptothecin; MMAE; maytansine; PBD (parabenzodiazepine ) dimer; eribulin; 5-FU; PD-318088; AS-703026; TAK-733; LY-3023414; calicheamicin; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; Aplysia 10; superdox; ciprofloxacin; and caderfloxacin hydrochloride (CS-940); or its analogs or derivatives; or derivatives of said analogs.

12. The antibody-multi-drug conjugate precursor or a salt thereof according to any one of claims 1 to 11, wherein D 1 and D 2 is a residue of an antitumor drug molecule independently selected from the group consisting of: camptothecin; MMAE; maytansine; PBD (parabenzodiazepine ) dimer; eribulin; 5-FU; PD-318088; AS-703026; TAK-733; LY-3023414; calicheamicin; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; Aplysia 10; and superdox; or an analog or derivative thereof; or a derivative of said analog.

13. The antibody-multi-drug conjugate precursor or a salt thereof according to any one of claims 1 to 12, wherein D 1 and D 2 is a residue of an antitumor drug molecule independently selected from the group consisting of: camptothecin; MMAE; maytansine; PBD (parabenzodiazepine ) dimer; and eribulin; or an analog or derivative thereof; or a derivative of the analog.

14. The antibody-multi-drug conjugate precursor or a salt thereof according to any one of claims 1 to 13, wherein D 1 and D 2 is the residue of: the same antitumor drug or its analog or derivative; or a derivative of the analog.

15. The antibody-multi-drug conjugate precursor or a salt thereof according to any one of claims 1 to 13, wherein D 1 and D 2 is the residue of: a different anti-tumor drug or an analog or derivative thereof; or a derivative of the analog.

16. The antibody-multi-drug conjugate precursor or a salt thereof according to any one of claims 1 to 15, wherein D 1 and D 2 At least one of the residues is an antitumor drug or an analog or derivative thereof having a hydroxyl group in the molecule and wherein at least one hydroxyl group is phosphorylated; or a derivative of the analog.

17. The antibody-multi-drug conjugate precursor or a salt thereof according to any one of claims 1 to 16, wherein One or more lactone groups and one or more phosphoryl groups are independently present as substituents or protecting groups on these anti-tumor drug residues or L 1 , L 2 or L 3 At any position of , the total number of the lactone groups is 1 to 8, when the number of the lactone groups is two or more, the lactone groups may be the same as or different from each other, and the total number of the phosphoryl groups is 1 to 4.

18. The antibody-multi-drug conjugate precursor or a salt thereof according to any one of claims 1 to 17, wherein One or more lactone groups and one or more phosphoryl groups are independently present as substituents or protecting groups on these anti-tumor drug residues or L 1 , L 2 or L 3 Any location, and In addition to the above, when these anti-tumor drug residues and L 1 , L 2 or L 3 When at least any one of the above independently has at any position one or more groups selected from phosphorylalkylcarbonyl groups (-C(=O)-alkylene-P(=O)(OH)2); dialkylamino groups; and cyclic amino groups which form a ring together with the dialkyl groups as substituents or protecting groups and a plurality of such groups are present in total, these groups may be the same as or different from each other.

19. An antibody-multi-drug conjugate precursor, or a salt thereof, selected from the group consisting of: Example 1 [C22] Example 2 [C23] Example 3 [C24] Example 4 [C25] Example 5 [C26] Example 6 [C00], and Example 7 [C00] [In this formula, the spatial configuration of the amino acid residues in the linker is all L-type].

20. A synthetic intermediate (II-1) of an antibody-multi-drug conjugate precursor, or a salt thereof, represented by the following general formula (II-1): [C27] [In this formula, Z 1 is a reactive group as defined in claim 1; or a bonding group for bonding the reactive group or antitumor drug residue as defined in claim 1 to the linker, and the bonding group may be a protected body protected by a protecting group, G 1 is a group represented by formula (i), (ii), (iii) or (iv), L 1-1 It is connected to G 1 and D 1-1 The connector, L 2-1 It is connected to G 1 and D 2-1 The connector, L 3-1 It is connected to G 1 and Z 1 The connector, L 1-1 , L 2-1 and L 3-1 can be the same or different from each other, D 1-1 and D 2-1 is an antitumor drug residue or bonding group or a protected form thereof as defined in claim 1, D 1-1 and D 2-1 can be the same or different from each other, When these antitumor drug residues or L 1-1 , L 2-1 or L 3-1 At any one or more positions of the present invention, there are one or more groups independently selected from lactone groups; phosphoryl groups; phosphorylalkylcarbonyl groups (-C(=O)-alkylene-P(=O)(OH)2); dialkylamino groups; and cyclic amino groups that form a ring together with the dialkyl groups, and when there are a plurality of said groups in total, these groups may be the same as or different from each other, and When Z 1 When D is a reactive group, 1-1 and D 2-1 At least one of them is a bonding group].

21. The synthetic intermediate (II-1) of the conjugate precursor according to claim 20, or a salt thereof, wherein G 1 is a group selected from the group consisting of the formulae described in claim 5 or 6.

22. The synthetic intermediate (II-1) of the conjugate precursor according to claim 20 or 21, or a salt thereof, wherein L 1-1 , L 2-1 and L 3-1 are each independently an optionally substituted alkylene group; and One or more methylene groups in the alkylene group chain are each independently substituted with one or more groups selected from the divalent groups as claimed in any one of claims 7 to 10.

23. The synthetic intermediate (II-1) of the conjugate precursor according to any one of claims 20 to 22, or a salt thereof, wherein Z 1 It is a bonding group or a protective body thereof, and the bonding group is a hydroxyl group, a nitro group, a cyano group, an amide group, an oxo group, an azide group, an amino group, a monoalkylamino group which may have a substituent, an imino group (also including -N= and the imino group of a cyclic amine), a carboxyl group, a phosphoryl group, an alkynyl group, a cycloalkynyl group or a thiol group.

24. The synthetic intermediate (II-1) of the conjugate precursor according to any one of claims 20 to 23, or a salt thereof, wherein Z 1 It is a bonding group or a protective body thereof, wherein the bonding group is a hydroxyl group, a nitro group, a cyano group, an oxo group, an azide group, an amino group, a monoalkylamino group which may have a substituent, an imino group (also including -N= and the imino group of a cyclic amine), a carboxyl group, a phosphoryl group, an alkynyl group, a cycloalkynyl group or a thiol group.

25. The synthetic intermediate (II-1) of the conjugate precursor according to any one of claims 20 to 24, or a salt thereof, wherein Z 1 It is a bonding group or a protective body thereof, and the bonding group is a hydroxyl group, a nitro group, an oxo group, an azide group, an amino group, a monoalkylamino group which may have a substituent, an imino group (also including -N= and the imino group of a cyclic amine), a carboxyl group, a phosphoryl group, an alkynyl group, a cycloalkynyl group or a thiol group.

26. The synthetic intermediate (II-1) of the conjugate precursor according to any one of claims 20 to 25, or a salt thereof, wherein Z 1 It is a bonding group or a protective body thereof, and the bonding group is a hydroxyl group, a nitro group, an oxo group, an azide group, an amino group, a monoalkylamino group which may have a substituent, an imino group (also including -N= and the imino group of a cyclic amine), a carboxyl group, a phosphoryl group, an alkynyl group or a cycloalkynyl group.

27. The synthetic intermediate (II-1) of the conjugate precursor according to any one of claims 20 to 26, or a salt thereof, wherein Z 1 is a group selected from the bonding groups according to any one of claims 23 to 26, and D 1-1 and D 2-1 One of them is a group selected from the antitumor drug residues as claimed in any one of claims 11 to 16, and the other is a group selected from the bonding groups as claimed in any one of claims 23 to 26.

28. The synthetic intermediate (II-1) of the conjugate precursor according to any one of claims 20 to 26, or a salt thereof, wherein Z 1 is a group selected from the bonding groups according to any one of claims 23 to 26, and D 1-1 and D 2-1 Both are independently selected from the group of antitumor drug residues as described in any one of claims 11 to 16.

29. The synthetic intermediate (II-1) of the conjugate precursor according to any one of claims 20 to 26, or a salt thereof, wherein Z 1 , D 1-1 and D 2-1 All are each independently a group selected from the bonding groups described in any one of claims 23 to 26.

30. The synthetic intermediate (II-1) of the conjugate precursor according to any one of claims 20 to 22, or a salt thereof, wherein Z 1 is a reactive group as defined in claim 1, and D 1-1 and D 2-1 One of them is a group selected from the antitumor drug residues as claimed in any one of claims 11 to 16, and the other is a group selected from the bonding groups as claimed in any one of claims 23 to 26.

31. The synthetic intermediate (II-1) of the conjugate precursor according to any one of claims 20 to 22, or a salt thereof, wherein Z 1 is a reactive group as defined in claim 1, and D 1-1 and D 2-1 Both are each independently a group selected from the bonding groups described in any one of claims 23 to 26.

32. The synthetic intermediate (II-1) of the conjugate precursor according to any one of claims 20 to 31, or a salt thereof, wherein One or more lactone groups and one or more phosphoryl groups are independently present as substituents or protecting groups on these anti-tumor drug residues or L 1-1 , L 2-1 or L 3-1 At any position of , the total number of the lactone groups is 1 to 8, when the number of the lactone groups is two or more, the lactone groups may be the same as or different from each other, and the total number of the phosphoryl groups is 1 to 4.

33. The synthetic intermediate (II-1) of the conjugate precursor according to any one of claims 20 to 32, or a salt thereof, wherein One or more lactone groups and one or more phosphoryl groups are independently present as substituents or protecting groups on these anti-tumor drug residues or L 1-1 , L 2-1 or L 3-1 Any location, and In addition to the above, when these anti-tumor drug residues or L 1-1 , L 2-1 or L 3-1 When there are one or more groups independently selected from a phosphorylalkylcarbonyl group (-C(=O)-alkylene-P(=O)(OH)2); a dialkylamino group; and a cyclic amino group which forms a ring together with the dialkyl group at any one or more positions of the alkylene group, and when there are a plurality of such groups in total, these groups may be the same as or different from each other.

34. A synthetic intermediate (II-2) of a conjugate precursor, or a salt thereof, which is represented by the following general formula (II-2): [C28] [In this formula, L 1-1 and L 2-1 are each independently an optionally substituted alkylene group, and one or more methylene groups in the chain of the alkylene group are each independently substituted by one or more groups selected from the divalent group as described in any one of claims 7 to 10, D 1-1 and D 2-1 is a group selected from the antitumor drug residues as claimed in any one of claims 11 to 16 or a group selected from the bonding groups as claimed in any one of claims 23 to 26, and D 1-1 and D 2-1 can be the same or different from each other, When the L 1-1 and L 2-1 or anti-tumor drug residues, there are one or more groups independently selected from lactone groups; phosphoryl groups; phosphorylalkylcarbonyl groups (-C(=O)-alkylene-P(=O)(OH)2); dialkylamino groups; and cyclic amino groups that form a ring together with the dialkyl groups as substituents or protective groups, and when there are a plurality of said groups in total, these groups may be the same or different from each other, and R 17 is a hydrogen atom or a protecting group].

35. A conjugate precursor synthetic intermediate (II-1) and (II-2), or a salt thereof, selected from the group consisting of: Examples 1-15 [C41] Example 2-10 [C46] Example 3-1 [C47] Example 4-3 [C50] Example 4-4[C51] Example 5-2[C52] Example 5-3 [C53] Example 6-4 [C557] Example 6-5 [C558] Example 7-6 [C559] Example 7-7 [C560] [In this formula, the spatial configuration of the amino acid residues in the linker is all L-type].

36. A precursor of an antibody-drug conjugate (ADC) containing an antibody and a drug, or a salt thereof, wherein the ADC is an ADC in which the antibody is directly or indirectly linked to the drug via a linker, The precursor has a linker and a drug, and The linker has a reactive group (the reactive group is the connecting part to the antibody), which can react with a functional group in the antibody (e.g., a thiol group), and is modified with a solubilizing group, which is, for example, a group selected from the group consisting of a lactone group, an optionally substituted C1-C6 aminoalkyl group and a phosphoryl group (particularly a solubilizing group).

37. A compound having the above formula (I), or a salt thereof, wherein This formula has D 1 and D 2 R 18 and R 19 , and R 18 and R 19 is independently a hydrogen atom, a protecting group or a bonding group.

38. A compound having the above formula (II-1), or a salt thereof, wherein This formula has D 1-1 and D 2-1 R 18 and R 19 , and R 18 and R 19 is independently a hydrogen atom, a protecting group or a bonding group.

39. A compound having the above formula (II-2), or a salt thereof, wherein This formula has D 1-1 and D 2-1 R 18 and R 19 , and R 18 and R 19 is independently a hydrogen atom, a protecting group or a bonding group.

40. A method for producing an antibody-drug conjugate (ADC) comprising an antibody and a drug, the method comprising: The compound or salt thereof according to any one of claims 37 to 39 is reacted with an antibody and an anti-tumor drug molecule, an analog or derivative thereof, and a derivative of the analog to obtain ADC.

41. A method for producing an antibody-drug conjugate (ADC) comprising an antibody and a drug, the method comprising: The antibody is reacted with the precursor or a salt thereof according to any one of claims 1 to 19 to obtain ADC.

Images